US20010001101A1 - Phenanthroline derivatives - Google Patents
Phenanthroline derivatives Download PDFInfo
- Publication number
- US20010001101A1 US20010001101A1 US09/747,254 US74725400A US2001001101A1 US 20010001101 A1 US20010001101 A1 US 20010001101A1 US 74725400 A US74725400 A US 74725400A US 2001001101 A1 US2001001101 A1 US 2001001101A1
- Authority
- US
- United States
- Prior art keywords
- phenanthroline
- oxo
- dihydro
- alkyl
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000005041 phenanthrolines Chemical class 0.000 title claims abstract description 14
- -1 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl Chemical group 0.000 claims abstract description 325
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 140
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 85
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 66
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 57
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- 239000001257 hydrogen Substances 0.000 claims abstract description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 43
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 35
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 33
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 22
- 230000003620 anti-fibroproliferative effect Effects 0.000 claims abstract description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 22
- 239000000203 mixture Substances 0.000 claims description 121
- 150000001875 compounds Chemical class 0.000 claims description 109
- 125000003545 alkoxy group Chemical group 0.000 claims description 43
- 125000001424 substituent group Chemical group 0.000 claims description 39
- 150000002148 esters Chemical class 0.000 claims description 35
- SWWIZACAXYXWIB-UHFFFAOYSA-N 4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C1=CN=C2C(N=CC(C3=O)C(=O)O)=C3C=CC2=C1 SWWIZACAXYXWIB-UHFFFAOYSA-N 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 17
- ATHCTVJMOQAXQV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethyl 4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound C1=CN=C2C(N=CC(C3=O)C(=O)OCCOCCOC)=C3C=CC2=C1 ATHCTVJMOQAXQV-UHFFFAOYSA-N 0.000 claims description 14
- WVBGSODIPXVALT-UHFFFAOYSA-N 8-(4-benzylpiperazine-1-carbonyl)-3-nitro-3h-1,10-phenanthrolin-4-one Chemical compound O=C1C([N+](=O)[O-])C=NC(C2=NC=3)=C1C=CC2=CC=3C(=O)N(CC1)CCN1CC1=CC=CC=C1 WVBGSODIPXVALT-UHFFFAOYSA-N 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- YEHPXUKDVUSOAE-UHFFFAOYSA-N 2-morpholin-4-ylethyl 4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound C1=NC(C2=NC=CC=C2C=C2)=C2C(=O)C1C(=O)OCCN1CCOCC1 YEHPXUKDVUSOAE-UHFFFAOYSA-N 0.000 claims description 12
- XHZZUTMSPWENJL-UHFFFAOYSA-N 8-hydroxy-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound OC1=CN=C2C(N=CC(C3=O)C(=O)O)=C3C=CC2=C1 XHZZUTMSPWENJL-UHFFFAOYSA-N 0.000 claims description 12
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- SEBYKUXMVPANQV-UHFFFAOYSA-N ethyl 5-methoxy-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound COC1=CC2=CC=CN=C2C2=C1C(=O)C(C(=O)OCC)C=N2 SEBYKUXMVPANQV-UHFFFAOYSA-N 0.000 claims description 12
- HVULDFJIRQNRKR-UHFFFAOYSA-N n-ethyl-8-nitro-7-oxo-n-propyl-8h-1,10-phenanthroline-3-carboxamide Chemical compound N1=CC([N+]([O-])=O)C(=O)C2=C1C1=NC=C(C(=O)N(CC)CCC)C=C1C=C2 HVULDFJIRQNRKR-UHFFFAOYSA-N 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- WNKYYOSKHYPJHP-UHFFFAOYSA-N 5-methoxy-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=CC=C1C=C2OC WNKYYOSKHYPJHP-UHFFFAOYSA-N 0.000 claims description 11
- VEFOBRKRVJFVLZ-UHFFFAOYSA-N 6-chloro-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C1=CN=C2C(N=CC(C3=O)C(=O)O)=C3C=C(Cl)C2=C1 VEFOBRKRVJFVLZ-UHFFFAOYSA-N 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 11
- LRGINGALCKTIGW-UHFFFAOYSA-N n-benzyl-8-cyano-n-methyl-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound C=1N=C2C=3N=CC(C#N)C(=O)C=3C=CC2=CC=1C(=O)N(C)CC1=CC=CC=C1 LRGINGALCKTIGW-UHFFFAOYSA-N 0.000 claims description 11
- LCMWQHYNEMXENA-UHFFFAOYSA-N 3-(trifluoromethylsulfonyl)-3h-1,10-phenanthrolin-4-one Chemical compound C1=CN=C2C(N=CC(C3=O)S(=O)(=O)C(F)(F)F)=C3C=CC2=C1 LCMWQHYNEMXENA-UHFFFAOYSA-N 0.000 claims description 10
- SPPHFBKOUJYNSA-UHFFFAOYSA-N ethyl 4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound C1=CN=C2C(N=CC(C3=O)C(=O)OCC)=C3C=CC2=C1 SPPHFBKOUJYNSA-UHFFFAOYSA-N 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- FGMQSROLLBGIBA-UHFFFAOYSA-N 4-oxo-3h-1,10-phenanthroline-3-carbonitrile Chemical compound C1=CC2=CC=CN=C2C2=C1C(=O)C(C#N)C=N2 FGMQSROLLBGIBA-UHFFFAOYSA-N 0.000 claims description 9
- JTQYMGVWMKHGCB-UHFFFAOYSA-N 5-chloro-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound ClC1=CC2=CC=CN=C2C2=C1C(=O)C(C(=O)O)C=N2 JTQYMGVWMKHGCB-UHFFFAOYSA-N 0.000 claims description 9
- AGOOEBVNFNAAKW-UHFFFAOYSA-N 5-methyl-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=CC=C1C=C2C AGOOEBVNFNAAKW-UHFFFAOYSA-N 0.000 claims description 9
- BTJNEWHXSBCPGE-UHFFFAOYSA-N 8-[(2,4-difluorophenyl)methyl-methylcarbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1N=C2C=3N=CC(C(O)=O)C(=O)C=3C=CC2=CC=1C(=O)N(C)CC1=CC=C(F)C=C1F BTJNEWHXSBCPGE-UHFFFAOYSA-N 0.000 claims description 9
- PCFSCCJKQDOUGO-UHFFFAOYSA-N 8-[benzyl(methyl)carbamoyl]-5-methyl-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1N=C2C=3N=CC(C(O)=O)C(=O)C=3C(C)=CC2=CC=1C(=O)N(C)CC1=CC=CC=C1 PCFSCCJKQDOUGO-UHFFFAOYSA-N 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- OKUBXIHCVLUWTF-UHFFFAOYSA-N ethyl 6-fluoro-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound C1=CN=C2C(N=CC(C3=O)C(=O)OCC)=C3C=C(F)C2=C1 OKUBXIHCVLUWTF-UHFFFAOYSA-N 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 8
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 7
- 230000009787 cardiac fibrosis Effects 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000000893 fibroproliferative effect Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- NSMJMUQZRGZMQC-UHFFFAOYSA-N 2-naphthalen-1-yl-1H-imidazo[4,5-f][1,10]phenanthroline Chemical compound C12=CC=CN=C2C2=NC=CC=C2C2=C1NC(C=1C3=CC=CC=C3C=CC=1)=N2 NSMJMUQZRGZMQC-UHFFFAOYSA-N 0.000 abstract description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 59
- 239000007858 starting material Substances 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 38
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 32
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 30
- 238000010992 reflux Methods 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 22
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 19
- 229940125797 compound 12 Drugs 0.000 description 19
- 102000008186 Collagen Human genes 0.000 description 17
- 108010035532 Collagen Proteins 0.000 description 17
- 229920001436 collagen Polymers 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 125000005843 halogen group Chemical group 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 12
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- BOSZKFJKQPLMBG-UHFFFAOYSA-N 8-nitro-4-oxo-3h-quinoline-3-carboxylic acid Chemical compound O=C1C(C(=O)O)C=NC2=C1C=CC=C2[N+]([O-])=O BOSZKFJKQPLMBG-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000003176 fibrotic effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229960002429 proline Drugs 0.000 description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 230000033444 hydroxylation Effects 0.000 description 6
- 238000005805 hydroxylation reaction Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 5
- QTVREUPPZINOFX-UHFFFAOYSA-N CC1=CNC2=C(C1=O)/C(C)=C(/C)C1=C(C)C(C)=CN=C21 Chemical compound CC1=CNC2=C(C1=O)/C(C)=C(/C)C1=C(C)C(C)=CN=C21 QTVREUPPZINOFX-UHFFFAOYSA-N 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 229940126543 compound 14 Drugs 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 239000012258 stirred mixture Substances 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 4
- 150000005012 8-aminoquinolines Chemical class 0.000 description 4
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 4
- 206010023421 Kidney fibrosis Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000004147 Sorbitan trioleate Substances 0.000 description 4
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019337 sorbitan trioleate Nutrition 0.000 description 4
- 229960000391 sorbitan trioleate Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
- 229940029284 trichlorofluoromethane Drugs 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 3
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 3
- PSBOMJUFAJVWQH-UHFFFAOYSA-N 3h-1,10-phenanthrolin-4-one Chemical compound C1=CC2=CC=CN=C2C2=C1C(=O)CC=N2 PSBOMJUFAJVWQH-UHFFFAOYSA-N 0.000 description 3
- DPNOQXXCAWZHAV-UHFFFAOYSA-N 6-fluoro-8-nitro-4-oxo-3h-quinoline-3-carboxylic acid Chemical compound O=C1C(C(=O)O)C=NC2=C1C=C(F)C=C2[N+]([O-])=O DPNOQXXCAWZHAV-UHFFFAOYSA-N 0.000 description 3
- DWIAJQOBEUSOFR-UHFFFAOYSA-N 8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC([N+]([O-])=O)C(=O)C2=C1C1=NC=C(C(=O)O)C=C1C=C2 DWIAJQOBEUSOFR-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000032594 Vascular Remodeling Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- UVMXISWKXFDSGZ-UHFFFAOYSA-N ethyl 4-chloro-8-nitroquinoline-3-carboxylate Chemical compound [O-][N+](=O)C1=CC=CC2=C(Cl)C(C(=O)OCC)=CN=C21 UVMXISWKXFDSGZ-UHFFFAOYSA-N 0.000 description 3
- BBZKFRDLBJHFMD-UHFFFAOYSA-N ethyl 8-nitro-4-oxo-3h-quinoline-3-carboxylate Chemical compound O=C1C(C(=O)OCC)C=NC2=C1C=CC=C2[N+]([O-])=O BBZKFRDLBJHFMD-UHFFFAOYSA-N 0.000 description 3
- OWQRXONQCPUOOH-UHFFFAOYSA-N ethyl 8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxylate Chemical compound N1=CC([N+]([O-])=O)C(=O)C2=C1C1=NC=C(C(=O)OCC)C=C1C=C2 OWQRXONQCPUOOH-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002064 heart cell Anatomy 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 229940039009 isoproterenol Drugs 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- GSEBLTZCJXGEOZ-UHFFFAOYSA-N (4-chloro-8-nitroquinolin-3-yl)-(3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1=CN=C2C([N+](=O)[O-])=CC=CC2=C1Cl GSEBLTZCJXGEOZ-UHFFFAOYSA-N 0.000 description 2
- BOJTVVVNARYCOZ-UHFFFAOYSA-N (8-aminoquinolin-3-yl)-(3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1=CN=C2C(N)=CC=CC2=C1 BOJTVVVNARYCOZ-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- IZYBEGHUZQSYII-UHFFFAOYSA-N 1h-1,10-phenanthrolin-4-one Chemical group C1=CC2=CC=CN=C2C2=C1C(=O)C=CN2 IZYBEGHUZQSYII-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MQPVOZGZDQLTSE-UHFFFAOYSA-N 3,6-dinitro-3h-1,10-phenanthrolin-4-one Chemical compound C1=CN=C2C(N=CC(C3=O)[N+](=O)[O-])=C3C=C([N+]([O-])=O)C2=C1 MQPVOZGZDQLTSE-UHFFFAOYSA-N 0.000 description 2
- ZRQFTWVPYMQJJF-UHFFFAOYSA-N 3-(2,2,2-trifluoroethylsulfonyl)-3h-1,10-phenanthrolin-4-one Chemical compound C1=CN=C2C(N=CC(C3=O)S(=O)(=O)CC(F)(F)F)=C3C=CC2=C1 ZRQFTWVPYMQJJF-UHFFFAOYSA-N 0.000 description 2
- GRMSMFRMCBXELF-UHFFFAOYSA-N 3-(imidazole-1-carbonyl)-3h-1,10-phenanthrolin-4-one Chemical compound C1=NC(C2=NC=CC=C2C=C2)=C2C(=O)C1C(=O)N1C=CN=C1 GRMSMFRMCBXELF-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XHOLZVUXFLGYTO-UHFFFAOYSA-N 4-chloro-6-fluoro-n-(2,2,3,3,4,4,4-heptafluorobutyl)-8-nitroquinoline-3-carboxamide Chemical compound FC(F)(F)C(F)(F)C(F)(F)CNC(=O)C1=CN=C2C([N+](=O)[O-])=CC(F)=CC2=C1Cl XHOLZVUXFLGYTO-UHFFFAOYSA-N 0.000 description 2
- GECNSLCYAWAWEZ-UHFFFAOYSA-N 4-chloro-8-nitroquinoline-3-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC2=C(Cl)C(C(=O)N)=CN=C21 GECNSLCYAWAWEZ-UHFFFAOYSA-N 0.000 description 2
- YILKRWIQSRTGDX-UHFFFAOYSA-N 4-chloro-n-(4-ethoxyphenyl)-8-nitroquinoline-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1NC(=O)C1=CN=C(C(=CC=C2)[N+]([O-])=O)C2=C1Cl YILKRWIQSRTGDX-UHFFFAOYSA-N 0.000 description 2
- JCDWEPVJKBWJGC-UHFFFAOYSA-N 4-chloro-n-[(4-fluorophenyl)methyl]-n-methyl-8-nitroquinoline-3-carboxamide Chemical compound C=1N=C2C([N+]([O-])=O)=CC=CC2=C(Cl)C=1C(=O)N(C)CC1=CC=C(F)C=C1 JCDWEPVJKBWJGC-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- XBXGOETWYUMYNX-UHFFFAOYSA-N 5-fluoro-8-(2,2,3,3,4,4,4-heptafluorobutylcarbamoyl)-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound FC1=CC2=CC(C(=O)NCC(F)(F)C(F)(F)C(F)(F)F)=CN=C2C2=C1C(=O)C(C(=O)O)C=N2 XBXGOETWYUMYNX-UHFFFAOYSA-N 0.000 description 2
- NEMUMZABVMUFEJ-UHFFFAOYSA-N 8-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1=CN=C2C(N=CC(C3=O)C(=O)O)=C3C=CC2=C1 NEMUMZABVMUFEJ-UHFFFAOYSA-N 0.000 description 2
- ZLFSCUSJGKTHKY-UHFFFAOYSA-N 8-[(4-ethoxyphenyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C1=CC(OCC)=CC=C1NC(=O)C1=CN=C(C2=C(C(=O)C(C(O)=O)C=N2)C=C2)C2=C1 ZLFSCUSJGKTHKY-UHFFFAOYSA-N 0.000 description 2
- KEMPTZSXMSNBRE-UHFFFAOYSA-N 8-[(4-fluorophenyl)methyl-methylcarbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1N=C2C=3N=CC(C(O)=O)C(=O)C=3C=CC2=CC=1C(=O)N(C)CC1=CC=C(F)C=C1 KEMPTZSXMSNBRE-UHFFFAOYSA-N 0.000 description 2
- ZMQUMKAACHOAND-UHFFFAOYSA-N 8-[benzyl(methyl)carbamoyl]-5-fluoro-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1N=C2C=3N=CC(C(O)=O)C(=O)C=3C(F)=CC2=CC=1C(=O)N(C)CC1=CC=CC=C1 ZMQUMKAACHOAND-UHFFFAOYSA-N 0.000 description 2
- SCUCGOJDGSOUHT-UHFFFAOYSA-N 8-[butyl(ethyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N(CC)CCCC)C=C1C=C2 SCUCGOJDGSOUHT-UHFFFAOYSA-N 0.000 description 2
- LVHDXKYJKTWNSG-UHFFFAOYSA-N 8-amino-6-fluoro-n-(2,2,3,3,4,4,4-heptafluorobutyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C(F)(F)C(F)(F)CNC(=O)C1=CN=C2C(N)=CC(F)=CC2=C1 LVHDXKYJKTWNSG-UHFFFAOYSA-N 0.000 description 2
- FXVRWAIYPIOHAY-UHFFFAOYSA-N 8-amino-n-(4-ethoxyphenyl)quinoline-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1NC(=O)C1=CN=C(C(N)=CC=C2)C2=C1 FXVRWAIYPIOHAY-UHFFFAOYSA-N 0.000 description 2
- ZDWINWGSJRSZOX-UHFFFAOYSA-N 8-amino-n-[(4-fluorophenyl)methyl]-n-methylquinoline-3-carboxamide Chemical compound C=1N=C2C(N)=CC=CC2=CC=1C(=O)N(C)CC1=CC=C(F)C=C1 ZDWINWGSJRSZOX-UHFFFAOYSA-N 0.000 description 2
- SNGIYHKXULUNTD-UHFFFAOYSA-N 8-amino-n-benzyl-4-(dimethylamino)-n-methylquinoline-3-carboxamide Chemical compound C1=NC2=C(N)C=CC=C2C(N(C)C)=C1C(=O)N(C)CC1=CC=CC=C1 SNGIYHKXULUNTD-UHFFFAOYSA-N 0.000 description 2
- YXJOOOJWSQXUQP-UHFFFAOYSA-N 8-amino-n-benzyl-6-fluoro-n-methylquinoline-3-carboxamide Chemical compound C=1N=C2C(N)=CC(F)=CC2=CC=1C(=O)N(C)CC1=CC=CC=C1 YXJOOOJWSQXUQP-UHFFFAOYSA-N 0.000 description 2
- OVIUXKXSRWOSQX-UHFFFAOYSA-N 8-amino-n-butyl-n-ethylquinoline-3-carboxamide Chemical compound NC1=CC=CC2=CC(C(=O)N(CC)CCCC)=CN=C21 OVIUXKXSRWOSQX-UHFFFAOYSA-N 0.000 description 2
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 2
- OQGZWSGZVDXFRZ-UHFFFAOYSA-N 8-aminoquinoline-3-carboxamide Chemical compound NC1=CC=CC2=CC(C(=O)N)=CN=C21 OQGZWSGZVDXFRZ-UHFFFAOYSA-N 0.000 description 2
- WYPXTCBCELLWMY-UHFFFAOYSA-N 8-carbamoyl-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N)C=C1C=C2 WYPXTCBCELLWMY-UHFFFAOYSA-N 0.000 description 2
- ZMJOCKROVABEKU-UHFFFAOYSA-N 8-n-benzyl-4-chloro-5-fluoro-8-n-methyl-1,10-phenanthroline-3,8-dicarboxamide Chemical compound C=1N=C(C2=NC=C(C(Cl)=C2C(F)=C2)C(N)=O)C2=CC=1C(=O)N(C)CC1=CC=CC=C1 ZMJOCKROVABEKU-UHFFFAOYSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000010867 Carotid Artery injury Diseases 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- JTGABQDBMSKAOX-UHFFFAOYSA-N diethyl 2-[(2-nitroanilino)methylidene]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)=CNC1=CC=CC=C1[N+]([O-])=O JTGABQDBMSKAOX-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- NUYBFVNTMAOXGX-UHFFFAOYSA-N ethyl 5-fluoro-8-(2,2,3,3,4,4,4-heptafluorobutylcarbamoyl)-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound FC1=CC2=CC(C(=O)NCC(F)(F)C(F)(F)C(F)(F)F)=CN=C2C2=C1C(=O)C(C(=O)OCC)C=N2 NUYBFVNTMAOXGX-UHFFFAOYSA-N 0.000 description 2
- IUOHZWLTFUVBMH-UHFFFAOYSA-N ethyl 6-fluoro-8-nitro-4-oxo-3h-quinoline-3-carboxylate Chemical compound O=C1C(C(=O)OCC)C=NC2=C1C=C(F)C=C2[N+]([O-])=O IUOHZWLTFUVBMH-UHFFFAOYSA-N 0.000 description 2
- JETCAMXJPNODAS-UHFFFAOYSA-N ethyl 7-oxo-8h-1,10-phenanthroline-3-carboxylate Chemical compound N1=CCC(=O)C2=C1C1=NC=C(C(=O)OCC)C=C1C=C2 JETCAMXJPNODAS-UHFFFAOYSA-N 0.000 description 2
- SYTMEYMCHGDGAC-UHFFFAOYSA-N ethyl 8-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1=CN=C2C(N=CC(C3=O)C(=O)OCC)=C3C=CC2=C1 SYTMEYMCHGDGAC-UHFFFAOYSA-N 0.000 description 2
- OBPIJRRUNOZWEG-UHFFFAOYSA-N ethyl 8-[(4-ethoxyphenyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound O=C1C(C(=O)OCC)C=NC(C2=NC=3)=C1C=CC2=CC=3C(=O)NC1=CC=C(OCC)C=C1 OBPIJRRUNOZWEG-UHFFFAOYSA-N 0.000 description 2
- YQOGKJUKAYFLFB-UHFFFAOYSA-N ethyl 8-[(4-fluorophenyl)methyl-methylcarbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound O=C1C(C(=O)OCC)C=NC(C2=NC=3)=C1C=CC2=CC=3C(=O)N(C)CC1=CC=C(F)C=C1 YQOGKJUKAYFLFB-UHFFFAOYSA-N 0.000 description 2
- BBQBRCYLNSYMKR-UHFFFAOYSA-N ethyl 8-[benzyl(methyl)carbamoyl]-5-fluoro-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound O=C1C(C(=O)OCC)C=NC(C2=NC=3)=C1C(F)=CC2=CC=3C(=O)N(C)CC1=CC=CC=C1 BBQBRCYLNSYMKR-UHFFFAOYSA-N 0.000 description 2
- JZYFHGJGKXTCLF-UHFFFAOYSA-N ethyl 8-[benzyl(methyl)carbamoyl]-7-(dimethylamino)-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound O=C1C(C(=O)OCC)C=NC(C2=NC=3)=C1C=CC2=C(N(C)C)C=3C(=O)N(C)CC1=CC=CC=C1 JZYFHGJGKXTCLF-UHFFFAOYSA-N 0.000 description 2
- BMALTTYUZHTBOR-UHFFFAOYSA-N ethyl 8-[butyl(ethyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound N1=CC(C(=O)OCC)C(=O)C2=C1C1=NC=C(C(=O)N(CC)CCCC)C=C1C=C2 BMALTTYUZHTBOR-UHFFFAOYSA-N 0.000 description 2
- VUDLUJUOVOTOHG-UHFFFAOYSA-N ethyl 8-acetyl-4-chloro-7-oxo-8h-1,10-phenanthroline-3-carboxylate Chemical compound N1=CC(C(C)=O)C(=O)C2=C1C1=NC=C(C(=O)OCC)C(Cl)=C1C=C2 VUDLUJUOVOTOHG-UHFFFAOYSA-N 0.000 description 2
- FKJJMZQDQXXUPZ-UHFFFAOYSA-N ethyl 8-amino-4-chloroquinoline-3-carboxylate Chemical compound NC1=CC=CC2=C(Cl)C(C(=O)OCC)=CN=C21 FKJJMZQDQXXUPZ-UHFFFAOYSA-N 0.000 description 2
- FLYPPJMEMJHTTQ-UHFFFAOYSA-N ethyl 8-aminoquinoline-3-carboxylate Chemical compound NC1=CC=CC2=CC(C(=O)OCC)=CN=C21 FLYPPJMEMJHTTQ-UHFFFAOYSA-N 0.000 description 2
- PMXIUFHPGPXGEZ-UHFFFAOYSA-N ethyl 8-carbamoyl-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound NC(=O)C1=CN=C2C(N=CC(C3=O)C(=O)OCC)=C3C=CC2=C1 PMXIUFHPGPXGEZ-UHFFFAOYSA-N 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- FDGDRAZKKFUSBQ-UHFFFAOYSA-N methyl 2-(2,2,2-trifluoroethylsulfonyl)acetate Chemical compound COC(=O)CS(=O)(=O)CC(F)(F)F FDGDRAZKKFUSBQ-UHFFFAOYSA-N 0.000 description 2
- UFLUUUPRAHBNEE-UHFFFAOYSA-N methyl 3-(quinolin-8-ylamino)-2-(2,2,2-trifluoroethylsulfonyl)prop-2-enoate Chemical compound C1=CN=C2C(NC=C(C(=O)OC)S(=O)(=O)CC(F)(F)F)=CC=CC2=C1 UFLUUUPRAHBNEE-UHFFFAOYSA-N 0.000 description 2
- FJFMICZFXWZEHW-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-n-methyl-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound C=1N=C2C=3N=CCC(=O)C=3C=CC2=CC=1C(=O)N(C)CC1=CC=C(F)C=C1 FJFMICZFXWZEHW-UHFFFAOYSA-N 0.000 description 2
- OJOUDRPZNGIOFF-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-n-methyl-8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound C=1N=C2C=3N=CC([N+]([O-])=O)C(=O)C=3C=CC2=CC=1C(=O)N(C)CC1=CC=C(F)C=C1 OJOUDRPZNGIOFF-UHFFFAOYSA-N 0.000 description 2
- GVAVIGKOCVXCPG-UHFFFAOYSA-N n-benzyl-4-chloro-6-fluoro-n-methyl-8-nitroquinoline-3-carboxamide Chemical compound C=1N=C2C([N+]([O-])=O)=CC(F)=CC2=C(Cl)C=1C(=O)N(C)CC1=CC=CC=C1 GVAVIGKOCVXCPG-UHFFFAOYSA-N 0.000 description 2
- PBPQASUCZGWZLB-UHFFFAOYSA-N n-benzyl-4-chloro-n-methyl-8-nitroquinoline-3-carboxamide Chemical compound C=1N=C2C([N+]([O-])=O)=CC=CC2=C(Cl)C=1C(=O)N(C)CC1=CC=CC=C1 PBPQASUCZGWZLB-UHFFFAOYSA-N 0.000 description 2
- XNNYIDSSGVVGAG-UHFFFAOYSA-N n-benzyl-8-cyano-6-fluoro-n-methyl-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound C=1N=C2C=3N=CC(C#N)C(=O)C=3C(F)=CC2=CC=1C(=O)N(C)CC1=CC=CC=C1 XNNYIDSSGVVGAG-UHFFFAOYSA-N 0.000 description 2
- YZIAFCAPNDCZPI-UHFFFAOYSA-N n-butyl-4-chloro-n-ethyl-8-nitroquinoline-3-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC2=C(Cl)C(C(=O)N(CC)CCCC)=CN=C21 YZIAFCAPNDCZPI-UHFFFAOYSA-N 0.000 description 2
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 2
- 230000000802 nitrating effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- VCQURUZYYSOUHP-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 2,2,2-trifluoroacetate Chemical compound FC1=C(F)C(F)=C(OC(=O)C(F)(F)F)C(F)=C1F VCQURUZYYSOUHP-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- AGOSFZUJVNKTHO-UHFFFAOYSA-N 1,1,1-trifluoro-3-$l^{1}-sulfanylpropane Chemical group FC(F)(F)CC[S] AGOSFZUJVNKTHO-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- XJDDLMJULQGRLU-UHFFFAOYSA-N 1,3-dioxane-4,6-dione Chemical group O=C1CC(=O)OCO1 XJDDLMJULQGRLU-UHFFFAOYSA-N 0.000 description 1
- YZZVUONPNCNGRX-UHFFFAOYSA-N 1,8-dihydro-1,10-phenanthroline-4,7-dione Chemical compound C1=CC(C(C=CN2)=O)=C2C2=C1C(=O)CC=N2 YZZVUONPNCNGRX-UHFFFAOYSA-N 0.000 description 1
- UBFJARFSWGMKCS-UHFFFAOYSA-N 1,8-dihydro-1,10-phenanthroline-4,7-dione;hydrochloride Chemical compound Cl.C1=CC(C(C=CN2)=O)=C2C2=C1C(=O)CC=N2 UBFJARFSWGMKCS-UHFFFAOYSA-N 0.000 description 1
- SZJIQLSCDIEJFC-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-methylmethanamine Chemical compound CNCC1=CC=C(F)C=C1 SZJIQLSCDIEJFC-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- FBKKYZMTAAQTJO-UHFFFAOYSA-N 1h-1,10-phenanthrolin-2-one Chemical class C1=CC=NC2=C(NC(=O)C=C3)C3=CC=C21 FBKKYZMTAAQTJO-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- WBGBQSRNXPVFDB-UHFFFAOYSA-N 2,2,3,3,4,4,4-heptafluorobutan-1-amine Chemical compound NCC(F)(F)C(F)(F)C(F)(F)F WBGBQSRNXPVFDB-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical class NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FYTNWDFBQJITJT-UHFFFAOYSA-N 3,8-diacetyl-1,8-dihydro-1,10-phenanthroline-4,7-dione Chemical compound C1=CC(C(C(C(C)=O)=CN2)=O)=C2C2=C1C(=O)C(C(=O)C)C=N2 FYTNWDFBQJITJT-UHFFFAOYSA-N 0.000 description 1
- NKZGOQAUTCWEQF-UHFFFAOYSA-N 3-(2-methoxyethoxy)propan-1-ol Chemical compound COCCOCCCO NKZGOQAUTCWEQF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- JDFDHBSESGTDAL-UHFFFAOYSA-N 3-methoxypropan-1-ol Chemical compound COCCCO JDFDHBSESGTDAL-UHFFFAOYSA-N 0.000 description 1
- ASLBKICWRCQSMW-UHFFFAOYSA-N 3-nitro-3h-1,10-phenanthrolin-4-one Chemical compound C1=CN=C2C(N=CC(C3=O)[N+](=O)[O-])=C3C=CC2=C1 ASLBKICWRCQSMW-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- AQTXYBMGOMZMHZ-UHFFFAOYSA-N 4,7-dioxo-1,8-dihydro-1,10-phenanthroline-3,8-dicarboxylic acid Chemical compound C1=CC(C(C(C(O)=O)=CN2)=O)=C2C2=C1C(=O)C(C(=O)O)C=N2 AQTXYBMGOMZMHZ-UHFFFAOYSA-N 0.000 description 1
- IMPPGHMHELILKG-UHFFFAOYSA-N 4-ethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1 IMPPGHMHELILKG-UHFFFAOYSA-N 0.000 description 1
- PUGDHSSOXPHLPT-UHFFFAOYSA-N 4-fluoro-2-nitroaniline Chemical compound NC1=CC=C(F)C=C1[N+]([O-])=O PUGDHSSOXPHLPT-UHFFFAOYSA-N 0.000 description 1
- WSMKQRKHYPJSAN-UHFFFAOYSA-N 4-oxo-3h-1,10-phenanthroline-3,8-dicarboxylic acid Chemical compound OC(=O)C1=CN=C2C(N=CC(C3=O)C(=O)O)=C3C=CC2=C1 WSMKQRKHYPJSAN-UHFFFAOYSA-N 0.000 description 1
- ZUPQDSWVDFWTRP-UHFFFAOYSA-N 5,6-dihydroxy-4-oxo-3H-1,10-phenanthroline-3-carboxylic acid Chemical compound OC(=O)C1C=Nc2c(C1=O)c(O)c(O)c1cccnc21 ZUPQDSWVDFWTRP-UHFFFAOYSA-N 0.000 description 1
- DVLSQHLXPRYYRC-UHFFFAOYSA-N 5-(methoxymethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC=C1C(=O)OC(C)(C)OC1=O DVLSQHLXPRYYRC-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- BLSBIVUBUUSFRD-UHFFFAOYSA-N 5-chloro-4-oxo-3h-1,10-phenanthroline-3-carbonitrile Chemical compound N1=CC(C#N)C(=O)C2=C1C1=NC=CC=C1C=C2Cl BLSBIVUBUUSFRD-UHFFFAOYSA-N 0.000 description 1
- WPDDKXLRHCASIC-UHFFFAOYSA-N 5-hydroxy-3h-1,10-phenanthrolin-4-one Chemical compound N1=CCC(=O)C2=C1C1=NC=CC=C1C=C2O WPDDKXLRHCASIC-UHFFFAOYSA-N 0.000 description 1
- FAEZROSXPWITHO-UHFFFAOYSA-N 5-hydroxy-4-oxo-3h-1,10-phenanthroline-3-carbonitrile Chemical compound N1=CC(C#N)C(=O)C2=C1C1=NC=CC=C1C=C2O FAEZROSXPWITHO-UHFFFAOYSA-N 0.000 description 1
- SFVYEHVTQSQIPT-UHFFFAOYSA-N 6-fluoro-3-nitro-3h-1,10-phenanthrolin-4-one Chemical compound C1=CN=C2C(N=CC(C3=O)[N+](=O)[O-])=C3C=C(F)C2=C1 SFVYEHVTQSQIPT-UHFFFAOYSA-N 0.000 description 1
- SJHOYFOSRHHCBE-UHFFFAOYSA-N 6-fluoro-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C1=CN=C2C(N=CC(C3=O)C(=O)O)=C3C=C(F)C2=C1 SJHOYFOSRHHCBE-UHFFFAOYSA-N 0.000 description 1
- CDAYOSOZMLIJMA-UHFFFAOYSA-N 6-methyl-4,7-dioxo-1,8-dihydro-1,10-phenanthroline-3,8-dicarboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C(NC=C(C(O)=O)C1=O)=C1C=C2C CDAYOSOZMLIJMA-UHFFFAOYSA-N 0.000 description 1
- CYQRJLSHZYWIGL-UHFFFAOYSA-N 7-(dimethylamino)-3h-1,10-phenanthrolin-4-one Chemical compound N1=CCC(=O)C2=CC=C3C(N(C)C)=CC=NC3=C21 CYQRJLSHZYWIGL-UHFFFAOYSA-N 0.000 description 1
- KZWYQTGDBGLCHI-UHFFFAOYSA-N 7-(dimethylamino)-8-[ethyl(methyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N(C)CC)C(N(C)C)=C1C=C2 KZWYQTGDBGLCHI-UHFFFAOYSA-N 0.000 description 1
- SSMORBZFHKHYIM-UHFFFAOYSA-N 7-oxo-8h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CCC(=O)C2=C1C1=NC=C(C(=O)O)C=C1C=C2 SSMORBZFHKHYIM-UHFFFAOYSA-N 0.000 description 1
- COBSHQMYDPSNBB-UHFFFAOYSA-N 8-(4-methylpiperidine-1-carbonyl)-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C1CC(C)CCN1C(=O)C1=CN=C(C2=C(C(=O)C(C(O)=O)C=N2)C=C2)C2=C1 COBSHQMYDPSNBB-UHFFFAOYSA-N 0.000 description 1
- ORWLGQVSJISRBW-UHFFFAOYSA-N 8-(carboxymethoxy)-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(OCC(=O)O)C=C1C=C2 ORWLGQVSJISRBW-UHFFFAOYSA-N 0.000 description 1
- QHNQSLVGHFJBMI-UHFFFAOYSA-N 8-(diethylcarbamoyl)-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N(CC)CC)C=C1C=C2 QHNQSLVGHFJBMI-UHFFFAOYSA-N 0.000 description 1
- ASZNFKWRBVKUMD-UHFFFAOYSA-N 8-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(NC(=O)OC(C)(C)C)C=C1C=C2 ASZNFKWRBVKUMD-UHFFFAOYSA-N 0.000 description 1
- FCHMANVOMMNWAF-UHFFFAOYSA-N 8-[benzyl(methyl)carbamoyl]-4,7-dioxo-3,10-dihydro-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1NC2=C3N=CC(C(O)=O)C(=O)C3=CC=C2C(=O)C=1C(=O)N(C)CC1=CC=CC=C1 FCHMANVOMMNWAF-UHFFFAOYSA-N 0.000 description 1
- MZZCTZYKAQKNPF-UHFFFAOYSA-N 8-[benzyl(methyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1N=C2C=3N=CC(C(O)=O)C(=O)C=3C=CC2=CC=1C(=O)N(C)CC1=CC=CC=C1 MZZCTZYKAQKNPF-UHFFFAOYSA-N 0.000 description 1
- PEESBMUCLUOBAE-UHFFFAOYSA-N 8-[benzyl(propan-2-yl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1N=C2C=3N=CC(C(O)=O)C(=O)C=3C=CC2=CC=1C(=O)N(C(C)C)CC1=CC=CC=C1 PEESBMUCLUOBAE-UHFFFAOYSA-N 0.000 description 1
- MZVLCULPXNBIJI-UHFFFAOYSA-N 8-[butyl(methyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N(C)CCCC)C=C1C=C2 MZVLCULPXNBIJI-UHFFFAOYSA-N 0.000 description 1
- XARPNXCXNWFBPV-UHFFFAOYSA-N 8-[ethyl(propan-2-yl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N(C(C)C)CC)C=C1C=C2 XARPNXCXNWFBPV-UHFFFAOYSA-N 0.000 description 1
- WYNFOFRETSKOOD-UHFFFAOYSA-N 8-[hexyl(methyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N(C)CCCCCC)C=C1C=C2 WYNFOFRETSKOOD-UHFFFAOYSA-N 0.000 description 1
- NZUAHDBVELEEDS-UHFFFAOYSA-N 8-[methyl(2-phenylethyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound C=1N=C2C=3N=CC(C(O)=O)C(=O)C=3C=CC2=CC=1C(=O)N(C)CCC1=CC=CC=C1 NZUAHDBVELEEDS-UHFFFAOYSA-N 0.000 description 1
- HSJXSLQSAXPADQ-UHFFFAOYSA-N 8-[methyl(4,4,5,5,5-pentafluoropentyl)carbamoyl]-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)N(CCCC(F)(F)C(F)(F)F)C)C=C1C=C2 HSJXSLQSAXPADQ-UHFFFAOYSA-N 0.000 description 1
- RWFVOPMRUGGEOT-UHFFFAOYSA-N 8-acetamido-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(NC(=O)C)C=C1C=C2 RWFVOPMRUGGEOT-UHFFFAOYSA-N 0.000 description 1
- MHTYJNRIRNHPLE-UHFFFAOYSA-N 8-acetyl-4,7-dioxo-1,8-dihydro-1,10-phenanthroline-3-carboxylic acid Chemical compound C1=CC(C(C(C(O)=O)=CN2)=O)=C2C2=C1C(=O)C(C(=O)C)C=N2 MHTYJNRIRNHPLE-UHFFFAOYSA-N 0.000 description 1
- YOPNAYNECGBUED-UHFFFAOYSA-N 8-acetyl-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(C(=O)C)C=C1C=C2 YOPNAYNECGBUED-UHFFFAOYSA-N 0.000 description 1
- FEMOOZHKJCHCPW-UHFFFAOYSA-N 8-amino-7-bromo-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(N)C(Br)=C1C=C2 FEMOOZHKJCHCPW-UHFFFAOYSA-N 0.000 description 1
- DZCCKDSGLPQNAB-UHFFFAOYSA-N 8-cyano-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N#CC1=CN=C2C(N=CC(C3=O)C(=O)O)=C3C=CC2=C1 DZCCKDSGLPQNAB-UHFFFAOYSA-N 0.000 description 1
- VLWMAGSNTDYEAV-UHFFFAOYSA-N 8-methoxy-4-oxo-3h-1,10-phenanthroline-3-carboxylic acid Chemical compound N1=CC(C(O)=O)C(=O)C2=C1C1=NC=C(OC)C=C1C=C2 VLWMAGSNTDYEAV-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001264 acyl cyanides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- CWBHKBKGKCDGDM-UHFFFAOYSA-N bis[(2,2,2-trifluoroacetyl)oxy]boranyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OB(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F CWBHKBKGKCDGDM-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- MEZATFJZJWUMIG-UHFFFAOYSA-N diethyl 4,7-dioxo-1,8-dihydro-1,10-phenanthroline-3,8-dicarboxylate Chemical compound C1=CC(C(C(C(=O)OCC)=CN2)=O)=C2C2=C1C(=O)C(C(=O)OCC)C=N2 MEZATFJZJWUMIG-UHFFFAOYSA-N 0.000 description 1
- GUJIIWPVLMWKIQ-UHFFFAOYSA-N diethyl 6-methyl-4,7-dioxo-1,8-dihydro-1,10-phenanthroline-3,8-dicarboxylate Chemical compound CC1=CC(C(C(C(=O)OCC)=CN2)=O)=C2C2=C1C(=O)C(C(=O)OCC)C=N2 GUJIIWPVLMWKIQ-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- PCQWSNPVLGWBGY-UHFFFAOYSA-N dimethyl 6-butyl-4,7-dioxo-1,8-dihydro-1,10-phenanthroline-3,8-dicarboxylate Chemical compound N1=CC(C(=O)OC)C(=O)C2=C1C(NC=C(C(=O)OC)C1=O)=C1C=C2CCCC PCQWSNPVLGWBGY-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- FNASCUBBFNCFQO-UHFFFAOYSA-N ethyl 2-(ethoxymethylidene)-3-oxobutanoate Chemical compound CCOC=C(C(C)=O)C(=O)OCC FNASCUBBFNCFQO-UHFFFAOYSA-N 0.000 description 1
- SKWQOKGQVSOASE-UHFFFAOYSA-N ethyl 5-chloro-4-oxo-3h-1,10-phenanthroline-3-carboxylate Chemical compound ClC1=CC2=CC=CN=C2C2=C1C(=O)C(C(=O)OCC)C=N2 SKWQOKGQVSOASE-UHFFFAOYSA-N 0.000 description 1
- CTVLAAKHSFYPEZ-UHFFFAOYSA-N ethyl 8-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)amino]quinoline-3-carboxylate Chemical compound C=1C=CC2=CC(C(=O)OCC)=CN=C2C=1N=C1C(=O)OC(C)(C)OC1=O CTVLAAKHSFYPEZ-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- YIAPLDFPUUJILH-UHFFFAOYSA-N indan-1-ol Chemical compound C1=CC=C2C(O)CCC2=C1 YIAPLDFPUUJILH-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- MJIVRKPEXXHNJT-UHFFFAOYSA-N lutidinic acid Chemical compound OC(=O)C1=CC=NC(C(O)=O)=C1 MJIVRKPEXXHNJT-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- NKZZYVFQZMHCJQ-UHFFFAOYSA-N methyl 2-(2,2,2-trifluoroethylsulfanyl)acetate Chemical compound COC(=O)CSCC(F)(F)F NKZZYVFQZMHCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- SQRUDRDZMMETRX-UHFFFAOYSA-N n,n-di(butan-2-yl)-8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound N1=CC([N+]([O-])=O)C(=O)C2=C1C1=NC=C(C(=O)N(C(C)CC)C(C)CC)C=C1C=C2 SQRUDRDZMMETRX-UHFFFAOYSA-N 0.000 description 1
- ZOVMSJNRDRXXDY-UHFFFAOYSA-N n-benzyl-6-fluoro-n-methyl-8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound C=1N=C2C=3N=CC([N+]([O-])=O)C(=O)C=3C(F)=CC2=CC=1C(=O)N(C)CC1=CC=CC=C1 ZOVMSJNRDRXXDY-UHFFFAOYSA-N 0.000 description 1
- FZUIQWPDWLJQKB-UHFFFAOYSA-N n-benzyl-n,6-dimethyl-5,8-dinitro-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound C=1N=C2C=3N=CC([N+]([O-])=O)C(=O)C=3C(C)=C([N+]([O-])=O)C2=CC=1C(=O)N(C)CC1=CC=CC=C1 FZUIQWPDWLJQKB-UHFFFAOYSA-N 0.000 description 1
- BUOFKILTAKNDLS-UHFFFAOYSA-N n-butyl-8-cyano-n-ethyl-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound N1=CC(C#N)C(=O)C2=C1C1=NC=C(C(=O)N(CC)CCCC)C=C1C=C2 BUOFKILTAKNDLS-UHFFFAOYSA-N 0.000 description 1
- IUCKBSKEJFSRSX-UHFFFAOYSA-N n-butyl-n-ethyl-8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound N1=CC([N+]([O-])=O)C(=O)C2=C1C1=NC=C(C(=O)N(CC)CCCC)C=C1C=C2 IUCKBSKEJFSRSX-UHFFFAOYSA-N 0.000 description 1
- VMVOSDCFCHSYQO-UHFFFAOYSA-N n-cyclohexyl-n-ethyl-8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound C=1N=C2C=3N=CC([N+]([O-])=O)C(=O)C=3C=CC2=CC=1C(=O)N(CC)C1CCCCC1 VMVOSDCFCHSYQO-UHFFFAOYSA-N 0.000 description 1
- QHCCDDQKNUYGNC-UHFFFAOYSA-N n-ethylbutan-1-amine Chemical compound CCCCNCC QHCCDDQKNUYGNC-UHFFFAOYSA-N 0.000 description 1
- CGNDFLGWRYQJGS-UHFFFAOYSA-N n-hexyl-n-methyl-8-nitro-7-oxo-8h-1,10-phenanthroline-3-carboxamide Chemical compound N1=CC([N+]([O-])=O)C(=O)C2=C1C1=NC=C(C(=O)N(C)CCCCCC)C=C1C=C2 CGNDFLGWRYQJGS-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
Definitions
- the present invention relates to phenanthroline derivatives which inhibit the enzyme prolyl 4-hydroxylase, processes for preparing these compounds and pharmaceutical compositions thereof.
- the present invention also relates to the therapeutical use of such compounds. More specifically, the present invention relates to the use of the phenanthroline derivatives in disorders that are related to the proliferation of fibrotic disorders and/or wherein the regeneration of normal cells, in contrast to fibrotic cells, are indicated.
- disorders known wherein the proliferation of fibrotic tissue is a characteristic feature.
- disorders include, for example, rheumatoid arthritis, chronic arthritis, osteoarthritis, hepatic fibrosis, hepatic cirrhosis, pulmonary fibrosis, renal fibrosis, cardiac fibrosis, arteriosclerosis tumour-associated fibrosis and the formation of scar tissue following injury or surgery.
- Additional examples include disorders related to the over proliferation of connective tissue in such areas systems as the central nervous system.
- a therapeutic agent which possesses anti-fibrotic properties may be of value in the treatment of one or more of these disorders.
- prolyl 4-hydroxylase is involved in the hydroxylation of proline residues in collagenous protein, and that 4-hydroxyproline residues are essential for the formation of the characteristic triple helical form of collagen which is secreted into fibrotic tissue. Consequently, a compound which inhibits the activity of prolyl 4-hydroxylase may be of potential value in the treatment of fibroproliferative disease, which is characterized by excessive collagen production.
- the present invention provides certain phenanthroline derivatives useful for inhibiting prolyl 4-hydroxylase.
- R 1 is hydrogen, carboxy or an ester derivative thereof, cyano, halo, nitro, amino, (1-4C)alkyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, hydroxy-(1-4C)alkyl, carbamoyl, N-(1-4C)alkylcarbamoyl, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, fluoro-(1-4C)alkylthio, fluoro-(1-4C)alkylsulfinyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-
- R 2 is hydrogen, hydroxy, amino, cyano, halo, (1-4C)alkyl, carboxy or an ester derivative thereof, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, (1-4C)alkoxy, carboxy-(1-4C)alkoxy, (1-4C)alkoxycarbonyl-(1-4C)alkoxy, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-[amino-(2-8C)alkyl)carbamoyl, N-[(1-4C)alkylamino-(1-8C)alkyl]carbamoyl, N-[di-(1-4C)alkylamino-(1-8C)alkyl]carbamoyl, N-cyclohexylcar
- R 3 and R 4 which may be the same or different, are hydrogen, (1-4C)alkyl, (2-4C)alkoxy, halo, nitro, hydroxy, fluoro-(1-4C)alkyl or pyridinyl;
- R 4 is methoxy
- R 5 is hydrogen, hydroxy, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, halo, (1-4C)alkoxy-(2-4C)alkoxy, fluoro-(1-6C)alkoxy, pyrrolidin-1-yl, piperidino, piperazin-1-yl or morpholino;
- R 1 may additionally include morpholino-(2-4C)alkoxycarbonyl and R 3 may additionally include methoxy.
- the phenyl groups in the afore-mentioned substituents are optionally substituted with one to four substituents selected from halo, (1-4C)alkoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl.
- the heterocyclic groups pyrrolidin-1-yl, piperidino, piperazin-1-yl and morpholino in the afore-mentioned substituents are optionally substituted in any vacant position with one to four substituents selected from (1-4C)alkyl and benzyl.
- ester derivatives preferably includes metabolically labile ester derivatives.
- alkyl includes both straight and branched chain groups. However, reference to individual groups such as propyl are specific for the straight chain version only.
- (1-4C)alkyl includes, for example, methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl and tert-butyl.
- halo includes, for example, fluoro, chloro, bromo and iodo.
- (1-4C)alkylamino includes methylamino, ethylamino and propyl amino.
- di-[(1-4C)alkyl]amino includes dimethylamino, N-ethyl-N-methyl amino, diethylamino, N-methyl-N-propylamino and dipropyl amino.
- (2-4C)alkanoyl includes acetyl, propionyl and butyryl.
- (1-6C)alkoxycarbonyl includes methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl and pentoxycarbonyl.
- N-[amino-(2-8C)alkyl]carbamoyl includes N-(3-aminopropyl)carbamoyl, N-(6-aminohexyl)carbamoyl and N-(8-aminooctyl)carbamoyl.
- (1-4C)alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.
- hydroxy-(1-4C)alkyl includes hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 3-hydroxypropyl.
- (1-4C)alkylthio includes methylthio, ethylthio and propylthio.
- (1-4C)alkylsulfinyl includes methylsulfinyl, ethylsulfinyl and propylsulfinyl.
- (1-4C)alkylsulfonyl includes methylsulfonyl, ethylsulfonyl and propylsulfonyl.
- fluoro-(1-4C)alkylthio includes trifluoromethylthio, 2,2,2-trifluoroethylthio and 3,3,3-trifluoropropylthio.
- fluoro-(1-4C)alkylsulfinyl includes trifluoromethylsulfinyl, 2,2,2-trifluoroethylsulfinyl and 3,3,3-trifluoropropylsulfinyl.
- fluoro-(1-4C)alkylsulfonyl includes trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl and 3,3,3-trifluoropropylsulfonyl.
- (1-4C)alkoxy-(2-4C)alkoxycarbonyl includes 2-methoxyethoxycarbonyl, 2-ethoxyethoxycarbonyl and 3-methoxypropoxycarbonyl.
- N-(1-4C)alkylcarbamoyl includes N-methylcarbamoyl, N-ethylcarbamoyl and N-butylcarbamoyl.
- N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl includes N,N-dimethylcarbamoylmethoxycarbonyl, N,N-diethylcarbamoylmethoxycarbonyl, 2-(N,N-dimethylcarbamoyl)-ethoxycarbonyl, 2-(N,N-diethylcarbamoyl)-ethoxycarbonyl and 3-(N,N-dimethylcarbamoyl)-propoxycarbonyl.
- (1-4C)alkylamino-(2-4C)alkoxycarbonyl includes 2-(methylamino) ethoxycarbonyl, 2-(ethylamino)ethoxycarbonyl and 3-(methylamino)propylcarbonyl.
- di-(1-4C)alkylamino-(2-4C)alkoxycarbonyl includes 2- (dimethylamino)ethoxycarbonyl, 2-(diethylamino)ethoxycarbonyl, 2-(N-ethyl N- methylamino)ethoxycarbonyl and 3-(dimethylamino)propoxycarbonyl.
- (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl includes 2-(2- methoxyethoxy)ethoxycarbonyl, 2-(2-ethoxyethoxy)ethoxycarbonyl and 3-(2- methoxyethoxy)propoxycarbonyl.
- (2-4)alkanoyloxy-(1-4C)alkyl includes acetoxymethyl, propionyloxymethyl, butyryloxymethyl, 2-acetoxyethyl and 3-acetoxypropyl.
- (2-4C)alkoxy includes ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, sec-butoxy and tert-butoxy.
- carboxy-(1-4C)alkoxy includes carboxymethoxy, 2-carboxyethoxy and 3-carboxypropoxy.
- (1-4C)alkoxycarbonyl-(1-4C)alkoxy includes methoxycarbonylmethoxy, 2-(methoxycarbonyl)ethoxy and 2-(ethoxycarbonyl)ethoxy
- N-(1-8C)alkylcarbamoyl includes N-methylcarbamoyl, N-ethylcarbamoyl, N-butylcarbamoyl, N-hexylcarbamoyl and N-octylcarbamoyl.
- N,N-di-(1-8C)alkylcarbamoyl includes N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N,N-di-sec-butylcarbamoyl, N,N-dibutylcarbamoyl, N-methyl-N-butylcarbamoyl, N-methyl-N-hexylcarbamoyl, N-methyl-N-ethyl carbamoyl, N-ethyl-N-butylcarbamoyl, N-ethyl-N-pentylcarbamoyl, N-ethyl-N-propylcarbamoyl and N-ethyl-N-isopropylcarbamoyl.
- N-(1-4C)alkylamino-(1-8C)alkyl]carbamoyl includes N-[methylaminomethyl]carbamoyl, N-[ethylaminomethyl]carbamoyl, N-[2-methylaminoethyl]carbamoyl, N-[3-methylaminopropyl]carbamoyl, N-[6-methylaminohexyl]carbamoyl and N-[8-methylaminooctyl]carbamoyl.
- N-[di-(1-4C)alkylamino(1-8C)alkyl]carbamoyl includes N-[dimethylaminomethyl]carbamoyl, N-[diethylaminomethyl]carbamoyl, N-[N-methyl-N-ethylaminomethyl]carbamoyl, N-[2-dimethylaminoethyl]carbamoyl, N-[6-dimethylaminohexyl]carbamoyl and N-[8-dimethylaminooctyl]carbamoyl.
- N-(1-4C)alkyl-N-cyclohexylcarbamoyl includes N-methyl-N-cyclohexylcarbamoyl, N-ethyl-N-cyclohexylcarbamoyl and N-propyl-N-cyclohexylcarbamoyl.
- N-(1-4C)alkyl-N-cyclopentylcarbamoyl includes N-methyl-N-cyclopentylcarbamoyl, N-ethyl-N-cyclopentylcarbamoyl and N-propyl-N-cyclopentylcarbamoyl.
- N-(1-4C)alkyl-N-phenylcarbamoyl incudes N-methyl -N-phenylcarbamoyl, N-ethyl-N-phenylcarbamoyl and N-propyl-N-phenylcarbamoyl.
- N-[phenyl-(1-4C)alkyl]carbamoyl includes N-benzylcarbamoyl, N-(2-phenylethyl)carbamoyl and N-(3-phenylpropyl)carbamoyl.
- N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl includes N-methyl-N-benzylcarbamoyl, N-ethyl-N-benzylcarbamoyl, N-isopropyl-N-benzylcarbamoyl, N-methyl-N-(2-phenylethyl)carbamoyl, N-ethyl-N-(2-phenylethyl)carbamoyl and N-methyl-N-(3-phenylpropyl)carbamoyl.
- N,N-di-[phenyl-(1-4)alkyl]carbamoyl includes N,N-dibenzylcarbamoyl, N,N-di-(2-phenylethyl)carbamoyl and N,N-di-(3-phenylpropyl)carbamoyl.
- N-[(2-4C)alkanoyl]carbamoyl includes N-acetylcarbamoyl, N-propionylcarbamoyl and N-butyrylcarbamoyl.
- N-(1-4C)alkoxycarbonyl]carbamoyl includes N-methoxycarbonylcarbamoyl, N-ethoxycarbonylcarbamoyl and N-propoxycarbonylcarbamoyl.
- N-[fluoro-(2-6C)alkyl]carbamoyl includes N-[2,2,2-trifluoroethyl]carbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]carbamoyl and N-[4,4,5,5,5-pentafluoropentyl]carbamoyl.
- N-[fluoro-(2-6C)alkyl]-N-(1-4C)alkylcarbamoyl includes N-[2,2,2-trifluoroethyl]-N-ethylcarbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]-N-methylcarbamoyl and N-[4,4,5,5,5-pentafluoropentyl]-N-methylcarbamoyl.
- N,N-[di-fluoro-(2-6C)alkyl]carbamoyl includes N,N-di-[2,2,3,3,4,4,4-heptafluorobutyl]carbamoyl and N,N-di-[4,4,5,5,5-pentafluoropentyl]carbamoyl.
- N,N-[di-(1-4C)alkyl]thiocarbamoyl includes N,N-dimethylthiocarbamoyl, N,N-diethylthiocarbamoyl and N-methyl-N-ethylthiocarbamoyl.
- N-(2-4C)alkanoylamino includes N-acetylamino-N-propionylamino and N-butyrylamino.
- N-[(1-4C)alkoxycarbonyl]amino includes N-methoxycarbonylamino, N-ethoxycarbonylamino, N-propoxycarbonylamino and N-tert-butoxycarbonylamino.
- fluoro-(1-4C)alkyl includes trifluoromethyl, 2,2,2-trifluoroethyl and 2,2,3,3,4,4,4-heptafluorobutyl.
- pyridinyl includes pyridin-3-yl and pyridin-4-yl.
- (1-4C)alkoxy-(2-4C)alkoxy includes 2-methoxyethoxy, 2-ethoxyethoxy and 3-methoxypropoxy.
- fluoro-(1-6C)alkoxy includes 2,2,2-trifluoroethoxy, 4,4,5,5,5-pentafluoropentoxy and 2,2,3,3,4,4,4-heptafluorobutoxy.
- morpholino-(2-4C)alkoxycarbonyl includes morpholinoethoxycarbonyl.
- novel compounds of the invention include, for example, phenanthroline derivatives of the formula (I), or pharmaceutically-acceptable salts thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, as defined in paragraphs (a) to (m) hereinafter and wherein, unless otherwise stated, each of R 1 , R 2 , R 3 , R 4 and R 5 have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention:
- R 1 is hydrogen, carboxy, cyano, nitro, amino, (1-4C)alkyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, fluoro-(1-4C)alkylsulfinyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkylamino-(2-4C)alkoxycarbonyl, di-(1-4C)alkylamino-(2-4C)alkoxy
- R 1 is hydrogen, carboxy, cyano, halo, nitro, amino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, hydroxy-(1-4C)alkyl, (1-4C)alkylsulfonyl, phenylsulfonyl, N-[amino-(2-8C)alkyl]carbamoyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl or (2-4C)alkanoyloxy-(1-4C)alkyl;
- R 1 is carboxy, cyano, nitro, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, fluoro-(1-4C)alkylsulfonyl or (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl;
- R 2 is hydrogen, hydroxy, amino, cyano, carboxy, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, (1-4C)alkoxy, carboxy-(1-4C)alkoxy, carbamoyl, N-[amino-(2-8C)alkyl]-carbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-(1-4C)alkyl-N-cyclohexylcarbamoyl, N-phenylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N-[phenyl-(1-4C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl, N,N-di-[phenyl-(1-4C)alkyl]carbamoyl,
- R 2 is hydrogen, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-phenylcarbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl, N-[fluoro-(2-6C)alkyl)carbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl, piperazin-1-ylcarbonyl or N,N- [di-(1-4C)alkyl]thiocarbamoyl;
- R 2 is hydrogen, hydroxy, carboxy, carboxy-(1-4C)alkoxy, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-[amino-(2-8C)alkyl)carbamoyl, N-[(1-4C)alkylamino-(1-8C)alkyl)carbamoyl, N-[di- (1-4C)alkylamino-(1-8C)alkyl)carbamoyl, N-[(2-4C)alkanoyl]carbamoyl, piperazin-1-ylcarbonyl, morpholinocarbonyl, N-(2-4C)alkanoylamino or N-[(1-4C)alkoxycarbonyl]amino;
- R 3 and R 4 which may be the same or different, are hydrogen, (1-4C)alkyl, halo, pyridinyl, fluoro-(1-4C)alkyl, nitro or hydroxy;
- R 3 and R 4 which may be the same or different, are hydrogen, (1-4C)alkyl, halo or pyridinyl;
- R 3 and R 4 which may be the same or different, are hydrogen, halo or nitro;
- R 5 is hydrogen, hydroxy, pyrrolidin-1-yl, di-(1-4C)alkylamino, (1-4C)alkylamino, halo, (1-4C)alkoxy-(2-4C)alkoxy or fluoro-(1-6C)alkoxy;
- R 5 is hydrogen, di-(1-4C)alkylamino or halo
- R 5 is hydrogen, hydroxy or piperazin-1-yl
- the phenyl groups in the afore-mentioned substituents in paragraphs (a), (b), (d) and (e) above are optionally substituted with one or two substituents selected from (1-4C)alkoxy, halo, hydroxy and trifluoromethyl; and the pyrrolidin-1-yl, piperidino and piperazin-1-yl groups in the aforementioned substituents in paragraphs (d), (e), (f) and (k) above are optionally substituted with one or two substituents selected from (1-4C)alkyl and benzyl.
- the following additional compounds are excluded from the scope of compounds of formula (I): 3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline; 5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 2); 3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 7); 3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 9); and 3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 15).
- R 1 , R 2 , R 3 , R 4 and R 5 are not together H;
- R 1 is carboxy and R 3 and R 4 are hydroxy; R 2 and R 5 are not together H;
- R 1 is carboxy
- R 2 is H or OH
- R 3 is H and R 5 is H
- R 4 is not H, OH alkoxy, alkyl or halo
- R 1 is carboxy, R 2 is H or OH, R 4 is H and R 5 is H; R 3 is not H, OH alkoxy, alkyl or halo;
- R 1 is ethoxycarbonyl
- R 2 , R 3 , R 4 and R 5 are not together H
- R 1 is ethoxycarbonyl and R 4 is F; R 2 , R 3 and R 5 are not together H
- R 1 is carboxy and R 3 is H or alkyl; R 2 , R 4 and R 5 are not together H;
- R 3 is OH; R 1 , R 2 , R 4 and R 5 are not together H;
- R 5 is OH, R 3 is H or alkyl, and R 4 is H; R 1 and R 2 are not together ethoxycarbonyl, carboxy, methoxycarbonyl or H; and
- R 5 is —N(CH 3 ) 2 ; R 1 , R 2 , R 3 and R 4 are not together H.
- a preferred compound of the invention comprises a phenanthroline derivative of the formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, wherein
- R 1 is hydrogen, carboxy, cyano, nitro, amino, bromo, methoxycarbonyl, ethoxycarbonyl, acetyl, 2,2,2-trifluoroethylsulfonyl, 2-[2-methoxyethoxy]ethoxycarbonyl, 1-hydroxyethyl, carbamoyl, methylsulfonyl, phenylsulfonyl, N-(6-aminohexyl)carbamoyl, 2-methoxyethoxycarbonyl, N,N-diethylcarbamoylmethoxycarbonyl or propionyloxymethyl;
- R 2 is hydrogen, hydroxy, amino, cyano, carboxy, methoxycarbonyl, ethoxycarbonyl, acetyl, carbamoyl, methoxy, carboxymethoxy, N-(6-aminohexyl)carbamoyl, N-ethyl-N-butylcarbamoyl, N,Ndiethylcarbamoyl, N-N di-sec-butylcarbamoyl, N-methyl-N-butylcarbamoyl, N-methyl-N-hexylcarbamoyl, N-ethyl-N-propylcarbamoyl, N-ethyl-N-isopropylcarbamoyl, N-ethyl-N-pentylcarbamoyl, N-ethyl-N-cyclohexylcarbamoyl, N-phenylcarbamoyl, N-e
- R 3 and R 4 which may be the same or different, are hydrogen, fluoro, chloro, bromo, nitro, hydroxy, pyridin-4-yl, trifluoromethyl or methyl;
- R 5 is hydrogen, dimethylamino, diethylamino, chloro, bromo, hydroxy, pyrrolidin-1-yl, methylamino, 2-methoxyethoxy, 2,2,2-trifluoroethoxy or 4,4,5,5,5-pentafluoropentoxy;
- any phenyl group contained in the afore-mentioned R 1 and R 2 substituents are optionally substituted with one or two substituents selected from ethoxy, fluoro and trifluoromethyl;
- any pyrrolidin-1-yl, piperidino or piperazin-1-yl group contained in the afore-mentioned R 2 substituents are optionally substituted with one methyl or benzyl substituent in any vacant position.
- a further preferred compound of the invention comprises a phenanthroline derivative of the formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, wherein
- R 1 is hydrogen, carboxy, cyano, nitro, methyl, ethyl, methoxycarbonyl, ethoxycarbonyl, methylamino, ethylamino, dimethylamino, 2,2,2-trifluoroethylsulfonyl, 2,2,2-trifluoroethylsulfinyl, phenylsulfinyl, phenylsulfonyl, phenylthio, methylthio, methylsulfinyl, methylsulfonyl, 2-[2-methoxyethoxy]ethoxycarbonyl, N-(6-aminohexyl)carbamoyl, 2-methoxyethoxycarbonyl, 2-(methylamino)ethoxycarbonyl, 2-(dimethylamino)ethoxycarbonyl, N,N-diethylcarbamoylmethoxycarbonyl or propionyloxymethyl
- R 2 is hydrogen, hydroxy, carboxy, carbamoyl, carboxymethoxy, N-(6-aminohexyl) carbamoyl, N-ethylcarbamoyl, N-ethyl-N-butylcarbamoyl, N-butylcarbamoyl, N,N-diethylcarbamoyl, N,N-di-sec-butylcarbamoyl, N-methyl-N-butylcarbamoyl, N-methyl-N-hexylcarbamoyl, N-ethyl-N-propylcarbamoyl, N-ethyl-N-isopropylcarbamoyl, N-ethyl-N-pentylcarbamoyl, piperazin-1-ylcarbonyl, N-[methylaminomethyl]carbamoyl, N-[dimethylaminomethyl]carbam
- R 3 and R 4 which may be the same or different, are hydrogen, fluoro, chloro, bromo, methyl or pyridin-4-yl; or R 3 is hydroxy; and
- R 5 is hydrogen, hydroxy or piperazin-1-yl
- any phenyl group contained in the afore-mentioned R 1 and R 2 substituents are optionally substituted with one or two substituents selected from ethoxy, fluoro and trifluoromethyl;
- any piperazin-1-yl group contained in the afore-mentioned R 2 substituents is optionally substituted with one methyl or benzyl substituent in any vacant position.
- a further preferred compound of the invention comprises a phenanthroline derivative of the formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, wherein
- R 1 is carboxy, cyano, nitro, ethoxycarbonyl, acetyl, 2,2,2-trifluoroethylsulfonyl or 2-[2-methoxyethoxy]ethoxycarbonyl;
- R 2 is hydrogen, carboxy, ethoxycarbonyl, carbamoyl, N-ethyl-N-butylcarbamoyl, N-(4-ethoxyphenyl)carbamoyl, N-methyl-N-benzylcarbamoyl, N-methyl-N-4-fluorobenzylcarbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]carbamoyl, 1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl, 4-benzylpiperazin-1-ylcarbonyl or N,N-diethylthiocarbamoyl;
- R 3 and R 4 which may be the same or different, are hydrogen, fluoro or nitro;
- R 5 is hydrogen, dimethylamino or chloro.
- Particularly preferred compounds of the invention include, for example, the following phenanthroline derivatives of the formula (I):
- FIG. 1 illustrates the histological results in the isoproterenol-induced myocardial fibrosis model.
- FIG. 2 illustrates the results of Compound 12, compared to control, in the rat restenosis model.
- FIG. 3 illustrates inhibition of prolyl hydroxylase by Compound 12 in restenosis.
- FIG. 4 illustrates oral treatment of Compound 12 in the brain injured model.
- FIG. 5 illustrates wound area after treatment of Compound 3 in the dermal punch model.
- FIG. 6 illustrates the tensile strength on dermal incisional wound on day 7 after oral treatment of Compound 3 and Compound 12.
- FIG. 7 illustrates the tensile strength of incisional wound after local injections of Compound 12.
- FIG. 8 illustrates certain embodiments of the invention.
- FIG. 9 illustrates certain embodiments of the invention.
- a compound of the invention comprising a phenanthroline derivative of the formula (I) as defined hereinbefore, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, may be prepared by any process known to be applicable to the preparation of structurally-related compounds.
- R 1 , R 2 , R 3 , R 4 and R 5 have any of the meanings defined hereinbefore, provided that, when there is an amino, hydroxy or carboxy group in R 1 , R 2 , R 3 , R 4 and R 5 , any such group may optionally be protected by a conventional protecting group which may be removed when so desired by conventional means.
- a nitrogen heteroatom may also be optionally protected by a conventional protecting group which may be removed when so desired by conventional means.
- a suitable protecting group for an amino group is, for example, an acyl group, for example, an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example, a methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl group, an arylmethoxycarbonyl group, for example, benzyloxycarbonyl, or an aroyl group, for example, benzoyl.
- the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example, lithium or sodium hydroxide.
- a suitable base such as an alkali metal hydroxide, for example, lithium or sodium hydroxide.
- an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris (trifluoroacetate).
- a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid
- an arylmethoxycarbonyl group such as a benzyloxycarbonyl group
- a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example, dimethylaminopropylamine, or with hydrazine.
- a suitable protecting group for a nitrogen heteroatom is, for example, a pivaloyloxymethyl group which may be removed by hydrolysis with a base, for example, sodium hydroxide or ammonia, in a suitable inert solvent or diluent, for example, methanol or ethanol.
- a suitable protecting group for a hydroxy group is, for example, an acyl group, for example, an alkanoyl group such as acetyl, an aroyl group, for example, benzoyl, or an arylmethyl group, for example, benzyl.
- the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example, lithium or sodium hydroxide.
- a suitable base such as an alkali metal hydroxide, for example, lithium or sodium hydroxide.
- an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- a suitable protecting group for a carboxy group is, for example, an esterifying group, for example, a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or, for example, a tert-butyl group which may be removed, for example, by treatment with an acid, for example, an organic acid such as trifluoroacetic acid, or, for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- an esterifying group for example, a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or, for example, a tert-butyl group which may be removed, for example, by treatment with an acid, for example, an organic acid such as trifluoroacetic acid, or, for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst
- R 1 is a (1-4C)alkoxy or a (1-4C)alkyl group
- R 2 is a (1-4C)alkoxycarbonyl, (1-4C)alkylsulfonyl, fluoro-(1-4C)alkylsulfonyl or a sulfonylphenyl group
- R 1 and R 2 are linked, and together with the carbonyl carbon atom to which R 1 is attached, and the carbon atom to which R 2 is attached, define a 1,3-dioxan-4,6-dione ring (with the carbonyl carbon to which R 1 is attached in the 4-position), and which ring is disubstituted in the 2-position by two (1-4C)alkyl groups:
- the reaction is preferably carried out in the presence of a suitable solvent such as ethanol.
- the reaction may also be carried out using neat reagents.
- the reaction is preferably carried out a temperature in the range 10° C. to 100° C., conveniently in the range 75° C. to 80° C.
- the cyclization is preferably carried out in the presence of an ether solvent such as, for example, diphenyl ether.
- the cyclization is preferably carried out at a temperature in the range 180° C. to 270° C., conveniently at, or near, the reflux temperature of the solvent.
- the hydrolysis is preferably carried out in the presence of a suitable acid or base.
- the reaction is also preferably carried out in aqueous solution, and at a temperature in the range 10° C. to 110° C., conveniently in the range 80° C. to 100° C.
- a suitable acid is, for example, a mineral acid such as, for example, hydrochloric acid.
- a suitable base is, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example, sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.
- a suitable nitrating agent is, for example, concentrated nitric acid in acetic anhydride, concentrated nitric acid in glacial acetic acid or a nitrate salt such as, for example, ammonium nitrate in trifluoroacetic acid.
- the reaction is preferably carried out at a temperature in the range 10° C. to 100° C.
- the reaction is preferably carried out in an inert solvent or diluent such as, for example, dichloromethane, acetonitrile or dimethylsulfoxide, and at a temperature in the range 0° C. to 100° C.
- the reaction is also preferably carried out in the presence of a suitable organic amine base such as, for example, triethylamine.
- a suitable reactive derivative of a carboxy substituent borne by a compound of the formula (I) is, for example, an acyl halide, for example, an acyl chloride formed by the reaction of the carboxy substituent and an acid chloride, for example, thionyl chloride or oxalyl chloride; a mixed anhydride, for example, an anhydride formed by the reaction of the carboxy substituent and a chloroformate such as isobutyl chloroformate; an active ester, for example, an ester formed by the reaction of the carboxy substituent and a phenol such as pentafluorophenol, an ester such as pentafluorophenyl trifluoroacetate or an alcohol such as N-hydroxybenzotriazole; an acyl azide, for example, an azide formed by the reaction of the carboxy substituent and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example, a cyanide formed by the reaction of
- the reaction is preferably carried out in an inert solvent or diluent such as, for example, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide, and at a temperature in the range 0° C. to 150° C., conveniently at or near ambient temperature.
- an inert solvent or diluent such as, for example, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide
- the reaction is also preferably carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for example, sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide, sodium hydroxide, potassium hydroxide, sodium hydride or potassium hydride, or an organometallic base such as an alkyl-lithium, for example, n-butyl-lithium, or a dialkylamino-lithium, for example, lithium di-isopropylamide, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo-[5.4.0]undec-7-ene.
- a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride,
- a suitable value for a (1-4C)alkoxy-(2-4C)alkanol is, for example, 2 -methoxyethanol, 2-ethoxyethanol and 3-methoxypropanol.
- a suitable value for a (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkanol is, for example, 2-(2-methoxyethoxy)ethanol, 2-(2-ethoxyethoxy)ethanol and 3-(2-methoxyethoxy)propanol.
- the dehydration is preferably carried out at a temperature in the range 0° C. to 100° C., conveniently at or near ambient temperature.
- a suitable dehydrating agent is, for example, a mixture of trifluoroacetic anhydride and pyridine, phosphorous pentachloride or phosphorous oxychloride.
- phenanthrolinone derivatives of the present invention possess at least one asymmetric carbon atom (for example, when the substituent R 1 is, for example, a 1-hydroxyethyl group) and can therefore exist in racemic and optically active forms. It is to be understood that the present invention encompasses a racemic form of any such phenanthroline derivative of the invention, any optically-active form thereof or a mixture thereof which possesses prolyl 4-hydroxylase inhibitory activity. It is a matter of common general knowledge how such optically-active forms may be obtained by stereospecific synthesis or by the separation of mixtures of isomeric compounds.
- a phenanthroline derivative of the formula (I) may exhibit the phenomenon of tautomerism.
- the 4-oxo-3,4-dihydro-1,10-phenanthroline group may be in the form, for example, of a 4-hydroxy-1,10-phenanthroline group, or in the form, for example, of a 4-oxo-1,4-dihydro-1,10-phenanthroline group.
- the invention encompasses any tautomeric form which possesses prolyl 4-hydroxylase inhibitory activity and is not to be limited merely to any one tautomeric form.
- a suitable pharmaceutically-acceptable salt of a phenanthroline derivative of the invention which is sufficiently basic is an acid-addition salt with, for example, an inorganic or organic acid, for example, hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
- a suitable pharmaceutically-acceptable salt of a phenanthroline derivative of the invention which is sufficiently acidic is an alkali metal salt, for example, a calcium or magnesium salt, an ammonium or tetra-(2-hydroxyethyl) ammonium salt or a salt with organic amines and quaternary bases which afford a physiologically-acceptable cation, for example, a salt with methylamine, dimethylamine, trimethylamine, ethylenediamine, piperidine, morpholine, pyrrolidine, piperazine, lysine, arginine, guanidine, ethanolamine, triethanolamine, N-methylglucamine, tetramethylammonium, hydroxide or benzyltrimethylammonium hydroxide.
- an alkali metal salt for example, a calcium or magnesium salt, an ammonium or tetra-(2-hydroxyethyl) ammonium salt or a salt with organic amines and quaternary bases which afford a physiologically
- a suitable metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group are esters formed with alcohols such as indanol; adamantol; (1-6C)alkanoyloxy-(l-4C)alkanols such as, for example, pivaloyloxymethyl; glycolamides; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl alcohol, (1-4C)alkoxycarbonyl-(1-4C)alkanols such as, for example, 2-(methoxycarbonyl)ethyl alcohol and oxa-(1-8C)alkandiols such as, for example, 3-oxapentan-1,5-diol and 3,6-dioxaoctan-1,8-diol.
- a pharmaceutically-acceptable salt of a compound of the formula (I) when required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure.
- an optically active form of a compound of the formula (I) when required, it may be obtained by carrying out one of the aforesaid processes using an optically active starting material, or by resolution of a racemic form of said compound using a conventional procedure.
- the compounds of the present invention are of potential use in treating fibroproliferative disease, and accordingly the present invention also concerns the use of a compound of the formula (I), including those derivatives hereinbefore excluded from the scope of formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, in the manufacture of a medicament for use in ameliorating fibroproliferative disease.
- the pharmacological activity may be demonstrated using one or more standard test procedures known in the art or as described in the examples.
- a phenanthroline derivative of the present invention may itself be active or it may be a pro-drug which is converted in vivo to an active compound.
- the present invention further provides a pharmaceutical composition comprising one or more phenanthroline derivatives of the formula (I) defined hereinbefore, and in addition those compounds named as excluded hereinbefore, which possess useful pharmacological activity; or a pharmaceutically-acceptable salt or metabolically labile ester thereof.
- the pharmaceutical composition which may be administered to a warm-blooded animal, including a human, comprises one or more phenanthroline derivatives in association with a pharmaceutically-acceptable diluent or carrier.
- a preferred pharmaceutical composition comprises the phenanthroline derivative selected from
- a further preferred pharmaceutical composition comprises the phenanthroline derivative, 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof or a metabolically labile ester derivative of the 3-carboxy substituent, in association with a pharmaceutically-acceptable diluent or carrier.
- the pharmaceutical composition may also comprise a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, a cyclodextrin and optionally a pharmaceutically- acceptable diluent or carrier.
- a suitable cyclodextrin is, for example, ⁇ -cyclodextrin, ⁇ -cyclodextrin or ⁇ -cyclodextrin.
- An alternative suitable cyclodextrin is, for example, a cyclodextrin derivative such as 2-hydroxypropyl- ⁇ -cyclodextrin, an alkylated cyclodextrin or a branched cyclodextrin.
- the cyclodextrin is ⁇ -cyclodextrin.
- the composition may be in a form suitable for oral use, for example, a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example, a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example, a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example, a suppository; for administration by inhalation, for example, as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example, a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example, a sterile aqueous or oily solution, emulsion or suspension.
- parenteral use including intravenous, subcutaneous, intramuscular, intravascular or infusion
- parenteral use including intravenous, subcutaneous, intramuscular, intravascular
- the composition may be a continuous release composition as either a solid or liquid depot formulation, as microparticles or as microparticulate suspensions.
- the above compositions may be prepared in a conventional manner using conventional excipients.
- the pharmaceutical composition may comprise a prodrug of a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions.
- prodrugs include, but are not limited to, metabolically labile ester derivatives of R 1 and R 2 when either, or both, is a carboxy group; other substituents, for example, hydroxy groups, may provide suitable positions for the formation of prodrugs.
- the preparation of suitable prodrugs is within the ordinary skill of a worker in the pharmaceutical sciences.
- the present invention concerns the use of a compound of the present invention, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, in combatting fibroproliferative disease.
- Other agents are currently known to possess activity against one or more fibroproliferative diseases.
- NSAIA cyclooxygenase inhibitory non-steroidal anti-inflammatory agents
- indomethacin such as indomethacin, acetylsalicyclic acid, ibuprofen, sulindac, tolmetin and piroxicam
- anti-inflammatory steroidal agents such as corticosteroidal agents, for example, beclomethasone dipropionate, betamethasone valerate, prednisolone or triamcinolone are used in the treatment of rheumatoid arthritis.
- Co-administration of a prolyl 4-hydroxylase inhibitor of the present invention with a NSAIA or a steroid derivative as defined hereinbefore can result in a reduction of the dose of the latter agents which is needed to produce a therapeutic effect.
- a pharmaceutical composition which comprises a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, as defined hereinbefore, in conjunction or admixture with a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent or an anti-inflammatory steroidal agent, and a pharmaceutically-acceptable diluent or carrier.
- certain agents are beneficial in the treatment of liver fibrosis, for example, certain alkaloids such as colchicine and ⁇ -adrenergic receptor blocking agents such as propranolol, atenolol, labetolol and metoprolol may be beneficial.
- Co-administration of a 4-prolyl hydroxylase inhibitor of the present invention with colchicine or a ⁇ -adrenergic receptor blocking agent can result in an improved therapeutic effect.
- a pharmaceutical composition which comprises a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, as defined hereinbefore, in conjunction or admixture with colchicine or a ⁇ -adrenergic receptor blocking agent, and a pharmaceutically-acceptable diluent or carrier.
- the phenanthroline derivative will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 1-100 mg/kg, and this normally provides a therapeutically-effective dose.
- the dose will preferably be 100-3500 mg/dose and more preferably 250-1250 mg/dose, administered 2-3 times daily.
- the daily dose will preferably be 3-150 mg/kg/day and more preferably 7-55 mg/kg/day.
- a unit dose form such as a tablet or capsule will usually contain, for example, 1-1000 mg of active ingredient whereas a capsule will usually contain 1-500 mg of active ingredient.
- the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- a method for producing an anti-fibroproliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group.
- a method for producing an anti-fibroproliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of the phenanthroline derivative selected from
- a method for producing an anti-fibroproliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of the phenanthroline derivative 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline or a pharmaceutically-acceptable salt thereof, or metabolically labile ester derivative of the 3-carboxy substituent.
- the invention also provides the use of a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group, in the manufacture of a novel medicament for use in the production of an anti-fibroproliferative effect in a warm blooded animal, such as man.
- a method for regenerating cells by producing an anti-fibroproliferative effect in a host, such a man, in need of such treatment which comprises administering to said host an effective amount of one or more phenanthroline derivatives of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions.
- a phenanthroline derivative and a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R 1 and R 2 when either, or both, is a carboxy group is selected from:
- the phenanthroline derivative is 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline and compositions thereof.
- a phenanthroline derivative of formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions preferably selected from:
- phenanthroline derivative 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of the 3-carboxy substituent in the manufacture of a novel medicament for use in the production of an anti-fibroproliferative (for example for treating the formation of scar tissue following injury or surgery) effect in a warm blooded animal, such as man.
- melting points were determined using a Mettler SP62 automatic melting point apparatus, a Koffler hot plate apparatus or an oil-bath apparatus;
- Trifluoroacetic anhydride (0.5 ml) was added dropwise to a stirred, ice-cooled mixture of 8-(N-benzyl-N-methylcarbamoyl)-3-carbamoyl-4-chloro-5-fluoro-1,10-phenanthroline (0.3 g) in pyridine (3 ml). The mixture was stirred at ambient temperature for 1 hour. The mixture was acidified with 3M hydrochloric acid and stirred at ambient temperature for 18 hours.
- proline and 4-hydroxyproline residues were separated by column chromatography on a reversed-phase Spherisorb S5ODS1 column using as eluent a 89.9:10:0.1 v/v mixture of water:isopropanol:trifluoroacetic acid to which 0.3% w/v of sodium dodecylsulphate had been added.
- the ratio of radioactivity found in each of the proline and 4-hydroxyproline fractions was determined by liquid scintillation counting to allow the measurement of the inhibition of hydroxylation by a test compound.
- the compound described in Example 2 has an IC 50 of 0.4 ⁇ M in test (a), an IC 50 of 1.2 ⁇ M in test (b), an IC 50 of 5.4 ⁇ M in test (c) and an inhibition of 46% at 50 mg/kg orally (compound dosed 2 hours before proline administration) in test (d).
- a cardiac fibrosis model in rats as generally described in Kondo et al., Cardiovascu. Res. 21:248-254 (1987), and Benjamin et al., Circulation Res. 65(3):657-670 (1989), may be used to measure the effectiveness of the compounds of the present invention to inhibit cardiac fibrosis, as well as provide evidence of the regeneration of cardiac cells upon inhibition of fibrotic cell proliferation.
- the left carotid artery injury model as described generally in Clowes et al., Lab Invest.
- the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
- the tablets (a)-(c) may be enteric coated by conventional means, for example, to provide a coating of cellulose acetate phthalate.
- the aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.
- the compound was administered after suspension in 1% CMC at 50 mg/kg by oral gavage twice daily from day 4 to day 11 and histological data was evaluated on day 11 by general histology (H&E and trichrome) and immunohistochemical staining for proliferating cell nuclear antigen (PCNA).
- Cardiac function left ventricular function was measured by inserting a catheter into the left ventricle for measurement of relaxation and contraction pressure on week 6.
- FIG. 1 The histological results of this test are set forth in FIG. 1. As set forth in FIG. 1, blocking collagen deposition appears to block cardiac fibrosis. As further evidenced by FIG. 1, blocking collagen deposition also appears to permit the regeneration of healthy cardiac cells.
- the effectiveness of Compound 12 in vascular remodeling was determined by using a left carotid artery injury rat model, as generally described above. More specifically, a total of 20 male SD rats (weighing between 250-300 g) were used. Under general anesthesia, the rat right common carotid artery and region of bifurcation were exposed through a midline incision. A 2F Fogarty balloon catheter (Baxter) was introduced through the external carotid artery and advanced into the thoracic aorta. The balloon was inflated with 0.3 ml or air to distend the common carotid artery.
- kidney fibrosis rat model As generally described above. More specifically, male SD rats weighing approximately 200-225 g each were injected intravenously with Adriamycin (Pharmacia, MI) on day 1 and again on day 15. The Adriamycin was dissolved in 0.5 ml sterile physiologic saline and infused slowly into the tail vein to ensure complete delivery and to avoid perivascular tissue destruction of the drug.
- Adriamycin Pharmacia, MI
Abstract
wherein, for example, R1 is hydrogen, carboxy, cyano, nitro, (1-4C)alkyl, (1-6C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkanoyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl or N-[amino-(2-8C)alkyl]carbamoyl;
R2 is, for example, hydrogen, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl or N,N-[di-(l -4C)alkyl]thiocarbamoyl;
R3 and R4, which may be the same or different, are, for example, hydrogen or halo; and
R5 is, for example, hydrogen, di-(1-4C)alkylamino or halo; or a pharmaceutically-acceptable salt thereof.
The invention further provides pharmaceutical compositions comprising phenanthroline derivatives, processes for making the same and their use in producing an anti-fibroproliferative effect.
Description
- 1. This application is a continuation-in-part of U.S. Ser. No. 09/179,542 filed Oct. 26, 1998, which is a continuation-in-part of U.S. Ser. No. 08/957,450 filed on Oct. 24, 1997.
- 2. The present invention relates to phenanthroline derivatives which inhibit the enzyme prolyl 4-hydroxylase, processes for preparing these compounds and pharmaceutical compositions thereof. The present invention also relates to the therapeutical use of such compounds. More specifically, the present invention relates to the use of the phenanthroline derivatives in disorders that are related to the proliferation of fibrotic disorders and/or wherein the regeneration of normal cells, in contrast to fibrotic cells, are indicated.
- 3. There are many disorders known wherein the proliferation of fibrotic tissue is a characteristic feature. Examples of such disorders include, for example, rheumatoid arthritis, chronic arthritis, osteoarthritis, hepatic fibrosis, hepatic cirrhosis, pulmonary fibrosis, renal fibrosis, cardiac fibrosis, arteriosclerosis tumour-associated fibrosis and the formation of scar tissue following injury or surgery. Additional examples include disorders related to the over proliferation of connective tissue in such areas systems as the central nervous system. Thus, a therapeutic agent which possesses anti-fibrotic properties may be of value in the treatment of one or more of these disorders.
- 4. It is known that the enzyme prolyl 4-hydroxylase is involved in the hydroxylation of proline residues in collagenous protein, and that 4-hydroxyproline residues are essential for the formation of the characteristic triple helical form of collagen which is secreted into fibrotic tissue. Consequently, a compound which inhibits the activity of prolyl 4-hydroxylase may be of potential value in the treatment of fibroproliferative disease, which is characterized by excessive collagen production.
- 5. Various chemical compounds have been reported to inhibit prolyl 4-hydroxylase; for example, 2,2′-dipyridyl (W. Muller et al., FEBS Letters, 90:218 (1978)), pyridine-2,4-dicarboxylic acid (K. Majamaa et al., Eur. J. Biochem., 138:239 (1984)), pyridine-2,4-dicarboxlic acid derivatives and pyridine-2,5-dicarboxylic acid deivatives (European Patent Application Nos. 278452, 278453, 278454 and 281943) and heterocyclic carbonylglycines (T. J. Franklin et al., Biochem. Soc. Trans., 19:812-815 (1991)). However, to the extent that these compounds have not been tested in in vivo systems, whether these compounds may be useful in modulating collagen production or permitting the regeneration of cells whose growth or propagation are otherwise inhibited by the presence of collagen overproduction has not been previously determined.
- 6. Despite previous efforts, a need exists for safe and effective means for the treatment of fibroproliferative diseases and disorders.
- 7. The present invention provides certain phenanthroline derivatives useful for inhibiting prolyl 4-hydroxylase.
-
- 9. wherein
- 10. R1 is hydrogen, carboxy or an ester derivative thereof, cyano, halo, nitro, amino, (1-4C)alkyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, hydroxy-(1-4C)alkyl, carbamoyl, N-(1-4C)alkylcarbamoyl, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, fluoro-(1-4C)alkylthio, fluoro-(1-4C)alkylsulfinyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkylamino-(2-4C)alkoxycarbonyl, di-(1-4C)alkylamino-(2-4C)alkoxycarbonyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl, (2-4C)alkanoyloxy-(1-4C)alkyl or N-[amino-(2-8C)alkyl]carbamoyl;
- 11. R2 is hydrogen, hydroxy, amino, cyano, halo, (1-4C)alkyl, carboxy or an ester derivative thereof, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, (1-4C)alkoxy, carboxy-(1-4C)alkoxy, (1-4C)alkoxycarbonyl-(1-4C)alkoxy, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-[amino-(2-8C)alkyl)carbamoyl, N-[(1-4C)alkylamino-(1-8C)alkyl]carbamoyl, N-[di-(1-4C)alkylamino-(1-8C)alkyl]carbamoyl, N-cyclohexylcarbamoyl, N-[cyclopentyl]carbamoyl, N-phenylcarbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl, N-(1-4C)alkylcyclopentylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N,N-diphenylcarbamoyl, N-[phenyl-(1-4C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl)carbamoyl, N,N-di-[phenyl-(1-4C)alkyl)carbamoyl, N-[(2-4C)alkanoyl]carbamoyl, N-[(1-4C)alkoxycarbonyl]carbamoyl, N-[fluoro-(2-6C)alkylcarbamoyl, N-[fluoro-(2-6C)alkyl]-N-(1-4C)alkylcarbamoyl, N,N-[di-fluoro-(2-6C)alkyl]carbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl, morpholinocarbonyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl, N,N-[di-(1-4C)alkyl]thiocarbamoyl, N-(2-4C)alkanoylamino or N-[(1-4)alkoxycarbonyl]amino;
- 12. R3 and R4, which may be the same or different, are hydrogen, (1-4C)alkyl, (2-4C)alkoxy, halo, nitro, hydroxy, fluoro-(1-4C)alkyl or pyridinyl;
- 13. or R4 is methoxy; and
- 14. R5 is hydrogen, hydroxy, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, halo, (1-4C)alkoxy-(2-4C)alkoxy, fluoro-(1-6C)alkoxy, pyrrolidin-1-yl, piperidino, piperazin-1-yl or morpholino;
- 15. or a pharmaceutically-acceptable salt thereof.
- 16. As a further feature R1 may additionally include morpholino-(2-4C)alkoxycarbonyl and R3 may additionally include methoxy.
- 17. It will be understood that the phenyl groups in the afore-mentioned substituents are optionally substituted with one to four substituents selected from halo, (1-4C)alkoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl. It will also be understood that the heterocyclic groups pyrrolidin-1-yl, piperidino, piperazin-1-yl and morpholino in the afore-mentioned substituents are optionally substituted in any vacant position with one to four substituents selected from (1-4C)alkyl and benzyl.
- 18. As used herein, the “ester derivatives” preferably includes metabolically labile ester derivatives.
- 19. As used herein, the term “alkyl” includes both straight and branched chain groups. However, reference to individual groups such as propyl are specific for the straight chain version only. The term “(1-4C)alkyl” includes, for example, methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl and tert-butyl.
- 20. As used herein, the term “halo” includes, for example, fluoro, chloro, bromo and iodo.
- 21. The term (1-4C)alkylamino includes methylamino, ethylamino and propyl amino.
- 22. The term di-[(1-4C)alkyl]amino includes dimethylamino, N-ethyl-N-methyl amino, diethylamino, N-methyl-N-propylamino and dipropyl amino.
- 23. The term (2-4C)alkanoyl includes acetyl, propionyl and butyryl.
- 24. The term (1-6C)alkoxycarbonyl includes methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl and pentoxycarbonyl.
- 25. The term N-[amino-(2-8C)alkyl]carbamoyl includes N-(3-aminopropyl)carbamoyl, N-(6-aminohexyl)carbamoyl and N-(8-aminooctyl)carbamoyl.
- 26. The term (1-4C)alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.
- 27. The term hydroxy-(1-4C)alkyl includes hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 3-hydroxypropyl.
- 28. The term (1-4C)alkylthio includes methylthio, ethylthio and propylthio.
- 29. The term (1-4C)alkylsulfinyl includes methylsulfinyl, ethylsulfinyl and propylsulfinyl.
- 30. The term (1-4C)alkylsulfonyl includes methylsulfonyl, ethylsulfonyl and propylsulfonyl.
- 31. The term fluoro-(1-4C)alkylthio includes trifluoromethylthio, 2,2,2-trifluoroethylthio and 3,3,3-trifluoropropylthio.
- 32. The term fluoro-(1-4C)alkylsulfinyl includes trifluoromethylsulfinyl, 2,2,2-trifluoroethylsulfinyl and 3,3,3-trifluoropropylsulfinyl.
- 33. The term fluoro-(1-4C)alkylsulfonyl includes trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl and 3,3,3-trifluoropropylsulfonyl.
- 34. The term (1-4C)alkoxy-(2-4C)alkoxycarbonyl includes 2-methoxyethoxycarbonyl, 2-ethoxyethoxycarbonyl and 3-methoxypropoxycarbonyl.
- 35. The term N-(1-4C)alkylcarbamoyl includes N-methylcarbamoyl, N-ethylcarbamoyl and N-butylcarbamoyl.
- 36. The term N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl includes N,N-dimethylcarbamoylmethoxycarbonyl, N,N-diethylcarbamoylmethoxycarbonyl, 2-(N,N-dimethylcarbamoyl)-ethoxycarbonyl, 2-(N,N-diethylcarbamoyl)-ethoxycarbonyl and 3-(N,N-dimethylcarbamoyl)-propoxycarbonyl.
- 37. The term (1-4C)alkylamino-(2-4C)alkoxycarbonyl includes 2-(methylamino) ethoxycarbonyl, 2-(ethylamino)ethoxycarbonyl and 3-(methylamino)propylcarbonyl.
- 38. The term di-(1-4C)alkylamino-(2-4C)alkoxycarbonyl includes 2- (dimethylamino)ethoxycarbonyl, 2-(diethylamino)ethoxycarbonyl, 2-(N-ethyl N- methylamino)ethoxycarbonyl and 3-(dimethylamino)propoxycarbonyl.
- 39. The term (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl includes 2-(2- methoxyethoxy)ethoxycarbonyl, 2-(2-ethoxyethoxy)ethoxycarbonyl and 3-(2- methoxyethoxy)propoxycarbonyl.
- 40. The term (2-4)alkanoyloxy-(1-4C)alkyl includes acetoxymethyl, propionyloxymethyl, butyryloxymethyl, 2-acetoxyethyl and 3-acetoxypropyl.
- 41. The term (2-4C)alkoxy includes ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, sec-butoxy and tert-butoxy.
- 42. The term carboxy-(1-4C)alkoxy includes carboxymethoxy, 2-carboxyethoxy and 3-carboxypropoxy.
- 43. The term (1-4C)alkoxycarbonyl-(1-4C)alkoxy includes methoxycarbonylmethoxy, 2-(methoxycarbonyl)ethoxy and 2-(ethoxycarbonyl)ethoxy
- 44. The term N-(1-8C)alkylcarbamoyl includes N-methylcarbamoyl, N-ethylcarbamoyl, N-butylcarbamoyl, N-hexylcarbamoyl and N-octylcarbamoyl.
- 45. The term N,N-di-(1-8C)alkylcarbamoyl includes N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N,N-di-sec-butylcarbamoyl, N,N-dibutylcarbamoyl, N-methyl-N-butylcarbamoyl, N-methyl-N-hexylcarbamoyl, N-methyl-N-ethyl carbamoyl, N-ethyl-N-butylcarbamoyl, N-ethyl-N-pentylcarbamoyl, N-ethyl-N-propylcarbamoyl and N-ethyl-N-isopropylcarbamoyl.
- 46. The term N-(1-4C)alkylamino-(1-8C)alkyl]carbamoyl includes N-[methylaminomethyl]carbamoyl, N-[ethylaminomethyl]carbamoyl, N-[2-methylaminoethyl]carbamoyl, N-[3-methylaminopropyl]carbamoyl, N-[6-methylaminohexyl]carbamoyl and N-[8-methylaminooctyl]carbamoyl.
- 47. The term N-[di-(1-4C)alkylamino(1-8C)alkyl]carbamoyl includes N-[dimethylaminomethyl]carbamoyl, N-[diethylaminomethyl]carbamoyl, N-[N-methyl-N-ethylaminomethyl]carbamoyl, N-[2-dimethylaminoethyl]carbamoyl, N-[6-dimethylaminohexyl]carbamoyl and N-[8-dimethylaminooctyl]carbamoyl.
- 48. The term N-(1-4C)alkyl-N-cyclohexylcarbamoyl includes N-methyl-N-cyclohexylcarbamoyl, N-ethyl-N-cyclohexylcarbamoyl and N-propyl-N-cyclohexylcarbamoyl.
- 49. The term N-(1-4C)alkyl-N-cyclopentylcarbamoyl includes N-methyl-N-cyclopentylcarbamoyl, N-ethyl-N-cyclopentylcarbamoyl and N-propyl-N-cyclopentylcarbamoyl.
- 50. The term N-(1-4C)alkyl-N-phenylcarbamoyl incudes N-methyl -N-phenylcarbamoyl, N-ethyl-N-phenylcarbamoyl and N-propyl-N-phenylcarbamoyl.
- 51. The term N-[phenyl-(1-4C)alkyl]carbamoyl includes N-benzylcarbamoyl, N-(2-phenylethyl)carbamoyl and N-(3-phenylpropyl)carbamoyl.
- 52. The term N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl includes N-methyl-N-benzylcarbamoyl, N-ethyl-N-benzylcarbamoyl, N-isopropyl-N-benzylcarbamoyl, N-methyl-N-(2-phenylethyl)carbamoyl, N-ethyl-N-(2-phenylethyl)carbamoyl and N-methyl-N-(3-phenylpropyl)carbamoyl.
- 53. The term N,N-di-[phenyl-(1-4)alkyl]carbamoyl includes N,N-dibenzylcarbamoyl, N,N-di-(2-phenylethyl)carbamoyl and N,N-di-(3-phenylpropyl)carbamoyl.
- 54. The term N-[(2-4C)alkanoyl]carbamoyl includes N-acetylcarbamoyl, N-propionylcarbamoyl and N-butyrylcarbamoyl.
- 55. The term N-(1-4C)alkoxycarbonyl]carbamoyl includes N-methoxycarbonylcarbamoyl, N-ethoxycarbonylcarbamoyl and N-propoxycarbonylcarbamoyl.
- 56. The term N-[fluoro-(2-6C)alkyl]carbamoyl includes N-[2,2,2-trifluoroethyl]carbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]carbamoyl and N-[4,4,5,5,5-pentafluoropentyl]carbamoyl.
- 57. The term N-[fluoro-(2-6C)alkyl]-N-(1-4C)alkylcarbamoyl includes N-[2,2,2-trifluoroethyl]-N-ethylcarbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]-N-methylcarbamoyl and N-[4,4,5,5,5-pentafluoropentyl]-N-methylcarbamoyl.
- 58. The term N,N-[di-fluoro-(2-6C)alkyl]carbamoyl includes N,N-di-[2,2,3,3,4,4,4-heptafluorobutyl]carbamoyl and N,N-di-[4,4,5,5,5-pentafluoropentyl]carbamoyl.
- 59. The term N,N-[di-(1-4C)alkyl]thiocarbamoyl includes N,N-dimethylthiocarbamoyl, N,N-diethylthiocarbamoyl and N-methyl-N-ethylthiocarbamoyl.
- 60. The term N-(2-4C)alkanoylamino includes N-acetylamino-N-propionylamino and N-butyrylamino.
- 61. The term N-[(1-4C)alkoxycarbonyl]amino includes N-methoxycarbonylamino, N-ethoxycarbonylamino, N-propoxycarbonylamino and N-tert-butoxycarbonylamino.
- 62. The term fluoro-(1-4C)alkyl includes trifluoromethyl, 2,2,2-trifluoroethyl and 2,2,3,3,4,4,4-heptafluorobutyl.
- 63. The term pyridinyl includes pyridin-3-yl and pyridin-4-yl.
- 64. The term (1-4C)alkoxy-(2-4C)alkoxy includes 2-methoxyethoxy, 2-ethoxyethoxy and 3-methoxypropoxy.
- 65. The term fluoro-(1-6C)alkoxy includes 2,2,2-trifluoroethoxy, 4,4,5,5,5-pentafluoropentoxy and 2,2,3,3,4,4,4-heptafluorobutoxy.
- 66. The term morpholino-(2-4C)alkoxycarbonyl includes morpholinoethoxycarbonyl.
- 67. Particular novel compounds of the invention include, for example, phenanthroline derivatives of the formula (I), or pharmaceutically-acceptable salts thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, as defined in paragraphs (a) to (m) hereinafter and wherein, unless otherwise stated, each of R1, R2, R3, R4 and R5 have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention:
- 68. (a) R1 is hydrogen, carboxy, cyano, nitro, amino, (1-4C)alkyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, fluoro-(1-4C)alkylsulfinyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkylamino-(2-4C)alkoxycarbonyl, di-(1-4C)alkylamino-(2-4C)alkoxycarbonyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl, (2-4C)alkanoyloxy-(1-4C)alkyl or N-[amino-(2-8C)alkyl]carbamoyl;
- 69. (b) R1 is hydrogen, carboxy, cyano, halo, nitro, amino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, hydroxy-(1-4C)alkyl, (1-4C)alkylsulfonyl, phenylsulfonyl, N-[amino-(2-8C)alkyl]carbamoyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl or (2-4C)alkanoyloxy-(1-4C)alkyl;
- 70. (c) R1 is carboxy, cyano, nitro, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, fluoro-(1-4C)alkylsulfonyl or (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl;
- 71. (d) R2 is hydrogen, hydroxy, amino, cyano, carboxy, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, (1-4C)alkoxy, carboxy-(1-4C)alkoxy, carbamoyl, N-[amino-(2-8C)alkyl]-carbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-(1-4C)alkyl-N-cyclohexylcarbamoyl, N-phenylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N-[phenyl-(1-4C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl, N,N-di-[phenyl-(1-4C)alkyl]carbamoyl, N-[(2-4C)alkanoyl]carbamoyl, N-[fluoro-(2-6C)alkyl]carbamoyl, N-[fluoro-(2-6C)alkyl)-N-(1-4C)alkylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl, 1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl, N-(2-4C)alkanoylamino, N-[di-(1-4C)alkoxycarbonyl]amino or N,N-[di-(1-4C)alkyl]thiocarbamoyl;
- 72. (e) R2 is hydrogen, carboxy, (1-6C)alkoxycarbonyl, carbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-phenylcarbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl, N-[fluoro-(2-6C)alkyl)carbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl, piperazin-1-ylcarbonyl or N,N- [di-(1-4C)alkyl]thiocarbamoyl;
- 73. (f) R2 is hydrogen, hydroxy, carboxy, carboxy-(1-4C)alkoxy, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-[amino-(2-8C)alkyl)carbamoyl, N-[(1-4C)alkylamino-(1-8C)alkyl)carbamoyl, N-[di- (1-4C)alkylamino-(1-8C)alkyl)carbamoyl, N-[(2-4C)alkanoyl]carbamoyl, piperazin-1-ylcarbonyl, morpholinocarbonyl, N-(2-4C)alkanoylamino or N-[(1-4C)alkoxycarbonyl]amino;
- 74. (g) R3 and R4, which may be the same or different, are hydrogen, (1-4C)alkyl, halo, pyridinyl, fluoro-(1-4C)alkyl, nitro or hydroxy;
- 75. (h) R3 and R4, which may be the same or different, are hydrogen, (1-4C)alkyl, halo or pyridinyl;
- 76. (i) R3 and R4, which may be the same or different, are hydrogen, halo or nitro;
- 77. (j) R3 is hydroxy;
- 78. (k) R5 is hydrogen, hydroxy, pyrrolidin-1-yl, di-(1-4C)alkylamino, (1-4C)alkylamino, halo, (1-4C)alkoxy-(2-4C)alkoxy or fluoro-(1-6C)alkoxy;
- 79. (l) R5 is hydrogen, di-(1-4C)alkylamino or halo; and
- 80. (m) R5 is hydrogen, hydroxy or piperazin-1-yl;
- 81. The phenyl groups in the afore-mentioned substituents in paragraphs (a), (b), (d) and (e) above are optionally substituted with one or two substituents selected from (1-4C)alkoxy, halo, hydroxy and trifluoromethyl; and the pyrrolidin-1-yl, piperidino and piperazin-1-yl groups in the aforementioned substituents in paragraphs (d), (e), (f) and (k) above are optionally substituted with one or two substituents selected from (1-4C)alkyl and benzyl.
- 82. It will be understood that the following compounds are excluded from the scope of compounds of formula (I): 3-carboxy-5,6-dihydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline; 3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline; 3, 8-diethoxycarbonyl-7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline; 3,8-dicarboxy-7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline; 3,8-diethoxycarbonyl-7-hydroxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline; 3,8-dicarboxy-7-hydroxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline; 5-butyl-3,8-dimethoxycarbonyl-7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline; 3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline; 7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline; 7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline hydrochloride; 4-oxo-3,4-dihydro-1,10-phenanthroline; 7-dimethylamino-4-oxo-3,4-dihydro-1,10-phenanthroline; 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 12); and 5-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline. Preferably, the following additional compounds are excluded from the scope of compounds of formula (I): 3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline; 5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 2); 3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 7); 3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 9); and 3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 15).
- 83. Thus, compounds per se preferably not within the scope of the claimed invention include compounds of formula (I) where
- 84. R1, R2, R3, R4 and R5 are not together H;
- 85. where R1 is carboxy and R3 and R4 are hydroxy; R2 and R5 are not together H;
- 86. where R1 is carboxy, R2 is H or OH, R3 is H and R5 is H; R4 is not H, OH alkoxy, alkyl or halo;
- 87. where R1 is carboxy, R2 is H or OH, R4 is H and R5 is H; R3 is not H, OH alkoxy, alkyl or halo;
- 88. where R1 is ethoxycarbonyl; R2, R3, R4 and R5 are not together H;
- 89. where R1 is ethoxycarbonyl and R4 is F; R2, R3 and R5 are not together H
- 90. where R1 is carboxy and R3 is H or alkyl; R2, R4 and R5 are not together H;
- 91. where R3 is OH; R1, R2, R4 and R5 are not together H;
- 92. where R5 is OH, R3 is H or alkyl, and R4 is H; R1 and R2 are not together ethoxycarbonyl, carboxy, methoxycarbonyl or H; and
- 93. where R5 is —N(CH3)2; R1, R2, R3 and R4 are not together H.
- 94. A preferred compound of the invention comprises a phenanthroline derivative of the formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, wherein
- 95. R1 is hydrogen, carboxy, cyano, nitro, amino, bromo, methoxycarbonyl, ethoxycarbonyl, acetyl, 2,2,2-trifluoroethylsulfonyl, 2-[2-methoxyethoxy]ethoxycarbonyl, 1-hydroxyethyl, carbamoyl, methylsulfonyl, phenylsulfonyl, N-(6-aminohexyl)carbamoyl, 2-methoxyethoxycarbonyl, N,N-diethylcarbamoylmethoxycarbonyl or propionyloxymethyl;
- 96. R2 is hydrogen, hydroxy, amino, cyano, carboxy, methoxycarbonyl, ethoxycarbonyl, acetyl, carbamoyl, methoxy, carboxymethoxy, N-(6-aminohexyl)carbamoyl, N-ethyl-N-butylcarbamoyl, N,Ndiethylcarbamoyl, N-N di-sec-butylcarbamoyl, N-methyl-N-butylcarbamoyl, N-methyl-N-hexylcarbamoyl, N-ethyl-N-propylcarbamoyl, N-ethyl-N-isopropylcarbamoyl, N-ethyl-N-pentylcarbamoyl, N-ethyl-N-cyclohexylcarbamoyl, N-phenylcarbamoyl, N-methyl-N-phenylcarbamoyl, N-(2-phenylethyl)carbamoyl, N-methyl-N-benzylcarbamoyl, N-methyl-N-(2-phenylethyl)carbamoyl, N-isopropyl-N-benzylcarbamoyl, N-ethyl-N-benzylcarbamoyl, N,N-dibenzylcarbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]carbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]-N-methylcarbamoyl, N-[4,4,5,5,5-pentafluoropentyl]-N-methylcarbamoyl, 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl, N,N-diethylthiocarbamoyl, N-acetylamino or N-tert-butoxycarbonylamino;
- 97. R3 and R4, which may be the same or different, are hydrogen, fluoro, chloro, bromo, nitro, hydroxy, pyridin-4-yl, trifluoromethyl or methyl; and
- 98. R5 is hydrogen, dimethylamino, diethylamino, chloro, bromo, hydroxy, pyrrolidin-1-yl, methylamino, 2-methoxyethoxy, 2,2,2-trifluoroethoxy or 4,4,5,5,5-pentafluoropentoxy;
- 99. wherein any phenyl group contained in the afore-mentioned R1 and R2 substituents are optionally substituted with one or two substituents selected from ethoxy, fluoro and trifluoromethyl; and
- 100. any pyrrolidin-1-yl, piperidino or piperazin-1-yl group contained in the afore-mentioned R2 substituents are optionally substituted with one methyl or benzyl substituent in any vacant position.
- 101. A further preferred compound of the invention comprises a phenanthroline derivative of the formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, wherein
- 102. R1 is hydrogen, carboxy, cyano, nitro, methyl, ethyl, methoxycarbonyl, ethoxycarbonyl, methylamino, ethylamino, dimethylamino, 2,2,2-trifluoroethylsulfonyl, 2,2,2-trifluoroethylsulfinyl, phenylsulfinyl, phenylsulfonyl, phenylthio, methylthio, methylsulfinyl, methylsulfonyl, 2-[2-methoxyethoxy]ethoxycarbonyl, N-(6-aminohexyl)carbamoyl, 2-methoxyethoxycarbonyl, 2-(methylamino)ethoxycarbonyl, 2-(dimethylamino)ethoxycarbonyl, N,N-diethylcarbamoylmethoxycarbonyl or propionyloxymethyl;
- 103. R2 is hydrogen, hydroxy, carboxy, carbamoyl, carboxymethoxy, N-(6-aminohexyl) carbamoyl, N-ethylcarbamoyl, N-ethyl-N-butylcarbamoyl, N-butylcarbamoyl, N,N-diethylcarbamoyl, N,N-di-sec-butylcarbamoyl, N-methyl-N-butylcarbamoyl, N-methyl-N-hexylcarbamoyl, N-ethyl-N-propylcarbamoyl, N-ethyl-N-isopropylcarbamoyl, N-ethyl-N-pentylcarbamoyl, piperazin-1-ylcarbonyl, N-[methylaminomethyl]carbamoyl, N-[dimethylaminomethyl]carbamoyl, N-acetylcarbamoyl, morpholinocarbonyl, N-acetylamino or N-tert-butoxycarbonylamino;
- 104. R3 and R4, which may be the same or different, are hydrogen, fluoro, chloro, bromo, methyl or pyridin-4-yl; or R3 is hydroxy; and
- 105. R5 is hydrogen, hydroxy or piperazin-1-yl;
- 106. wherein any phenyl group contained in the afore-mentioned R1 and R2 substituents are optionally substituted with one or two substituents selected from ethoxy, fluoro and trifluoromethyl; and
- 107. any piperazin-1-yl group contained in the afore-mentioned R2 substituents is optionally substituted with one methyl or benzyl substituent in any vacant position.
- 108. A further preferred compound of the invention comprises a phenanthroline derivative of the formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, wherein
- 109. R1 is carboxy, cyano, nitro, ethoxycarbonyl, acetyl, 2,2,2-trifluoroethylsulfonyl or 2-[2-methoxyethoxy]ethoxycarbonyl;
- 110. R2 is hydrogen, carboxy, ethoxycarbonyl, carbamoyl, N-ethyl-N-butylcarbamoyl, N-(4-ethoxyphenyl)carbamoyl, N-methyl-N-benzylcarbamoyl, N-methyl-N-4-fluorobenzylcarbamoyl, N-[2,2,3,3,4,4,4-heptafluorobutyl]carbamoyl, 1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl, 4-benzylpiperazin-1-ylcarbonyl or N,N-diethylthiocarbamoyl;
- 111. R3 and R4, which may be the same or different, are hydrogen, fluoro or nitro; and
- 112. R5 is hydrogen, dimethylamino or chloro.
- 113. Further preferred compounds of the invention include, for example, the following phenanthroline derivatives of the formula (I):
- 114. 3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 1);
- 115. 3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 3);
- 116. 3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 4);
- 117. 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 5);
- 118. 3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 6);
- 119. 3,8-dicarboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 120. 8-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 121. 3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 122. 3-cyano-5-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 123. 5-chloro-3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 124. 5-chloro-3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 125. 3-acetyl-8-carboxy-7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 126. 3,8-diacetyl-7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 127. 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 128. 3-carboxy-8-(4-methylpiperidinocarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 129. 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 130. 8-acetyl-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 131. 3-carboxy-8-(N-methyl-N-{2-phenylethyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 132. 3-carboxy-8-(N-benzyl-N-isopropylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 133. 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-7-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 134. 3-carboxy-8-(N-methyl-N-{4-fluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 135. 3-carboxy-8-(N,N-diethylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 136. 8-(N-benzyl-N-methylcarbamoyl)-5-fluoro-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 137. 8-(N-benzyl-N-methylcarbamoyl)-3 ,6-dinitro-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 138. 8-ethoxycarbonyl-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 139. 8-(N-butyl-N-ethylcarbamoyl)-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 140. 3-carboxy-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 141. 8-(N,N-di-sec-butylcarbamoyl)-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 142. 8-(N-butyl-N-ethylcarbamoyl)-3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 143. 3-carboxy-8-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 144. 8-(N-cyclohexyl-N-ethylcarbamoyl)-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 145. 3-carboxy-8-(N-hexyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 146. 8-(N-hexyl-N-methylcarbamoyl)-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 147. 6-fluoro-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 148. 3-carboxy-8-(N-butyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 149. 3-carboxy-8-(N-ethyl-N-isopropylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 150. 8-(N-acetylamino)-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 151. 3-carboxy-8-(N-{4,4,5,5,5-pentafluoropentyl}-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 152. 3-carboxy-8-(N-methyl-N-ethylcarbamoyl)-7-dimethylamino-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 153. 3-carboxy-8-(N-tert-butoxycarbonylamino)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 154. 3-carboxy-6-chloro-8-(N-butyl-N-ethylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenathroline;
- 155. 8-amino-7-bromo-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 156. 3-carboxy-8-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 157. 3-carboxy-8-carboxymethoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 158. 8-(4-benzylpiperazin-1-ylcarbonyl)-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline; or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of those compounds bearing a carboxy group or groups.
- 159. Particularly preferred compounds of the invention include, for example, the following phenanthroline derivatives of the formula (I):
- 160. 3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 8);
- 161. 3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 10);
- 162. 3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 11);
- 163. 8-(N-butyl-N-ethylcarbamoyl)-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 164. 3,6-dinitro-4-oxo-3,4-dihydro-1 ,10-phenanthroline;
- 165. 8-carboxy-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 166. 8-(4-benzylpiperazin-1-ylcarbonyl)-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 167. 3-(2,2,2-trifluoroethylsulfonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 168. 8-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 169. 3-carboxy-8-N,N-diethylthiocarbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 170. 8-(N-benzyl-N-methylcarbamoyl)-3-cyano-5-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 171. 3-acetyl-7-chloro-8-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 172. 3-carboxy-5-fluoro-8-(N-2,2,3,3,4,4,4-heptafluorobutylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 173. 3-carboxy-8-(N-4-ethoxyphenylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 174. 3-carboxy-8-carbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 175. 3-carboxy-4-oxo-8-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)-3,4-dihydro-1,10-phenanthroline;
- 176. 3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 13);
- 177. 3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline (Compound 14); or
- 178. 8-(N-benzyl-N-methylcarbamoyl)-7-dimethylamino-3-ethoxycarbonyl-4-
oxo 3,4-dihydro-1,10-phenanthroline; - 179. or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of those compounds bearing a carboxy group.
- 180.FIG. 1 illustrates the histological results in the isoproterenol-induced myocardial fibrosis model.
- 181.FIG. 2 illustrates the results of
Compound 12, compared to control, in the rat restenosis model. - 182.FIG. 3 illustrates inhibition of prolyl hydroxylase by
Compound 12 in restenosis. - 183.FIG. 4 illustrates oral treatment of
Compound 12 in the brain injured model. - 184.FIG. 5 illustrates wound area after treatment of
Compound 3 in the dermal punch model. - 185.FIG. 6 illustrates the tensile strength on dermal incisional wound on
day 7 after oral treatment ofCompound 3 andCompound 12. - 186.FIG. 7 illustrates the tensile strength of incisional wound after local injections of
Compound 12. - 187.FIG. 8 illustrates certain embodiments of the invention.
- 188.FIG. 9 illustrates certain embodiments of the invention.
- 189. A compound of the invention comprising a phenanthroline derivative of the formula (I) as defined hereinbefore, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, may be prepared by any process known to be applicable to the preparation of structurally-related compounds. Such procedures are provided as a further feature of the invention and are illustrated by the examples presented herein in which, unless otherwise stated, R1, R2, R3, R4 and R5 have any of the meanings defined hereinbefore, provided that, when there is an amino, hydroxy or carboxy group in R1 , R2, R3, R4 and R5, any such group may optionally be protected by a conventional protecting group which may be removed when so desired by conventional means. A nitrogen heteroatom may also be optionally protected by a conventional protecting group which may be removed when so desired by conventional means.
- 190. A suitable protecting group for an amino group is, for example, an acyl group, for example, an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example, a methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl group, an arylmethoxycarbonyl group, for example, benzyloxycarbonyl, or an aroyl group, for example, benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example, lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris (trifluoroacetate).
- 191. A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example, dimethylaminopropylamine, or with hydrazine.
- 192. A suitable protecting group for a nitrogen heteroatom is, for example, a pivaloyloxymethyl group which may be removed by hydrolysis with a base, for example, sodium hydroxide or ammonia, in a suitable inert solvent or diluent, for example, methanol or ethanol.
- 193. A suitable protecting group for a hydroxy group is, for example, an acyl group, for example, an alkanoyl group such as acetyl, an aroyl group, for example, benzoyl, or an arylmethyl group, for example, benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example, lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- 194. A suitable protecting group for a carboxy group is, for example, an esterifying group, for example, a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or, for example, a tert-butyl group which may be removed, for example, by treatment with an acid, for example, an organic acid such as trifluoroacetic acid, or, for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- 195. Methods for reactions (a)-(f) are described below:
- 196. (a) The reaction of an 8-aminoquinoline derivative with a (1-4C)alkoxymethylene compound of the formula (II)
- R1—CO—C(R2)=CH—(1-4C)alkoxy (II)
- 197. followed by cyclization of the reaction product; wherein R1 is a (1-4C)alkoxy or a (1-4C)alkyl group; and R2 is a (1-4C)alkoxycarbonyl, (1-4C)alkylsulfonyl, fluoro-(1-4C)alkylsulfonyl or a sulfonylphenyl group; or R1 and R2 are linked, and together with the carbonyl carbon atom to which R1 is attached, and the carbon atom to which R2 is attached, define a 1,3-dioxan-4,6-dione ring (with the carbonyl carbon to which R1 is attached in the 4-position), and which ring is disubstituted in the 2-position by two (1-4C)alkyl groups:
- 198. The reaction is preferably carried out in the presence of a suitable solvent such as ethanol. The reaction may also be carried out using neat reagents. The reaction is preferably carried out a temperature in the
range 10° C. to 100° C., conveniently in the range 75° C. to 80° C. The cyclization is preferably carried out in the presence of an ether solvent such as, for example, diphenyl ether. The cyclization is preferably carried out at a temperature in the range 180° C. to 270° C., conveniently at, or near, the reflux temperature of the solvent. - 199. The preparation of starting 8-aminoquinoline derivatives is described within the accompanying non-limiting Examples which are provided for the purpose of illustration only. Other necessary 8-aminoquinoline derivatives are obtainable by analogous procedures to those described or by modifications thereto which are within the ordinary skill of an organic chemist. Suitable 8-aminoquinoline derivatives are substituted at the 3-position by any of the R2 substituents defined hereinbefore, at the 4-position by any of the R5 substituents defined hereinbefore, at the 5-position by any of the R4 substituents defined hereinbefore and at the 6-position by any of the R3 substituents defined hereinbefore.
- 200. The preparation of certain starting materials of the formula (II) is described within the accompanying Examples. Other necessary starting materials of the formula (II) are obtainable by analogous procedures to those described or by modifications thereto which are within the ordinary skill of an organic chemist. Other necessary starting materials of the formula (II) are obtainable by standard reactions of organic chemistry which are within the ordinary skill of an organic chemist.
- 201. (b) For the production of those compounds of the formula (I) in which each, or both of, the substituents R1 and R2 are carboxy groups, the hydrolysis of a compound of the formula (I) in which each, or both of, the substituents R1 and R2 are (1-6C)alkoxycarbonyl groups:
- 202. The hydrolysis is preferably carried out in the presence of a suitable acid or base. The reaction is also preferably carried out in aqueous solution, and at a temperature in the
range 10° C. to 110° C., conveniently in therange 80° C. to 100° C. A suitable acid is, for example, a mineral acid such as, for example, hydrochloric acid. A suitable base is, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example, sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide. - 203. The preparation of starting materials of formula (I) in which each, or both of, the substituents R1 and R2 are (1-4C)alkoxycarbonyl groups is described within the accompanying non-limiting Examples which are provided for the purpose of illustration only. Other necessary starting materials are obtainable by analogous procedures to those described or by modifications thereto which are within the ordinary skill of an organic chemist.
- 204. (c) For the production of those compounds of the formula (I) which bear a nitro substituent, the nitration of a compound of the formula (I) using a suitable nitrating agent:
- 205. A suitable nitrating agent is, for example, concentrated nitric acid in acetic anhydride, concentrated nitric acid in glacial acetic acid or a nitrate salt such as, for example, ammonium nitrate in trifluoroacetic acid.
- 206. The reaction is preferably carried out at a temperature in the
range 10° C. to 100° C. - 207. (d) The reaction of a compound of the formula (I) which bears a carboxy substituent, or a reactive derivative thereof, with ammonia, a primary amine or a secondary amine:
- 208. The reaction is preferably carried out in an inert solvent or diluent such as, for example, dichloromethane, acetonitrile or dimethylsulfoxide, and at a temperature in the
range 0° C. to 100° C. The reaction is also preferably carried out in the presence of a suitable organic amine base such as, for example, triethylamine. - 209. A suitable reactive derivative of a carboxy substituent borne by a compound of the formula (I) is, for example, an acyl halide, for example, an acyl chloride formed by the reaction of the carboxy substituent and an acid chloride, for example, thionyl chloride or oxalyl chloride; a mixed anhydride, for example, an anhydride formed by the reaction of the carboxy substituent and a chloroformate such as isobutyl chloroformate; an active ester, for example, an ester formed by the reaction of the carboxy substituent and a phenol such as pentafluorophenol, an ester such as pentafluorophenyl trifluoroacetate or an alcohol such as N-hydroxybenzotriazole; an acyl azide, for example, an azide formed by the reaction of the carboxy substituent and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example, a cyanide formed by the reaction of the carboxy substituent and a cyanide such as diethylphosphoryl cyanide; or the product of the reaction of the carboxy substituent and a carbodiimide such as dicyclohexylcarbodiimide.
- 210. (e) For the production of those compounds of the formula (I) in which R1 is a (1-4C)alkoxy-(2-4C)alkoxycarbonyl or a (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl group, the reaction of a compound of the formula (I) bearing an imidazol-1-ylcarbonyl group in the 3-position with a (1-4C)alkoxy-(2-4C)alkanol or a (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkanol:
- 211. The reaction is preferably carried out in an inert solvent or diluent such as, for example, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulfoxide, and at a temperature in the
range 0° C. to 150° C., conveniently at or near ambient temperature. The reaction is also preferably carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for example, sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide, sodium hydroxide, potassium hydroxide, sodium hydride or potassium hydride, or an organometallic base such as an alkyl-lithium, for example, n-butyl-lithium, or a dialkylamino-lithium, for example, lithium di-isopropylamide, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo-[5.4.0]undec-7-ene. - 212. The preparation of starting materials of the formula (I) bearing an imidazol-1-ylcarbonyl group in the 3-position is described within the accompanying Examples. Other necessary starting materials of the formula (I) bearing an imidazol-1-ylcarbonyl group in the 3-position are obtainable by analogous procedures to those described or by modifications thereto which are within the ordinary skill of an organic chemist.
- 213. A suitable value for a (1-4C)alkoxy-(2-4C)alkanol is, for example, 2 -methoxyethanol, 2-ethoxyethanol and 3-methoxypropanol. A suitable value for a (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkanol is, for example, 2-(2-methoxyethoxy)ethanol, 2-(2-ethoxyethoxy)ethanol and 3-(2-methoxyethoxy)propanol.
- 214. (f) For the production of those compounds of the formula (I) in which each, or both of, the substituents R1 and R2 are cyano groups, the dehydration of a compound of the formula (I) in which each, or both of, the substituents R1 and R2 are carbamoyl groups using a suitable dehydrating agent:
- 215. The dehydration is preferably carried out at a temperature in the
range 0° C. to 100° C., conveniently at or near ambient temperature. - 216. A suitable dehydrating agent is, for example, a mixture of trifluoroacetic anhydride and pyridine, phosphorous pentachloride or phosphorous oxychloride.
- 217. The preparation of a compound of the formula (I) in which each, or both of, the substituents R1 and R2 are carbamoyl groups is described, for example, in the section (d) hereinbefore and in the accompanying Examples. Other necessary starting materials of the formula (I) in which each, or both of, the substituents R1 and R2 are carbamoyl groups are obtainable by analogous procedures to those described or by modification thereto which are within the ordinary skill of an organic chemist.
- 218. It will be observed that certain phenanthrolinone derivatives of the present invention possess at least one asymmetric carbon atom (for example, when the substituent R1 is, for example, a 1-hydroxyethyl group) and can therefore exist in racemic and optically active forms. It is to be understood that the present invention encompasses a racemic form of any such phenanthroline derivative of the invention, any optically-active form thereof or a mixture thereof which possesses prolyl 4-hydroxylase inhibitory activity. It is a matter of common general knowledge how such optically-active forms may be obtained by stereospecific synthesis or by the separation of mixtures of isomeric compounds.
- 219. It is also to be understood that a phenanthroline derivative of the formula (I) may exhibit the phenomenon of tautomerism. In particular, it will be appreciated that the 4-oxo-3,4-dihydro-1,10-phenanthroline group may be in the form, for example, of a 4-hydroxy-1,10-phenanthroline group, or in the form, for example, of a 4-oxo-1,4-dihydro-1,10-phenanthroline group. It is to be understood that the invention encompasses any tautomeric form which possesses prolyl 4-hydroxylase inhibitory activity and is not to be limited merely to any one tautomeric form.
- 220. It is also to be understood that certain phenanthroline derivatives of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess prolyl 4-hydroxylase inhibitory activity.
- 221. A suitable pharmaceutically-acceptable salt of a phenanthroline derivative of the invention which is sufficiently basic is an acid-addition salt with, for example, an inorganic or organic acid, for example, hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically-acceptable salt of a phenanthroline derivative of the invention which is sufficiently acidic is an alkali metal salt, for example, a calcium or magnesium salt, an ammonium or tetra-(2-hydroxyethyl) ammonium salt or a salt with organic amines and quaternary bases which afford a physiologically-acceptable cation, for example, a salt with methylamine, dimethylamine, trimethylamine, ethylenediamine, piperidine, morpholine, pyrrolidine, piperazine, lysine, arginine, guanidine, ethanolamine, triethanolamine, N-methylglucamine, tetramethylammonium, hydroxide or benzyltrimethylammonium hydroxide.
- 222. A suitable metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group are esters formed with alcohols such as indanol; adamantol; (1-6C)alkanoyloxy-(l-4C)alkanols such as, for example, pivaloyloxymethyl; glycolamides; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl alcohol, (1-4C)alkoxycarbonyl-(1-4C)alkanols such as, for example, 2-(methoxycarbonyl)ethyl alcohol and oxa-(1-8C)alkandiols such as, for example, 3-oxapentan-1,5-diol and 3,6-dioxaoctan-1,8-diol.
- 223. When a pharmaceutically-acceptable salt of a compound of the formula (I) is required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure. When an optically active form of a compound of the formula (I) is required, it may be obtained by carrying out one of the aforesaid processes using an optically active starting material, or by resolution of a racemic form of said compound using a conventional procedure.
- 224. When a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group is required, it may be obtained, for example, by esterifying said carboxy group or groups using a conventional technique.
- 225. As stated above, the compounds of the present invention are of potential use in treating fibroproliferative disease, and accordingly the present invention also concerns the use of a compound of the formula (I), including those derivatives hereinbefore excluded from the scope of formula (I), or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, in the manufacture of a medicament for use in ameliorating fibroproliferative disease. The pharmacological activity may be demonstrated using one or more standard test procedures known in the art or as described in the examples.
- 226. A phenanthroline derivative of the present invention may itself be active or it may be a pro-drug which is converted in vivo to an active compound.
- 227. The present invention further provides a pharmaceutical composition comprising one or more phenanthroline derivatives of the formula (I) defined hereinbefore, and in addition those compounds named as excluded hereinbefore, which possess useful pharmacological activity; or a pharmaceutically-acceptable salt or metabolically labile ester thereof. The pharmaceutical composition which may be administered to a warm-blooded animal, including a human, comprises one or more phenanthroline derivatives in association with a pharmaceutically-acceptable diluent or carrier.
- 228. A preferred pharmaceutical composition comprises the phenanthroline derivative selected from
- 229. 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 12);
- 230. 3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 231. 3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 13);
- 232. 3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline (Compound 14);
- 233. 3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 15);
- 234. 3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline; and
- 235. 3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of the 3-carboxy substituent when present, in association with a pharmaceutically-acceptable diluent or carrier.
- 236. A further preferred pharmaceutical composition comprises the phenanthroline derivative, 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof or a metabolically labile ester derivative of the 3-carboxy substituent, in association with a pharmaceutically-acceptable diluent or carrier.
- 237. The pharmaceutical composition may also comprise a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, a cyclodextrin and optionally a pharmaceutically- acceptable diluent or carrier.
- 238. A suitable cyclodextrin is, for example, α-cyclodextrin, β-cyclodextrin or α-cyclodextrin. An alternative suitable cyclodextrin is, for example, a cyclodextrin derivative such as 2-hydroxypropyl-β-cyclodextrin, an alkylated cyclodextrin or a branched cyclodextrin. Preferably, the cyclodextrin is β-cyclodextrin.
- 239. The composition may be in a form suitable for oral use, for example, a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example, a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example, a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example, a suppository; for administration by inhalation, for example, as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example, a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example, a sterile aqueous or oily solution, emulsion or suspension.
- 240. Alternatively, the composition may be a continuous release composition as either a solid or liquid depot formulation, as microparticles or as microparticulate suspensions. In general the above compositions may be prepared in a conventional manner using conventional excipients. It is to be understood that the pharmaceutical composition may comprise a prodrug of a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions. Such prodrugs include, but are not limited to, metabolically labile ester derivatives of R1 and R2 when either, or both, is a carboxy group; other substituents, for example, hydroxy groups, may provide suitable positions for the formation of prodrugs. The preparation of suitable prodrugs is within the ordinary skill of a worker in the pharmaceutical sciences.
- 241. As stated above, the present invention concerns the use of a compound of the present invention, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, in combatting fibroproliferative disease. Other agents are currently known to possess activity against one or more fibroproliferative diseases. Thus, for example, cyclooxygenase inhibitory non-steroidal anti-inflammatory agents (NSAIA), such as indomethacin, acetylsalicyclic acid, ibuprofen, sulindac, tolmetin and piroxicam, are used in the treatment of rheumatoid arthritis. Also certain anti-inflammatory steroidal agents such as corticosteroidal agents, for example, beclomethasone dipropionate, betamethasone valerate, prednisolone or triamcinolone are used in the treatment of rheumatoid arthritis. Co-administration of a prolyl 4-hydroxylase inhibitor of the present invention with a NSAIA or a steroid derivative as defined hereinbefore can result in a reduction of the dose of the latter agents which is needed to produce a therapeutic effect. According to a further feature of the present invention there is provided a pharmaceutical composition which comprises a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, as defined hereinbefore, in conjunction or admixture with a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent or an anti-inflammatory steroidal agent, and a pharmaceutically-acceptable diluent or carrier.
- 242. In addition certain agents are beneficial in the treatment of liver fibrosis, for example, certain alkaloids such as colchicine and β-adrenergic receptor blocking agents such as propranolol, atenolol, labetolol and metoprolol may be beneficial. Co-administration of a 4-prolyl hydroxylase inhibitor of the present invention with colchicine or a β-adrenergic receptor blocking agent can result in an improved therapeutic effect. According to a further feature of the present invention there is provided a pharmaceutical composition which comprises a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, as defined hereinbefore, in conjunction or admixture with colchicine or a β-adrenergic receptor blocking agent, and a pharmaceutically-acceptable diluent or carrier.
- 243. The phenanthroline derivative will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 1-100 mg/kg, and this normally provides a therapeutically-effective dose. Where orally administered, the dose will preferably be 100-3500 mg/dose and more preferably 250-1250 mg/dose, administered 2-3 times daily. The daily dose will preferably be 3-150 mg/kg/day and more preferably 7-55 mg/kg/day. A unit dose form such as a tablet or capsule will usually contain, for example, 1-1000 mg of active ingredient whereas a capsule will usually contain 1-500 mg of active ingredient. However, the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- 244. According to a further feature of the invention there is provided a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, for use in a method of therapeutic treatment of the human or animal body.
- 245. According to a further preferred feature of the invention there is provided the phenanthroline derivative selected from
- 246. 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 247. 3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 248. 3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthrolline;
- 249. 3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 13);
- 250. 3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline (Compound 14);
- 251. 3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 15); and
- 252. 3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of the 3-carboxy substituent when present, for use in a method of therapeutic treatment of the human or animal body.
- 253. According to a further preferred feature of the invention there is provided the phenanthroline derivative 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of the 3-carboxy substituent, for use in a method of therapeutic treatment of the human or animal body.
- 254. According to a further feature of the present invention there is provided a method for producing an anti-fibroproliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group.
- 255. According to a further preferred feature of the invention there is provided a method for producing an anti-fibroproliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of the phenanthroline derivative selected from
- 256. 3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 257. 3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 258. 3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 259. 3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 260. 3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 261. 3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 262. 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 263. 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 264. 5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 265. 3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 266. 3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 267. 3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 268. 3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 269. 3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 270. 3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 271. 3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 272. 3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline; and
- 273. 3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline; or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of the 3-carboxy substituent when present.
- 274. According to a further preferred feature of the invention there is provided a method for producing an anti-fibroproliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of the phenanthroline derivative 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline or a pharmaceutically-acceptable salt thereof, or metabolically labile ester derivative of the 3-carboxy substituent.
- 275. The invention also provides the use of a phenanthroline derivative of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, in the manufacture of a novel medicament for use in the production of an anti-fibroproliferative effect in a warm blooded animal, such as man.
- 276. According to a further preferred feature of the invention there is provided a method for regenerating cells by producing an anti-fibroproliferative effect in a host, such a man, in need of such treatment which comprises administering to said host an effective amount of one or more phenanthroline derivatives of the formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions. Preferably a phenanthroline derivative and a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group, is selected from:
- 277. 3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 1);
- 278. 3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 3);
- 279. 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 12);
- 280. 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 5);
- 281. 5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 2);
- 282. 3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 4);
- 283. 3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 6);
- 284. 3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 7);
- 285. 3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 8);
- 286. 3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 9);
- 287. 3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 10);
- 288. 3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 11);
- 289. 3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 13);
- 290. 3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline (Compound 14); and
- 291. 3-carboxyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline (Compound 15).
- 292. Preferrably, the phenanthroline derivative is 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline and compositions thereof.
- 293. According to a further preferred feature of the invention there is provided the use of a phenanthroline derivative of formula (I) as defined hereinbefore in the section relating to pharmaceutical compositions, preferably selected from:
- 294. 3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 295. 3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 296. 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 297. 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 298. 5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 299. 3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 300. 3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 301. 3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 302. 3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 303. 3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 304. 3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 305. 3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 306. 3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 307. 3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
- 308. 3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline;
- 309. 3-carboxy-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline;
- 310. 3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline; and
- 311. 3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of the 3-carboxy substituent when present, in the manufacture of a novel medicament for use in the production of an anti-fibroproliferative effect (for example for treating the formation of scar tissue following injury or surgery) in a warm blooded animal, such as man.
- 312. According to a further preferred feature of the invention there is provided the use of the phenanthroline derivative 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of the 3-carboxy substituent, in the manufacture of a novel medicament for use in the production of an anti-fibroproliferative (for example for treating the formation of scar tissue following injury or surgery) effect in a warm blooded animal, such as man.
- 313. The invention is illustrated but not limited by the following Examples in which unless otherwise stated.
- 314. (i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration;
- 315. (ii) operations were carried out at ambient temperature, that is in the range 18-20° C. and under an atmosphere of an inert gas such as argon;
- 316. (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 reversed-phase silica (Art. 9303) obtained from E. Merck, Darmstadt, Germany;
- 317. (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- 318. (v) the end-products of the formula (I) generally have satisfactory microanalysis and their structures were confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra were determined using a Jeol FX 90Q or a Bruker AM200 spectrometer operating at a field strength of 200 MHz; chemical shifts are reported in parts per million downfield from tetramethysilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet, d, doublet; dd, doublet of doublets; t, triplet, m, multiplet; fast-atom bombardment (FAB) mass spectral data were obtained using a VG Analytical MS9 spectrometer and xenon gas and, where appropriate, either positive ion data or negative ion data were collected];
- 319. (vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, infra-red (IR) or NMR analysis;
- 320. (vii) melting points were determined using a Mettler SP62 automatic melting point apparatus, a Koffler hot plate apparatus or an oil-bath apparatus; and
- 321. (viii) the following abbreviations have been used:
- 322. THF tetrahydrofuran;
- 323. DMF N,N-dimethylformamide;
- 324. DMSO dimethylsulfoxide; and
- 325. TFA trifluoroacetic acid.
- 326. 3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 8)
- 327. 1,1′-Carbonyldiimidazole (30.4 g ) was added to a stirred mixture of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (18 g) and DMF (400 ml). The mixture was stirred at 100° C. for 2.5 hours, and then cooled to ambient temperature. The resulting solid was filtered to give 3-(imidazol-1-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline in 92% yield.
- 328. Sodium hydride (3.15 g, 60%) was added in portions to a mixture of 2-(2-methoxyethoxy)ethanol (15 ml) and DMF (200 ml). The mixture was stirred for approximately 30 minutes until effervescence ceased. 3-(imidazol-l-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline (21.05 g) was added and the mixture stirred for 18 hours. The mixture was acidified to pH 5-6 with acetic acid, and evaporated to dryness under reduced pressure. Water (50 ml) was added and the mixture extracted with dichloromethane. The organic layer was washed with brine, dried (MgSO4) and evaporated to dryness under reduced pressure. The residue was purified by flash chromatography on silica using dichloromethane, followed by a 24:1:0.1 mixture of dichloromethane methanol:triethylamine as eluant. The product so obtained was triturated with ethyl acetate to give 3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline in 68% overall yield, mp 164-165° C.
- 329. NMR Spectrum (D6-DMSO+D4-HOAc): 3.22(s,3H); 3.45(m,2H); 3.58(m,2H); 3.7(t,3H); 4.3 (t,2H); 7.75(dd,2H); 7.8(d,2H); 8.2(d,2H); 8.48(dd,2H); 8.55(s,1H); 9.05(dd,1H).
- 330. The 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline (Compound 12) used as starting material was obtained as follows:
- 331. A mixture of 8-aminoquinoline (14.4 g) and diethyl ethoxymethylenemalonate (26 g) in ethanol (100 ml) was heated at reflux for 18 hours. The mixture was cooled, filtered and the solid washed with ethanol. The solid so obtained was added to refluxing diphenyl ether (1000 ml), and the resulting mixture stirred at reflux for 45 minutes. The mixture was cooled to approximately 60° C. and diluted with hexane (500 ml). The mixture was cooled to ambient temperature, filtered and the solid washed with hexane to give 3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline in 84% yield, mp 242-244° C.
- 332. A mixture of 3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline (20 g) and 5M hydrochloric acid (100 ml) was stirred at reflux for 2 hours. The mixture was cooled and filtered. The solid so obtained was recrystallised from DMF to give the required starting material in 95% yield.
- 333. NMR Spectrum (D6-DMSO): 7.88(m,1H); 8.0(d,1H); 8.25(d,1H); 8.6(m,1H) 8.72 (m, 1H); 9.12 (m, 1H).
- 334. A mixture of 8-(N-butyl-N-ethylcarbamoyl)-3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline (12 g) and 2M hydrochloric acid (300 ml) was stirred at reflux for 2 hours. The mixture was cooled to ambient temperature, filtered and the solid washed with water. The solid so obtained was recrystallised from acetonitrile to give 8-(N-butyl-N-ethylcarbamoyl)-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline in 76% yield, mp 236-237° C.
- 335. NMR Spectrum (D6-DMSO-at 100° C.): 0.86(t,3H); 1.18(t,3H); 1.30(q,2H) 1.63(m,2H); 8.08(d,1H); 8.35(d,1H); 8.60(d,1H); 8.82(s,1H); 9.08 (d, 1H).
- 336. The 8-(N-butyl-N-ethylcarbamoyl)-3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 337. A mixture of 2-nitroaniline (41.4 g) and diethyl ethoxymethylenemalonate (66 ml) was heated on a steam bath for 24 hours. The hot reaction mixture was treated with ethanol (300 ml), cooled and filtered to give diethyl (2-nitroanilino)methylenemalonate in 88% yield, mp 104-105° C.
- 338. Diethyl (2-nitroanilino)methylenemalonate (43 g) was added to refluxing diphenyl ether (600 ml). The mixture was stirred at reflux for 1.5 hours, then cooled to ambient temperature. Diethyl ether (600 ml) was added and the mixture filtered. The solid so obtained was washed with diethyl ether to give 3-ethoxycarbonyl-8-nitro-4-oxo-3,4-dihydroquinoline in 85% yield, mp 241-243° C.
- 339. A mixture of 3-ethoxycarbonyl-8-nitro-4-oxo-3,4-dihydro-quinoline (12 g) and 2M sodium hydroxide solution (100 ml) was stirred at reflux for 1 hour. The mixture was cooled to ambient temperature and acidified to
pH 5 with glacial acetic acid. The mixture was filtered and the solid so obtained washed with water to give 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline in 93% yield, mp 263-265° C. - 340. DMF (0.2 ml) was added to a mixture of 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline (30 g) and thionyl chloride (150 ml) and the mixture stirred at reflux for approximately 2 hours until a clear solution was obtained. The solution was evaporated to dryness under reduced pressure, the residue dissolved in toluene and the solution again evaporated to dryness under reduced pressure. N-ethylbutylamine (19.1 ml, 14.14 g) followed by triethylamine (30 ml) were added dropwise to a stirred, ice-cold solution of the residue so obtained in acetonitrile. The mixture was stirred at ambient temperature for 1 hour and then evaporated to dryness under reduced pressure. The residue was partitioned between water and ethyl acetate. The orgainc layer was dried (MgSO4) and evaporated to dryness under reduced pressure. The residue was purified by flash chromatography on silica using a 1:19 mixture of ethyl acetate:chloroform as eluant. There was thus obtained 3-(N-butyl-N-ethylcarbamoyl)-4-chloro-8-nitro-quinoline in 93% yield.
- 341. Ammonium formate (26.5 g) was added in portions to a stirred mixture of 3-(N-butyl-N-ethylcarbamoyl)-4-chloro-8-nitro-quinoline (40 g), 10% palladium on carbon (20 g) and ethanol (500 ml) at reflux. The mixture was stirred at relux for 1 hour, the hot mixture was filtered through a pad of celite and the filtrates evaporated to dryness. The residue was partitioned between water and chloroform and the organic layer dried, and evaporated to dryness under reduced pressure. There was thus obtained 3-{-butyl-N-ethylcarbamoyl)-8-amino-quinoline in 99% yield.
- 342. A mixture of 3-(N-butyl-N-ethylcarbamoyl)-8-amino-quinoline (25 g) and diethyl ethoxymethylenemalonate (23.8 g) in ethanol was heated at reflux for 18 hours. The mixture was evaporated to dryness under reduced pressure and the residue purified by flash chromatography on silica using chloroform, followed by 1:19 mixture of methanol:chloroform as eluant. The solvent was evaporated and the residue obtained on standing was added to refluxing diphenyl ether (500 ml) . The mixture was stirred at reflux for 1.5 hours, then cooled to ambient temperature and added to a stirred 1:1 mixture of hexane:ether (500 ml) . The mixture was stirred for 18 hours, filtered and the solid so obtained washed with diethyl ether to give the required starting material in 55% yield, mp 128-129° C.
- 343. A solution of concentrated nitric acid (1 ml) in acetic anhydride (10 ml) was added dropwise to a stirred mixture of 4-oxo-3,4-dihydro-1,10-phenanthroline (0.98 g) in acetic anhydride (10 ml) The mixture was stirred at ambient temperature for 3 hours, diluted with ethyl acetate (50 ml) and filtered. The solid so obtained was recrystallised from a mixture of DMF and ethyl acetate to give 3,6-dinitro-4-oxo-3,4-dihydro-1,10-phenanthroline in 50% yield.
- 344. NMR Spectrum (D6-DMSO): 8.08(dd,1H); 8.92(s,1H); 8.95(s,1H); 9.06(dd, 1H); 9.23 (dd, 1H).
- 345. A mixture of 8-ethoxycarbonyl-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline (0.55 g) and 2M sodium hydroxide solution (5 ml) was stirred at reflux for 2 hours. The hot suspension was neutralised with glacial acetic acid, cooled and diluted with water. The mixture was filtered and washed with water to give 8-carboxy-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline in 98% yield.
- 346. NMR Spectrum (D6-DMSO): 8.1(d,1H); 8.35(d,1H); 8.98(s,1H); 9.06(d,1H); 9.5(d,1H).
- 347. The 8-ethoxycarbonyl-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 348. A mixture of 3-ethoxycarbonyl-8-nitro-4-oxo-3,4-dihydro-quinoline (10.2 g) and phosphorous oxychloride (10 ml) was stirred at reflux for 2 hours. The warm reaction mixture was added cautiously to a vigorously stirred mixture of ice, concentrated aqueous ammonia and chloroform. The organic layer was separated, washed with water, dried and evaporated to dryness. The residue was purified by flash chromatography on silica using chloroform as eluant to give 4-chloro-3-ethoxycarbonyl-8-nitro-quinoline in 75% yield, mp 253-254° C.
- 349. Ammonium formate was added to a vigorously stirred mixture of 4-chloro-3-ethoxycarbonyl-8-nitro-quinoline (5.6 g), ethanol (1000 ml) and 10% palladium on carbon catalyst (2 g). The mixture was stirred at ambient temperature for 1 hour, filtered through a pad of celite and the pad washed with dichloromethane. The combined filtrate and washings were evaporated to dryness. The residue so obtained was purified by flash chromatography on silica using chloroform as eluant to give 3-ethoxycarbonyl-8-amino-quinoline in 58% yield, mp 94-96° C.
- 350. A mixture of 3-ethoxycarbonyl-8-amino-quinoline (9.9 g), 2, 2-dimethyl-5-methoxymethylene-1,3-dioxan-4,6-dione (Monatsh. Chem., 98:564-78 (1967))(10.3 g) and ethanol (80 ml) was stirred at reflux for 2 hours. The mixture was cooled and filtered. The solid so obtained was washed with ethanol to give 8-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylideneamino)-3-ethoxycarbonylquinoline in 80% yield, mp 228-231° C.
- 351. The solid was added in portions over 5 minutes to stirred diphenyl ether at 260° C. and stirring was continued for 30 minutes. The mixture was cooled to ambient temperature and diluted with hexane (200 ml). The mixture was filtered to give 8-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline as a solid in 73% yield, mp 250-252° C.
- 352. A mixture of 8-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline (0.8 g), ammonium nitrate (0.26 g) and trifluoroacetic acid (10 ml) was stirred at reflux for 6 hours. Further portions (0.26 g) of ammonium nitrate were added after 2 hours and 4 hours at reflux. The mixture was cooled to ambient temperature and stirred whilst water (50 ml) was added. The mixture was filtered and the solid so obtained was stirred with a 1:1 mixture of ethanol:chloroform. The mixture was filtered to give the required starting material as a solid in 60% yield.
- 353. A mixture of 8-carboxy-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline (228 mg), thionyl chloride (5 ml) and DMF (0.1 ml) was stirred at reflux for 3 hours. The mixture was cooled to ambient temperature and evaporated to dryness. The residue was dissolved in dichloromethane (10 ml) and the solution stirred whilst a solution of N-benzylpiperazine (158 mg) and triethylamine (1 ml) in dichloromethane was added over 5 minutes. The mixture was stirred for 1 hour, washed with water, dried and evaporated to dryness. A solution of the residue in DMSO (3 ml) and water (0.5 ml) was heated at 90° C. for 18 hours. After cooling to ambient temperature, the solution was treated with water (20 ml) and ethyl acetate (5 ml) and the mixture filtered. The residue was recrystallised from a mixture of methanol and chloroform to give 8-(4-benzylpiperazin-1-ylcarbonyl)-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline as a solid in 42% yield, mp 213-216° C.
- 354. NMR Spectrum (D6-DMSO): 2.54(m,4H); 3.55-3.7(m,6H); 7.2-7.4(m,5H) 8.0(d,1H); 8.35(d,1H); 8.58(d,1H); 8.97(s,1H); 9.08(d,1H).
- 355. 8-[2-Methoxycarbonyl-2-(2,2,2-trifluoroethylsulfonyl)-ethenylamino]quinoline (4 g) was added to diphenyl ether (100 ml) with stirring at 260° C., and stirring was continued for 2 hours. The mixture was allowed to cool to ambient temperature and hexane (100 ml) was added. The mixture was filtered, and the residue purified by flash chromatography on silica using increasingly polar mixtures of methanol and chloroform as eluant. The product so obtained was recrystallised from acetic acid to give 3-(2,2,2-trifluoroethyl-sulfonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline, mp 272-274° C.
- 356. NMR Spectrum (D6-DMSO): 4.87(q,2H); 8.0(dd,1H); 8.03(d,1H); 8.25(d, 1H); 8.52(d, 1H); 8.64(m, 1H); 9.15(dd, 1H).
- 357. The 8-[2-methoxycarbonyl-2-(2,2,2-trifluoroethylsulfonyl)ethenylamino]quinoline used as starting material was obtained as follows:
- 358. 3-Chloroperbenzoic acid (22.2 g, 60%) was added in portions to a stirred solution of methyl-2-(2,2,2-trifluoroethylthio)acetate (J. Med. Pharm. Chem., 5:491 (1962))(6 g) in dichloromethane (120 ml). The mixture was stirred at ambient temperature for 24 hours and then filtered. The filtrate was washed successively with aqueous sodium hydrogen sulphite, aqueous sodium carbonate and brine, dried and evaporated to dryness. There was thus obtained methyl 2-(2,2,2-trifluoroethylsulfonyl)acetate in 84% yield as a solid, mp 59-60° C.
- 359. A mixture of 8-aminoquinoline (1.87 g), triethyl orthoformate (2.4 ml) and methyl 2-(2,2,2-trifluoroethylsulfonyl)acetate (2.86 g) was stirred at reflux for 30 minutes. The mixture was cooled to ambient temperature and diethyl ether (20 ml) added. The mixture was filtered to give the required starting material in 86% yield, mp 221-223° C.
- 360. A mixture of 8-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-4-oxo-3,4-dihydro-1,10-phenanthroline (0.3 g), glacial acetic acid (5 ml) and concentrated nitric acid (0.15 ml) was heated at 90° C. for 18 hours. The mixture was cooled to ambient temperature and water (20 ml) and ethyl acetate (10 ml) were added. The mixture was filtered, and the solid so obtained recrystallised from a mixture of DMF and ethyl acetate. There was thus obtained 8-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-3-nitro-4-oxo-3,4-dihydro-1,10-phenanthroline in 27% yield, mp 294-296° C.
- 361. NMR Spectrum (D6-DMSO): 3.12(s,3H); 4.7(s,2H); 7.15(m,2H); 7.4(m,2H) 7.98 (d, 1H); 8.36 (d, 1H); 8.62 (d, 1H); 8.98 (s, 1H); 9.12 (d, 1H).
- 362. The 8-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-4-oxo-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 363. Using a procedure analogous to that described in Example 2, in the section relating to the prepartion of starting materials, 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline was reacted with N-(4-fluorobenzyl)-N-methylamine to give 3-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-4-chloro-8-nitroquinoline in 89% yield, mp 135-137° C.
- 364. Using a procedure analogous to that described in Example 2, in the section relating to the prepartion of starting materials, 3-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-4-chloro-8-nitroquinoline was hydrogenated to give 3-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-8-aminoquinoline in 99% yield.
- 365. Using a procedure analogous to that described in Example 2, in the section relating to the preparation of starting materials, 3-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-8-aminoquinoline was reacted with diethyl ethoxymethylenemalonate to give 3-ethoxycarbonyl-8-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-4-oxo-3,4-dihydro-1,10-phenanthroline in 64% yield, mp 206-207° C.
- 366. Using a procedure analogous to that described in Example 2, in the section relating to the prepartion of starting materials, 3-ethoxycarbonyl-8- [N- (4-fluorobenzyl)-N-methylcarbamoyl]-4-oxo-3,4-dihydro-1,10-phenanthroline was hydrolysed. The product so obtained was recrystallised from acetic acid to give 3-carboxy-8-[N-(4-fluoro-benzyl)-N-methylcarbamoyl]-4-oxo-3,4-dihydro-1,10-phenanthroline, mp 245-246° C.
- 367. A solution of 3-carboxy-8-[N-(4-fluorobenzyl)-N-methylcarbamoyl]-4-oxo-3,4-dihydro-l,10-phenanthroline (0.5 g) in diphenyl ether (3 ml) was stirred at reflux for 6 hours. The mixture was cooled and filtered. The solid so obtained was washed with hexane and purified by flash chromatography on silica using increasingly polar mixtures of methanol and ethyl acetate as eluant. There was thus obtained the required starting material.
- 368. Using a procedure analogous to that described in Example 2,3-ethoxycarbonyl-8-N,N-diethylthiocarbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline was hydrolysed. The product so obtained was recrystallised from a mixture of methanol and chloroform to give 3-carboxy-8-N,N-diethylthiocarbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline.
- 369. NMR Spectrum (D6-DMSO at 100° C.): [mixture of rotamers] 1.1-1.5(m,6H); 3.4-4.3(m,4H); 8.04(d,1H); 8.35(d,1H); 8.42(d,1H); 8.82(s,1H); 9.0(d,1H).
- 370. The 3-ethoxycarbonyl-8-N,N-diethylthiocarbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 371. Using a procedure analogous to that described in Example 2, in the section relating to the preparation of starting materials, 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline was reacted in turn with thionyl chloride and diethylamine, and was hydrogenated to give 8-amino-3-N,N-diethylcarbamoylquinoline in 71% yield.
- 372. A mixture of 8-amino-3-N,N-diethylcarbamoylquinoline (1.22 g), toluene (10 ml) and Lawesson's Reagent (1.22 g) was stirred at reflux for 2 hours. The mixture was evaporated to dryness and the residue purified by flash chromatography on silica using increasingly polar mixtures of methanol and chloroform. There was thus obtained 8-amino-3-N,N-diethylthiocarbamoylquinoline in 100% yield.
- 373. Using a procedure analogous to that described in Example 2, in the section relating to the preparation of starting materials, 8-amino-3-N,N-diethylthiocarbamoylquinoline was reacted with diethyl ethoxymethylenemalonate, and then refluxed with diphenyl ether to give the required starting material in 47% yield.
- 374. Trifluoroacetic anhydride (0.5 ml) was added dropwise to a stirred, ice-cooled mixture of 8-(N-benzyl-N-methylcarbamoyl)-3-carbamoyl-4-chloro-5-fluoro-1,10-phenanthroline (0.3 g) in pyridine (3 ml). The mixture was stirred at ambient temperature for 1 hour. The mixture was acidified with 3M hydrochloric acid and stirred at ambient temperature for 18 hours. The mixture was filtered and the solid so obtained recrystallised from a mixture of methanol and ethyl acetate to give 8-(N-benzyl-N-methylcarbamoyl)-3-cyano-5-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline in 24% yield, mp 267-269° C.
- 375. NMR Spectrum (D6-DMSO at 100° C.): 3.05(s,3H); 4.7(s,2H); 7.3-7.5(m,5H) 7.65(d,1H); 8.5(s,1H); 8.55(d,1H); 9.05(d,1H).
- 376. The 8-(N-benzyl-N-methylcarbamoyl)-3-carbamoyl-4-chloro-5-fluoro-1,10-phenanthroline used as starting material was obtained as follows:
- 377. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 4-fluoro-2-nitroaniline and diethyl ethoxymethylenemalonate were reacted, and then refluxed in diphenyl ether to give 3-ethoxycarbonyl-6-fluoro-8-nitro-4-oxo-3,4-dihydroquinoline in 45% yield, mp 278-280° C.
- 378. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-ethoxycarbonyl-6-fluoro-8-nitro-4-oxo-3,4-dihydroquinoline was hydrolysed to give 3-carboxy-6-fluoro-8-nitro-4-oxo-3,4-dihydroquinoline in 84% yield, mp 254-256° C.
- 379. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-carboxy-6-fluoro-8-nitro-4-oxo-3,4-dihydroquinoline was reacted with thionyl chloride and then N-benzylmethylamine to give 3-[N-benzyl-N-methylcarbamoyl]-4-chloro-6-fluoro-8-nitroquinoline in 63% yield.
- 380. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-[N-benzyl-N-methylcarbamoyl]-4-chloro-6-fluoro-8-nitroquinoline was hydrogenated to give 8-amino-3[N-benzyl-N-methylcarbamoyl]-6-fluoro-quinoline in 63% yield.
- 381. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 8-amino-3-[N-benzyl-N-methylcarbamoyl]-6-fluoroquinoline was reacted with diethyl ethoxymethylenemalonate, and then refluxed in diphenyl ether. The product so obtained was recrystallised from a mixture of ethyl acetate and hexane to give 3-ethoxycarbonyl-8-(N-benzyl-N-methylcarbamoyl)-5-fluoro-4-oxo-3,4-dihydro-l,10-phenanthroline in 70% yield, mp 201-203° C.
- 382. Using an analogous procedure to that described in Example 2,3-ethoxycarbonyl-8-(N-benzyl-N-methylcarbamoyl)-5-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline was hydrolysed. The product so obtained was recrystallised from acetic acid to give 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline in 81% yield, mp 168-171° C.
- 383. A mixture of 3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-fluoro-4-oxo-3,4-dihydro-l,10-phenanthroline (0.7 g) and thionyl chloride was stirred at reflux for 30 minutes, and then evaporated to dryness. A solution of concentrated ammonia (2 ml) and triethylamine (5 ml) in acetonitrile (25 ml) were added to the residue, and the mixture stirred at ambient temperature for one hour. The mixture was evaporated to dryness, and the residue stirred with water (10 ml) and ethyl acetate (10 ml). The mixture was filtered and the product so obtained recrystallised from a mixture of methanol and ethyl acetate. There was thus obtained the required starting material in 69% yield, mp 180-183° C.
- 384. A mixture of 8-amino-4-chloro-3-ethoxycarbonylquinoline (0.3 g) and ethyl 2-ethoxymethyleneacetoacetate (Annalen, 1897, 297, 16, 0.25 g) was heated at 90° C. for 2.5 hours. The mixture was cooled to ambient temperature and the resulting solid added to diphenyl ether at reflux. The mixture was refluxed for 45 minutes, and cooled to 60° C. The mixture was diluted with carbon tetrachloride (50 ml) and cooled to ambient temperature with stirring. The mixture was filtered and the solid so obtained purified by flash chromatography on silica using increasingly polar mixtures of methanol and chloroform. The product so obtained was recrystallised from methanol to give 3-acetyl-7-chloro-8-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline in 29% yield, mp 288-290° C.
- 385. NMR Spectrum (D6-DMSO): 1.4(t,3H ); 2.66(s,3H); 4.5(q,2H ); 8.2(d,1H); 8.45(d,1H);
- 386. 8.5(d,1H); 9.27(s,1H).
- 387. The 8-amino-4-chloro-3-ethoxycarbonylquinoline used as starting material was obtained as follows:
- 388. A mixture of 4-chloro-3-ethoxycarbonyl-8-nitroquinoline (1.4 g), ethanol (10 ml), triethylamine (0.7 ml) and 10% palladium on carbon catalyst (0.2 g) was stirred under an atmosphere of hydrogen for 2.5 hours. The mixture was filtered and the filtrate was evaporated to dryness. The residue was purified by MPLC on silica using chloroform as eluant to give the required starting material in 24% yield, mp 110-1 12° C.
- 389. Using an analogous procedure to that described in Example 2, 3-ethoxycarbonyl-5-fluoro-8-(N-2,2,3,3,4,4,4-heptafluorobutyl-carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline was hydrolysed to give 3-carboxy-5-fluoro-8-(N-2,2,3,3,4,4,4-heptafluorobutylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline in 46% yield.
- 390. NMR Spectrum (D6-DMSO): 4.2-4.45(2H,m); 7.9(1H,d); 8.76(1H,s) 9.0(1H,d); 9.42(1H,d);
- 391. 9.65(1H,t).
- 392. The 3-ethoxycarbonyl-5-fluoro-8-(N-2,2,3,3,4,4,4-heptafluorobutylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 393. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-carboxy-6-fluoro-8-nitro-4-oxo-3,4-dihydroquinoline was reacted with thionyl chloride and then 2,2,3,3,4,4,4-heptafluorobutylamine to give 3-[N-2,2,3,3,4,4,4-heptafluorobutylcarbamoyl]-4-chloro-6-fluoro-8-nitroquinoline in 33% yield, mp 159-160° C.
- 394. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-[N-2,2,3,3,4,4,4-heptafluorobutylcarbamoyl]-4-chloro-6-fluoro-8-nitroquinoline was hydrogenated to give 8-amino-6-fluoro-3-[N-2,2,3,3,4,4,4-heptafluorobutylcarbamoyl]quinoline in 73% yield, mp 202-204° C.
- 395. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 8-amino-6-fluoro-3-[N-2,2,3,3,4,4,4-heptafluorobutylcarbamoyl]quinoline was reacted with diethyl ethoxymethylenemalonate, and then refluxed in diphenyl ether. There was thus obtained the required starting material in 87% yield, mp 288-290° C.
- 396. Using an analogous procedure to that described in Example 2, 3-ethoxycarbonyl-8-(N-4-ethoxyphenylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline was hydrolysed. The product so obtained was recrystallised from DMF to give 3-carboxy-8-(N-4-ethoxyphenylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline in 41% yield.
- 397. NMR Spectrum (D6-DMSO+TFA): 1.27(3H,t); 4.0(2H,m); 6.85(2H,m); 7.65(2H,m); 7.98(1H,d); 8.28(1H,d); 8.75(1H,s); 9.0(1H,d); 9.45(1H,d).
- 398. The 3-ethoxycarbonyl-8-(N-4-ethoxyphenylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 399. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline was reacted with thionyl chloride and then 4-ethoxyaniline to give 3-[N-4-ethoxyphenylcarbamoyl]-4-chloro-8-nitroquinoline in 43% yield, mp 232-233° C.
- 400. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-[N-4-ethoxyphenylcarbamoyl]-4-chloro-8-nitroquinoline was hydrogenated to give 8-amino-3-[N-4-ethoxyphenylcarbamoyl]quinoline in 74% yield, mp 187-189° C.
- 401. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 8-amino-3-[N-4-ethoxyphenylcarbamoyl]quinoline was reacted with diethyl ethoxymethylenemalonate, and then refluxed in diphenyl ether. There was thus obtained the required starting material in 70% yield.
- 402. Using an analogous procedure to that described in Example 2, 3-ethoxycarbonyl-8-carbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline was hydrolysed. The product so obtained was recrystallised from DMF to give 3-carboxy-8-carbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline in 96% yield.
- 403. NMR Spectrum (D6-DMSO): 7.9(broad s,1H); 8.1(d,1H); 8.22(d,1H); 8.5(broad s,1H); 8.75 (S, 1H); 9.05(d,1H); 9.5(d,1H).
- 404. The 3-ethoxycarbonyl-8-carbamoyl-4-oxo-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 405. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline was reacted with thionyl chloride and then concentrated aqueous ammonia. The product so obtained was recrystallised from ethanol to give 3-carbamoyl-4-chloro-8-nitroquinoline in 79% yield, mp 277-279° C.
- 406. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-carbamoyl-4-chloro-8-nitroquinoline was hydrogenated to give 8-amino-3-carbamoylquinoline in 54% yield, mp 164-165° C.
- 407. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 8-amino-3-carbamoylquinoline was reacted with diethyl ethoxymethylenemalonate, and then refluxed in diphenyl ether. There was thus obtained the required starting material in 64% yield.
- 408. Using an analogous procedure to that described in Example 2, 3-ethoxycarbonyl-4-oxo-8-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)-3,4-dihydro-1,10-phenanthroline was hydrolysed. The product so obtained was recrystallised from a mixture of methanol and chloroform to give 3-carboxy-4-oxo-8-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)-3,4-dihydro-1,10-phenanthroline in 72% yield, mp 171-182° C.
- 409. NMR Spectrum (D6-DMSO at 100° C.) 2.96(t,2H); 3.82(t,2H); 4.8(s,2H) 7.7(m,4H); 8.1(d,1H); 8.4(d,1H): 8.72(d,1H); 8.85(s,1H); 9.18(d,1H).
- 410. The 3-ethoxycarbonyl-4-oxo-8-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)-3,4-dihydro-1,10-phenanthroline used as starting material was obtained as follows:
- 411. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline was reacted with thionyl chloride and then 1,2,3,4-tetrahydroisoquinoline to give 3-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)-4-chloro-8-nitro-quinoline in 71% yield.
- 412. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)-4-chloro-8-nitro-quinoline was hydrogenated to give 8-amino-3-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)quinoline in 100% yield.
- 413. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 8-amino-3-(1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl)quinoline was reacted with diethyl ethoxymethylenemalonate, and then refluxed in diphenyl ether. There was thus obtained the required starting material in 50% yield, mp 238-240° C.
- 414. A mixture of 8-amino-3-(N-benzyl-N-methylcarbamoyl)-4-dimethylaminoquinoline (1.28 g), diethyl ethoxymethylenemalonate (1 g) and ethanol (5 ml) was heated at reflux for 2 hours. The mixture was evaporated to dryness and a solution of the residue in diphenyl ether (70 ml) was stirred at reflux for 1 hour. The mixture was cooled to ambient temperature and stirred whilst a 1:2 mixture (200 ml) of diethyl ether:hexane was added. The mixture was filtered and the solid so obtained recrystallised from ethyl acetate. There was thus obtained 8-(N-benzyl-N-methylcarbamoyl)-7-dimethylamino-3-ethoxy-carbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline in 80% yield, mp 169-170° C.
- 415. NMR Spectrum (D6-DMSO): 1.3(m,3H); 2.85-3.35(m,9H); 4.25(m,2H); 4.35-5.3(m,2H); 7.2-7.5(m,5H); 8.0(d,1H); 8.15(m,1H); 8.5(m,1H); 8.62(s,1H).
- 416. The 8-amino-3-(N-benzyl-N-methylcarbamoyl)-4-dimethylamino-quinoline used as starting material was obtained as follows:
- 417. Using an analogous procedure to that described in Example 2, in the section relating to the preparation of starting materials, 3-carboxy-8-nitro-4-oxo-3,4-dihydroquinoline was reacted with thionyl chloride and then N-benzylmethylamine. The product so obtained was recrystallised from ethanol to give 3-(N-benzyl-N-methylcarbamoyl)-4-chloro-8-nitroquinoline in 82% yield, mp 120-121° C.
- 418. A mixture of 3-(N-benzyl-N-methylcarbamoyl)-4-chloro-8-nitroquinoline (1.42 g), ethanol (20 ml) and a 33% solution of dimethylamine in ethanol (5 ml) was heated at 90° C. for 6 minutes. The mixture was evaporated to dryness and the residue was partitioned between water and ethyl acetate. The organic layer was dried and evaporated to dryness. The residue was dissolved in ethanol and 10% palladium on carbon catalyst (0.3 g) and ammonium formate (1 g) were added to the solution. The mixture was stirred at reflux for 2 hours, and the mixture filtered. The filtrate was evaporated to dryness and the residue was partitioned between water and ethyl acetate. The organic layer was dried and evaporated to dryness to give the required starting material in 96% yield, which was used without further purification.
- 419. To assess the enzymatic activity of compounds of the present invention, the following assays ((a)-(d)) were used:
- 420. (a) An in vitro enzyme assay system, which assesses the inhibitory properties of a test compound in a cell free system using a highly purified preparation of prolyl 4-hydroxylase. The enzyme preparation was obtained using the method described by N. Kedersha and R. Berg (Collagen Related Research, 1:345 (1981)) and the activity of a test compound was measured using the method described by C. J. Cunliffe, T. J. Franklin and R. Gaskell (Biochem. J., 240:617 (1986)).
- 421. (b) An in vitro assay system involving incubating embryonic chick tendon cells in the presence of a test compound and measuring the inhibition of hydroxylation at the 4-position of prolyl residues within the available collagen. The embryonic chick tendon cells were prepared from the leg tendons of 17-day chick embryos using the method of P. Dehm and D. Prockop (Biochem. Biophys Acta, 240:358 (1971)). The cells were incubated in the presence of [14C]- and [3H]-labelled L-proline and the extent of hydroxylation at the 4-trans-position of the prolyl residues within the collagen was determined using the procedure described by T. J. Franklin and M. Hitchen (Biochem. J, 261:127-130 (1989)).
- 422. (c) An in vitro assay involving incubating cultures of 3T6 cells with a test compound and [14C]- and [3H]-labelled L-proline, and measuring the inhibition of hydroxylation at the 4-trans-position of prolyl residues within the available collagen using the procedure described by T. J. Franklin and M. Hitchen (Biochem. J., 261:127-130 (1989)).
- 423. (d) An in vivo assay involving the measurement of the inhibition by a test compound of hydroxylation at the 4-trans-position of prolyl residues within collagen within the uteri of immature (20-21 day) female rats. The test compounds were administered either orally or intraperitoneally to the rats in which uterine collagen synthesis had been stimulated by the subcutaneous administration of a solution of oestradiol benzoate (0.5 μg on each of two successive days) in
arachis 14 oil. The rats were dosed with 5 μCuries of [14C]-L-proline and the uteri were taken 2 hours after the dosing of the radiolabelled proline and sonicated. Collagen was extracted by treatment of the tissue with water at 120° C. for 1 hour in an autoclave and hydrolysed by treatment with 6N hydrochloric acid for 18 hours at reflux temperature. The proline and 4-hydroxyproline residues were separated by column chromatography on a reversed-phase Spherisorb S5ODS1 column using as eluent a 89.9:10:0.1 v/v mixture of water:isopropanol:trifluoroacetic acid to which 0.3% w/v of sodium dodecylsulphate had been added. The ratio of radioactivity found in each of the proline and 4-hydroxyproline fractions was determined by liquid scintillation counting to allow the measurement of the inhibition of hydroxylation by a test compound. - 424. The compound described in Example 2 has an IC50 of 0.4 μM in test (a), an IC50 of 1.2 μM in test (b), an IC50 of 5.4 μM in test (c) and an inhibition of 46% at 50 mg/kg orally (compound dosed 2 hours before proline administration) in test (d).
- 425. (e) An in vivo wound chamber model involving the measurement of histological changes in granulation tissue. The test compounds were tested in rats according to the procedures generally described in Schilling et al., Surgery 46(4):702-710 (1959), Hunt et al., Am. J. Surgery 114:302-307 (1967), and Grotendorst et al., J. Clin Inves. 76:2323-2329 (1985). More specifically, stainless wire mesh cylinders were implanted subcutaneously under the back skin of rats (two chambers per animal). The compounds of the present invention were then dissolved in DMSO and injected into each chamber on a daily basis at various concentrations from either day 0-14 or day 7-14. On
day 14, the chambers were collected and the granulation tissues contained within the chambers were collected for biochemical (collagen content) or histological evaluation. - 426. (f) Various in vivo animal models to determine the applicability of utilizing the compounds of the present invention to treat fibrotic disorders specific to certain cell types or organs. For example, a cardiac fibrosis model in rats, as generally described in Kondo et al., Cardiovascu. Res. 21:248-254 (1987), and Benjamin et al., Circulation Res. 65(3):657-670 (1989), may be used to measure the effectiveness of the compounds of the present invention to inhibit cardiac fibrosis, as well as provide evidence of the regeneration of cardiac cells upon inhibition of fibrotic cell proliferation. Similarly, the left carotid artery injury model, as described generally in Clowes et al., Lab Invest. 49:327-33 (1983), Muller et al., Am. Col. Cardio. 19(2):418 (1992), and Jackson, Trends Cardiovasc. Med. 4:122-130 (1994), may be used to determine the effectiveness of the compounds of the instant invention in vascular remodeling. Other models, such as in vivo brain injury models (see e.g., Berry et al., Acto Neurochrurgica, Suppl., 32:31-53 (1993), Logan et al., Brain Research 587:216-255 (1992)), in vivo kidney fibrosis models (see e.g., DiDonato et al., Nephron 76(2):192-200 (1997), in vivo post-surgical abdominal adhesions model (see e.g., Cohen et al., J. Trauma 30(12):S149-154 (1990), Stein & Keiser, J. Surg. Res. 11:277 (1971),, Diegelman et al., J. Surg. Res. 19:239-43 (1975)) may be used to determine the effectiveness of the compounds of the instant invention to treat fibrotic disorders related to the brain, kidney, abdomen and dermis, as well as provide information related to the treatment of other major organs.
- 427. The following illustrate representative pharmaceutical dosage forms containing the compound of the formula (I) as defined hereinbefore in the section relating to pharmaceutical composition, or a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of substituents R1 and R2 when either, or both, is a carboxy group (hereafter compound X), for therapeutic or prophylactic use in humans:
(a) Tablet I mg/tablet Compound X 100 Lactose Ph.Eur 182.75 Croscarmellose sodium 12.0 Maize starch paste (5% w/v paste) 2.25 Magnesium stearate 3.0 (b) Tablet II mg/ tablet Compound X 50 Lactose Ph. Eur 223.75 Croscarmellose sodium 6.0 Maize starch 15.0 Polyvinylpyrrolidone (5% w/v paste) 2.25 Magnesium stearate 3.0 (c) Tablet III mg/tablet Compound X 1.0 Lactose Ph. Eur 93.25 Croscarmellose sodium 4.0 Maize starch paste (5% w/v paste) 0.75 Magnesium stearate 1.0 (d) Capsule mg/ capsule Compound X 10 Lactose Ph. Eur 488.5 Magnesium stearate 1.5 (e) Injection I (50 mg/ml) Compound X 5.0% w/v 1 M Sodium hydroxide solution 15.0% v/v 0.1 M Hydrochloric acid (to adjust pH to 7.6) Polyethylene glycol 400 4.5% w/v Water for injection to 100% (f) Injection II (10 mg/ml) Compound X 1.0% w/v Sodium phosphate BP 3.6% w/v 0.1 M Sodium hydroxide solution 15.0% v/v Water for injection to 100% (g) Injection III (1 mg/ml,buffered to pH 6) Compound X 0.1% w/v Sodium phosphate BP 2.26% w/v Citric acid 0.38% w/v Polyethylene glycol 400 3.5% w/v Water for injection to 100% (h) Aerosol I mg/ml Compound X 10.0 Sorbitan trioleate 13.5 Trichlorofluoromethane 910.0 Dichlorodifluoromethane 490.0 (i) Aerosol II mg/ml Compound X 0.2 Sorbitan trioleate 0.27 Trichlorofluoromethane 70.0 Dichlorodifluoromethane 280.0 Dichlorotetrafluoroethane 1094.0 (j) Aerosol III mg/ml Compound X 2.5 Sorbitan trioleate 3.38 Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0 Dichlorotetrafluoroethane 191.6 (k) Aerosol IV mg/ml Compound X 2.5 Soya lecithin 2.7 Trichlorofluoromethane 67.5 Dichlorodifluoromethane 1086.0 Dichlorotetrafluoroethane 191.6 (l) Ointment /ml Compound X 40 mg Ethanol 300 μl Water 300 μl 1-Dodecylazacycloheptan-2-one 50 μl Propylene glycol to 1 ml - 428. The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example, to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative suspending agent such as sorbitan monooleate, sorbitan sesquioleate,
polysorbate 80, polyglycerol oleate or oleic acid. - 429. Following the in vivo wound chamber model described above, fourteen of the claimed compounds tested to determine the effectiveness of the claimed compounds in inhibiting collagen deposition in the wound chamber. The results of these tests are set forth at Table 1:
TABLE 1 Mean Collagen content (% of Control) On Day 14 (after day 7-14 treatment) Compound 10 μg dosage 50 μg dosage 1 109.50 112.29 2 91.73 82.69 3 108.45 79.76 4 81.14 66.03 5 99.10 80.91 6 58.77 51.06 7 81.88 74.54 8 113.94 92.52 9 80.26 79.87 10 94.81 76.54 11 90.83 80.83 12 — 80.68 13 95.55 84.26 14 72.19 70.29 - 430. With respect to Compound 12, apoptotic cell numbers were also counted and data provided that treatment dose-dependently increased positive staining of apoptotic cells. With respect to this compound, it was also shown that, at higher doses, the compound prevented rebound of collagen accumulation after discontinuing administration of the compound.
- 431.
Compounds 1 through 14 were prepared as described herein, or using analogous processess to those described within this specification and the Examples, or processes known to the skilled organic chemist. - 432. The effectiveness of one of the compounds of the present invention to inhibit cardiac fibrosis and permit the regeneration of cardiac cells was tested in the cardiac fibrosis model generally described above. More specifically,
Compound 12 was tested in a rat isoproterenol-induced myocardial fibrosis model (wherein isoproterenol was injected into rats at 1 mg/kg subcutaneously, for four consecutive days) to determine the effectiveness of the compound in inhibiting collagen deposition and improving ventricular function of the heart. The compound was administered after suspension in 1% CMC at 50 mg/kg by oral gavage twice daily fromday 4 today 11 and histological data was evaluated onday 11 by general histology (H&E and trichrome) and immunohistochemical staining for proliferating cell nuclear antigen (PCNA). Cardiac function (left ventricular function) was measured by inserting a catheter into the left ventricle for measurement of relaxation and contraction pressure onweek 6. - 433. The histological results of this test are set forth in FIG. 1. As set forth in FIG. 1, blocking collagen deposition appears to block cardiac fibrosis. As further evidenced by FIG. 1, blocking collagen deposition also appears to permit the regeneration of healthy cardiac cells.
- 434. The effect of the compound on the left ventricular function, as measured at
week 6, is set forth in TABLE 2.TABLE 2 Relaxation pressure Contraction pressure (Min-P, mm Hg) (dP/dt, mm Hg) Normal −0.5 ± 0.6 4702.9 ± 19.6 Fibrotic 11.4 ± 0.31 1765 ± 54.9 Compound 122.7 ± 0.8 5770 ± 95.1 - 435. As set forth in Table 2, oral treatment with the prolyl-4-hydroxylase inhibitors of the claimed invention significantly reduced scar formation in a cardiac model and encouraged the regeneration/hypertrophy of normal myocytes. Blocking scarring also prevented the deterioration of cardiac function.
- 436. The effectiveness of
Compound 12 in vascular remodeling, as determined in a rat restenosis model, was determined by using a left carotid artery injury rat model, as generally described above. More specifically, a total of 20 male SD rats (weighing between 250-300 g) were used. Under general anesthesia, the rat right common carotid artery and region of bifurcation were exposed through a midline incision. A 2F Fogarty balloon catheter (Baxter) was introduced through the external carotid artery and advanced into the thoracic aorta. The balloon was inflated with 0.3 ml or air to distend the common carotid artery. After three repetitions of this procedure, the endothelium was removed completely and some injury to smooth muscle layers throughout the common carotid artery resulted. After removal of the catheter, the external carotid artery was ligated and the wound closed.Compound 12 was then suspended in 1% CMC at 50 mg/kg and given to the rats by oral gavage twice daily from day 0-14. Onday 14 after surgery, both the common carotid artery (left as control) were harvested and fixed in formalin. The results of this experiment are set forth in FIGS. 2 and 3. As evidenced by these figures, oral administration ofCompound 12 appears to significantly reduce the development of neointimal formation in balloon injured carotid arteries, indicating that the compound will be a useful agent for vascular remodeling. - 437. The effectiveness of the compounds of the instant invention to inhibit the formation of scar tissue in the brain following injury was tested using the brain injury model described above. Specifically, experiments were conducted using rat models wherein a lesion was made with an iridectomy knife to a depth of 3.5 mm along a 4.5 mm line parallel with the sagittal suture, 3 mm lateral to the mid-line and spanning the frontal-parietal suture. The animals were orally administered Compound 12 (as formulated above at Example 19) by oral gavage twice daily from
day 0 to 14. All animals were sacrificed atday 14 after lesion. - 438. From immunohistochemical staining, the perfusion fixed brains were post-fixed overnight at 4 degrees C. in 4% PFA in 0.1 borate buffer containing 10% sucrose. The brains were then rapidly frozen on powdered dry ice in Tissue Tek OCT compound and stored at −80 degrees C. Frozen sections (10 um) were mounted on poly-L-lysine coated slides, air dried and stored at −80 degrees C. for staining of type I collagen and GFAP. The results of such staining are set forth in FIG. 4. As set forth in FIG. 4, oral treatment with
Compound 12 reduced collagen deposition in the scar and decreased the activation of actrocytes. The compound also appears to reduce physical barriers produced by the scarring and suggests improvement of functional recovery. - 439. The effectiveness of the compounds of the instant invention to treat kidney fibrosis was determined using a kidney fibrosis rat model, as generally described above. More specifically, male SD rats weighing approximately 200-225 g each were injected intravenously with Adriamycin (Pharmacia, MI) on
day 1 and again on day 15. The Adriamycin was dissolved in 0.5 ml sterile physiologic saline and infused slowly into the tail vein to ensure complete delivery and to avoid perivascular tissue destruction of the drug. - 440. Three treatment groups were established following Adriamycin injections. The rats were randomly assigned to receive a twice daily gavage of
Compound 12 or control (1% CMC). Five animals from each group were sacrificed onweek - 441. Histology examination provided that treatment with the compound, versus control, prevented the development of kidney fibrosis after Adriamycin injection and blocked the development of renal hypertension. Cardiac function was improved on
week 12 and long term toxicity, as measured by mean body weight and bone density onweek 12, was not material. - 442. The effectiveness of the compounds in dermal wound healing was tested using two wound healing models—rat punch model and rat incisional model—as described above. The results of these experiments, as conducted with
Compound 12 andCompound 14, are set forth in FIGS. 5, 6 and 7. As set forth in these figures, administration of the compounds resulted in reduced tensil strength and increased healing time, as compared to control.
Claims (24)
wherein R1 is hydrogen, carboxy or a metabolically labile ester derivative thereof, cyano, halo, nitro, amino, (1-4C)alkyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, hydroxy-(1-4C)alkyl, carbamoyl, N-(1-4C)alkylcarbamoyl, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl; phenylthio, phenylsulfinyl or phenylsulfonyl said phenyl being optionally substituted with 1 to 4 substituents selected from halo, (1-4C)alkyoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl; fluoro-(1-4C)alkylthio, fluoro-(1-4C)alkylsulfinyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkylamino-(2-4C)alkoxycarbonyl, di-(1-4C)alkylamino-(2-4C)alkoxycarbonyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl, (2-4C)alkanoyloxy-(1-4C)alkyl, morpholino-(2-4C)alkoxycarbonyl or N-[amino-(2-8C)alkyl]carbamoyl;
R2 is hydrogen, hydroxy, amino, cyano, halo, (1-4C)alkyl, carboxy or a metabolically labile ester derivative thereof, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, (1-4C)alkoxy, carboxy-(1-4C)alkoxy, (1-4C)alkoxycarbonyl-(1-4C)alkoxy, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-[amino-(2-8C)alkyl)carbamoyl, N-[(1-4C)alkylamino-(1-8C)alkyl]carbamoyl, N-[di-(1-4C)alkylamino-(1-8C)alkyl)carbamoyl, N-cyclohexylcarbamoyl, N-[cyclopentyl]carbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl or N-(1-4C)alkylcyclopentylcarbamoyl; N-phenylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N,N-diphenylcarbamoyl, N-[phenyl-(1-4C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl, or N,N-di-[phenyl-(1-4C)alkyl]carbamoyl said phenyl or phenyl groups being optionally substituted with 1 to 4 substituents selected from halo, (1-4C)alkyoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl; N-[(2-4C)alkanoyl]carbamoyl, N-[(1-4C)alkoxycarbonyl]carbamoyl, N-[fluoro-(2-6C)alkyl]carbamoyl, N-[fluoro-(2-6C)alkyl]-N-(1-4C)alkylcarbamoyl or N,N-[di-fluoro-(2-6C)alkyl]carbamoyl; pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl or morpholinocarbonyl wherein the heterocyclic group is optionally substituted with 1 to 4 substituents selected from (1-4C)alkyl and benzyl; 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl, N,N-[di-(1-4C)alkyl]thiocarbamoyl, N-(2-4C)alkanoylamino or N-[(1-4)alkoxycarbonyl]amino;
R3 and R4, which may be the same or different, are hydrogen, (1-4C)alkyl, (2-4C)alkoxy, halo, nitro, hydroxy, fluoro-(1-4C)alkyl or pyridinyl;
or R4 is methoxy; or R3 is methoxy; and
R5 is hydrogen, hydroxy, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, halo, (1-4C)alkoxy-(2-4C)alkoxy or fluoro-(1-6C)alkoxy; pyrrolidin-1-yl, piperidino, piperazin-1-yl or morpholino wherein the heterocyclic group is optionally substituted with 1 to 4 substituents selected from (1-4C)alkyl and benzyl; or
a pharmaceutically-acceptable salt thereof; provided that:
R1, R2, R3 , R4 and R5 are not together H;
where R1 is carboxy and R3 and R4 are hydroxy; R2 and R5 are not together H;
where R1 is carboxy, R2 is H or OH, R3 is H and R5 is H; R4is not H, OH alkoxy, alkyl or halo;
where R1 is carboxy, R2 is H or OH, R4 is H and R5 is H; R3 is not H, OH alkoxy, alkyl or halo;
where R1 is ethoxycarbonyl; R2, R3, R4 and R5 are not together H;
where R1 is ethoxycarbonyl and R4 is F; R2, R3 and R5 are not together H
where R1 is carboxy and R3 is H or alkyl; R2, R4 and R5 are not together H;
where R3 is OH; R1 , R2, R4 and R5 are not together H;
where R5 is OH, R3 is H or alkyl, and R4 is H; R1 and R2 are not together ethoxycarbonyl, carboxy, methoxycarbonyl or H; and
where R5 is —N(CH3)2; R1, R2, R3 and R4 are not together H.
2. A compound of :
claim 1
3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(4-benzylpiperazin-1-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-trifluoromethylsulphonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline; or
3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline; or
a pharmaceutically-acceptable salt thereof, or a metabolically labile ester derivative of those compounds bearing a carboxy group.
wherein R1 is hydrogen, carboxy or a metabolically labile ester derivative thereof, cyano, halo, nitro, amino, (1-4C)alkyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, hydroxy-(1-4C)alkyl, carbamoyl, N-(1-4C)alkylcarbamoyl, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl; phenylthio, phenylsulfinyl or phenylsulfonyl said phenyl being optionally substituted with 1 to 4 substituents selected from halo, (1-4C)alkyoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl; fluoro-(1-4C)alkylthio, fluoro-(1-4C)alkylsulfinyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkylamino-(2-4C)alkoxycarbonyl, di-(1-4C)alkylamino-(2-4C)alkoxycarbonyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl, (2-4C)alkanoyloxy-(1-4C)alkyl, morpholino-(2-4C)alkoxycarbonyl or N-[amino-(2-8C)alkyl]carbamoyl;
R2 is hydrogen, hydroxy, amino, cyano, halo, (1-4C)alkyl, carboxy or a metabolically labile ester derivative thereof, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, (1-4C)alkoxy, carboxy-(1-4C)alkoxy, (1-4C)alkoxycarbonyl-(1-4C)alkoxy, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-[amino-(2-8C)alkyl)carbamoyl, N-[(1-4C)alkylamino-(1-8C)alkyl]carbamoyl, N-[di-(1-4C)alkylamino-(1-8C)alkyl)carbamoyl, N-cyclohexylcarbamoyl, N-[cyclopentyl]carbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl or N-(1-4C)alkylcyclopentylcarbamoyl; N-phenylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N,N-diphenylcarbamoyl, N-[phenyl-(1-4C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl or N,N-di-[phenyl-(1-4C)alkyl]carbamoyl said phenyl or phenyl groups being optionally substituted with 1 to 4 substituents selected from halo, (1-4C) alkyoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl; N-[(2-4C)alkanoyl]carbamoyl, N-[(1-4C)alkoxycarbonyl]carbamoyl, N-[fluoro-(2-6C)alkyl]carbamoyl, N-[fluoro-(2-6C)alkyl]-N-(1-4C)alkylcarbamoyl or N,N-[di-fluoro-(2-6C)alkyl]carbamoyl; pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl or morpholinocarbonyl wherein the heterocyclic group is optionally substituted with 1 to 4 substituents selected from (1-4C)alkyl and benzyl; 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl, N,N-[di-(1-4C)alkyl]thiocarbamoyl, N-(2-4C)alkanoylamino or N-[(1-4)alkoxycarbonyl]amino;
R3 and R4, which may be the same or different, are hydrogen, (1-4C)alkyl, (2-4C)alkoxy, halo, nitro, hydroxy, fluoro-(1-4C)alkyl or pyridinyl;
or R4 is methoxy; or R3 is methoxy; and
R5 is hydrogen, hydroxy, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, halo, (1-4C)alkoxy-(2-4C)alkoxy or fluoro-(1-6C)alkoxy; pyrrolidin-1-yl, piperidino, piperazin-1-yl or morpholino wherein the heterocyclic group is optionally substituted with 1 to 4 substituents selected from (1-4C)alkyl and benzyl; or
a pharmaceutically-acceptable salt thereof; and
a pharmaceutically-acceptable diluent or carrier.
4. The composition of , comprising a compound selected from:
claim 3
3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro 1,10-phenanthroline;
3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro 1,10-phenanthroline;
3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline; or
3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
or a pharmaceutically acceptable salt, or a metabolically labile ester derivative thereof.
5. A method for producing an anti-fibroproliferative effect in a host in need of such treatment, comprising administering an effective amount of a composition of .
claim 3
6. The method of wherein said composition comprises:
claim 5
3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline; or
3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
or a pharmaceutically acceptable salt, or a metabolically labile ester derivative thereof.
7. A method of treating the symptoms of a fibroproliferative disease or disorder in a host in need of such treatment comprising administering an effective amount of a composition of .
claim 3
8. The method of wherein said composition comprises:
claim 7
3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline; or
3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
or a pharmaceutically acceptable salt, or a metabolically labile ester derivative thereof.
9. The method of wherein the disease is rheumatoid arthritis, chronic arthritis or osteoarthritis.
claim 7
10. The method of wherein the disease is hepatic cirrhosis.
claim 7
11. The method of wherein the disease is pulmonary fibrosis, renal fibrosis, cardiac fibrosis, arteriosclerosis or tumor associated fibrosis.
claim 7
12. A method of treating scar tissue formation following injury or surgery in a host in need of such treatment comprising administering an effective amount of a composition of .
claim 3
13. The method of wherein said composition comprises:
claim 12
3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-(2-{morpholino }ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline; or
3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
or a pharmaceutically acceptable salt, or a metabolically labile ester derivative thereof.
wherein R1 is hydrogen, carboxy or a metabolically labile ester derivative thereof, cyano, halo, nitro, amino, (1-4C)alkyl, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, hydroxy-(1-4C)alkyl, carbamoyl, N-(1-4C)alkylcarbamoyl, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl; phenylthio, phenylsulfinyl or phenylsulfonyl said phenyl being optionally substituted with 1 to 4 substituents selected from halo, (1-4C)alkyoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl; fluoro-(1-4C)alkylthio, fluoro-(1-4C)alkylsulfinyl, fluoro-(1-4C)alkylsulfonyl, (1-4C)alkoxy-(2-4C)alkoxycarbonyl, N,N-di-[(1-4C)alkyl]carbamoyl-(1-4C)alkoxycarbonyl, (1-4C)alkylamino-(2-4C)alkoxycarbonyl, di-(1-4C)alkylamino-(2-4C)alkoxycarbonyl, (1-4C)alkoxy-(2-4C)alkoxy-(2-4C)alkoxycarbonyl, (2-4C)alkanoyloxy-(1-4C)alkyl, morpholino-(2-4C)alkoxycarbonyl or N-[amino-(2-8C)alkyl]carbamoyl;
R2 is hydrogen, hydroxy, amino, cyano, halo, (1-4C)alkyl, carboxy or a metabolically labile ester derivative thereof, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxycarbonyl, (2-4C)alkanoyl, (1-4C)alkoxy, carboxy-(1-4C)alkoxy, (1-4C)alkoxycarbonyl-(1-4C)alkoxy, carbamoyl, N-(1-8C)alkylcarbamoyl, N,N-di-(1-8C)alkylcarbamoyl, N-[amino-(2-8C)alkyl)carbamoyl, N-[(1-4C)alkylamino-(1-8C)alkyl]carbamoyl, N-[di-(1-4C)alkylamino-(1-8C)alkyl)carbamoyl, N-cyclohexylcarbamoyl, N-[cyclopentyl]carbamoyl, N-(1-4C)alkylcyclohexylcarbamoyl or N-(1-4C)alkylcyclopentylcarbamoyl; N-phenylcarbamoyl, N-(1-4C)alkyl-N-phenylcarbamoyl, N,N-diphenylcarbamoyl, N-[phenyl-(1-4C)alkyl]carbamoyl, N-(1-4C)alkyl-N-[phenyl-(1-4C)alkyl]carbamoyl or N,N-di-[phenyl-(1-4C)alkyl]carbamoyl said phenyl or phenyl groups being optionally substituted with 1 to 4 substituents selected from halo, (1-4C)alkyoxy, (1-4C)alkyl, cyano, hydroxy and trifluoromethyl; N-[(2-4C)alkanoyl]carbamoyl, N-[(1-4C)alkoxycarbonyl]carbamoyl, N-[fluoro-(2-6C)alkyl]carbamoyl, N-[fluoro-(2-6C)alkyl]-N-(1-4C)alkylcarbamoyl or N,N-[di-fluoro-(2-6C)alkyl]carbamoyl; pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl or morpholinocarbonyl wherein the heterocyclic group is optionally substituted with 1 to 4 substituents selected from (1-4C)alkyl and benzyl; 1,2,3,4-tetrahydro-isoquinolin-2-ylcarbonyl, N,N-[di-(1-4C)alkyl]thiocarbamoyl, N-(2-4C)alkanoylamino or N-[(1-4)alkoxycarbonyl]amino;
R3 and R4, which may be the same or different, are hydrogen, (1-4C)alkyl, (2-4C)alkoxy, halo, nitro, hydroxy, fluoro-(1-4C)alkyl or pyridinyl;
or R4 is methoxy; or R3 is methoxy; and
R5 is hydrogen, hydroxy, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, halo, (1-4C)alkoxy-(2-4C)alkoxy or fluoro-(1-6C)alkoxy; pyrrolidin-1-yl, piperidino, piperazin-1-yl or morpholino wherein the heterocyclic group is optionally substituted with 1 to 4 substituents selected from (1-4C)alkyl and benzyl in the manufacture of a medicament for use in the production of an anti-fibroproliferative effect.
15. The use of 3-carboxy-5-methoxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-6-fluoro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-methyl-N-{2,4-difluorobenzyl}carbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-(N-benzyl-N-methylcarbamoyl)-5-methyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
5-chloro-3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-cyano-8-(N-benzyl-N-methylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(N-ethyl-N-propylcarbamoyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-8-hydroxy-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-[2-(2-methoxyethoxy)ethoxycarbonyl]-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-carboxy-6-chloro-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-nitro-8-(4-benzylpiperazine-ylcarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-(2-{morpholino}ethoxycarbonyl)-4-oxo-3,4-dihydro-1,10-phenanthroline;
3-ethoxycarbonyl-4-oxo-5-methoxy-3,4-dihydro-1,10-phenanthroline; or
3-trifluoromethylsulfonyl-4-oxo-3,4-dihydro-1,10-phenanthroline;
or a pharmaceutically acceptable salt, or a metabolically labile ester derivative thereof, according to .
claim 14
16. The use of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline according to .
claim 14
17. A pharmaceutical composition comprising 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt, or a metabolically labile ester derivative thereof; and a pharmaceutically-acceptable diluent or carrier.
18. A pharmaceutical composition comprising 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline and a pharmaceutically-acceptable diluent or carrier.
19. A pharmaceutical composition comprising a pharmaceutically-acceptable salt of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline and a pharmaceutically-acceptable diluent or carrier.
20. A pharmaceutical composition comprising a metabolically labile ester derivative of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline and a pharmaceutically-acceptable diluent or carrier.
21. A method for producing an anti-fibroproliferative effect in a host in need of such treatment, comprising administering an effective amount of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt, or a metabolically labile ester derivative thereof; or an effective amount of a composition comprising 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline, or a pharmaceutically-acceptable salt, or a metabolically labile ester derivative thereof; and a pharmaceutically-acceptable diluent or carrier.
22. A method for producing an anti-fibroproliferative effect in a host in need of such treatment, comprising administering an effective amount of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline.
23. A method for producing an anti-fibroproliferative effect in a host in need of such treatment, comprising administering an effective amount of a pharmaceutically-acceptable salt of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline.
24. A method for producing an anti-fibroproliferative effect in a host in need of such treatment, comprising administering an effective amount of a metabolically labile ester derivative of 3-carboxy-4-oxo-3,4-dihydro-1,10-phenanthroline.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/747,254 US20010001101A1 (en) | 1997-10-24 | 2000-12-20 | Phenanthroline derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/957,450 US5916898A (en) | 1997-10-24 | 1997-10-24 | Phenanthroline derivatives |
US17954298A | 1998-10-26 | 1998-10-26 | |
US09/304,677 US6200974B1 (en) | 1997-10-24 | 1999-05-04 | Phenanthroline derivatives |
US09/747,254 US20010001101A1 (en) | 1997-10-24 | 2000-12-20 | Phenanthroline derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/304,677 Continuation US6200974B1 (en) | 1997-10-24 | 1999-05-04 | Phenanthroline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010001101A1 true US20010001101A1 (en) | 2001-05-10 |
Family
ID=27391133
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/304,677 Expired - Lifetime US6200974B1 (en) | 1997-10-24 | 1999-05-04 | Phenanthroline derivatives |
US09/747,254 Abandoned US20010001101A1 (en) | 1997-10-24 | 2000-12-20 | Phenanthroline derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/304,677 Expired - Lifetime US6200974B1 (en) | 1997-10-24 | 1999-05-04 | Phenanthroline derivatives |
Country Status (1)
Country | Link |
---|---|
US (2) | US6200974B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060013851A1 (en) * | 2002-02-07 | 2006-01-19 | Giroux Karen J | Therapeutic polyanhydride compounds for drug delivery |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2324834B1 (en) * | 2001-12-06 | 2019-05-08 | Fibrogen, Inc. | Methods of Increasing Endogenous Erythropoietin (EPO) |
EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
GB0206711D0 (en) * | 2002-03-21 | 2002-05-01 | Isis Innovation | HIF Inhibitor |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
JP2007530522A (en) * | 2004-03-26 | 2007-11-01 | アイシス・イノベーション・リミテッド | Assay |
US8530404B2 (en) | 2005-06-15 | 2013-09-10 | Fibrogen, Inc. | Compounds and methods for treatment of cancer |
GB0519605D0 (en) * | 2005-09-26 | 2005-11-02 | Isis Innovation | Assay |
KR100959538B1 (en) * | 2006-03-30 | 2010-05-27 | 엘지전자 주식회사 | A method and apparatus for decoding/encoding a video signal |
GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
US20220143211A1 (en) * | 2019-03-11 | 2022-05-12 | The Regents Of The University Of California | Hydrogels and methods of using the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1147759A (en) | 1965-06-17 | 1969-04-10 | Sterling Drug Inc | Aromatic derivatives and preparation thereof |
GB1335623A (en) | 1971-04-26 | 1973-10-31 | Ici Ltd | Pyridoquinoline derivatives |
US4156726A (en) | 1974-12-07 | 1979-05-29 | Fisons Limited | 4-Oxo-2-carboxyl quinoline derivatives used as antiallergic compounds |
GB1504709A (en) | 1974-12-07 | 1978-03-22 | Fisons Ltd | N-substituted quinolinone-2-carboxyl. acid der |
US3951833A (en) | 1975-02-27 | 1976-04-20 | Olin Corporation | Method for preserving functional fluids and liquid hydrocarbon fuels with selected 1,10-phenanthrolines |
NZ227505A (en) | 1988-01-13 | 1992-02-25 | Univ Illinois | Insecticidal composition comprising delta-ala or inducers and enhancers thereof |
RU2024513C1 (en) | 1989-04-28 | 1994-12-15 | Санкио Компани Лимитед | Method of synthesis of n-acryloylpiperazine derivatives |
US5369106A (en) | 1989-04-28 | 1994-11-29 | Sankyo Company, Limited | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists |
US5393614A (en) | 1992-04-03 | 1995-02-28 | Pioneer Electronic Corporation | Organic electroluminescence device |
EP0878480A1 (en) | 1997-05-14 | 1998-11-18 | H.W. Prof. Dr. Müller | A method for the improvement of neuronal regeneration |
-
1999
- 1999-05-04 US US09/304,677 patent/US6200974B1/en not_active Expired - Lifetime
-
2000
- 2000-12-20 US US09/747,254 patent/US20010001101A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060013851A1 (en) * | 2002-02-07 | 2006-01-19 | Giroux Karen J | Therapeutic polyanhydride compounds for drug delivery |
Also Published As
Publication number | Publication date |
---|---|
US6200974B1 (en) | 2001-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2153495C2 (en) | Quinazoline derivatives, method of preparation thereof, pharmaceutical composition, and a method for reaching antiproliferative effects | |
EP1167364B1 (en) | Benzopyran-containing compounds and prodrug forms thereof | |
JP4205430B2 (en) | Condensed pyridine derivatives for use as vanilloid receptor antagonists to treat pain | |
US6200974B1 (en) | Phenanthroline derivatives | |
US5916898A (en) | Phenanthroline derivatives | |
TWI324066B (en) | A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor | |
CA2308551C (en) | Phenanthroline derivatives | |
KR20200022480A (en) | Compositions and Methods for Controlling Hair Growth | |
JP2005089334A (en) | 8-hydroxyadenine compound | |
ES2384967T3 (en) | Quinazolinone derivatives and their use as CB agonists | |
TWI293301B (en) | A1 adenosine receptor antagonists | |
JPH11501926A (en) | 6-Arylpyrazolo [3,4-d] pyrimidin-4-ones and compositions and uses thereof | |
US20090036482A1 (en) | Imidazopyridine-derivatives as inductible no-synthase inhibitors | |
SK280336B6 (en) | Pharmaceutical compositions containing pyridazino[4,5-b]quinolines, methods for their preparation | |
CN111936470B (en) | Amidopyrazoles useful as irreversible FGFR inhibitors | |
KR20000064618A (en) | Indol-morphinan derivatives and brain disorder treatment / prevention agent | |
AU697643B2 (en) | Use of xanthine oxidase inhibitors as anti-ischaemic agents | |
JP2008528552A (en) | New indolopyridines, benzofuranopyridines and benzothienopyridines | |
AU760232B2 (en) | Benzopyran-containing compounds and method for their use | |
WO2023187561A1 (en) | 2-[(2-oxo-4-phenyl-2h-chromen-7-yl)oxy] propanamido derivatives | |
AU2002302469A1 (en) | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ZENECA LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EDWARDS, PHILIP NEIL;LARGE, MICHAEL STEWART;HALES, NEIL JAMES;REEL/FRAME:011415/0595;SIGNING DATES FROM 19990602 TO 19990609 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |